# 2025年12月14日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 气动驱动的液态金属频率可重构天线

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388495)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41388495
**DOI：** 10.1002/advs.202512996

### 第一部分 原文与翻译

**英文原标题：** Pneumatically-Actuated Liquid Metal-Based Frequency Reconfigurable Antenna.

> **英文摘要：**
> Software-defined radios and cognitive radios can switch their operating frequency across a wide range. Although analog and digital circuits enable cross-frequency operation of much of the RF frontend, there is a lack of practical antennas that are frequency-reconfigurable over such a wide range. Prior rigid antennas are either narrow-band with high radiation efficiency, or wide-band with low radiation efficiency. This study presents a soft, stretchable, compact, omnidirectional liquid metal composite antenna system to enable high radiation efficiency when reconfiguring to different frequencies across a wide band. On the hardware front, an extendable multi-branch stretchable liquid metal based antenna geometry is optimized that preserves high efficiency when switching across a wide range of frequencies. On the software front, a control algorithm is incorporated that ensures that the antenna automatically configures to the optimal received signal strength. The antenna design enables a strain limit of 33% for two independent actuatable branches, further enabling a switchable operating frequency range across 1-5 GHz. Experimental characterization demonstrates that PASTA reduces the radiation loss by 10-20 dB over the operating frequency range compared to state-of-the-art rigid and flexible antennas.

> **中文摘要：**
> 软件定义无线电和认知无线电可以在宽频率范围内切换其工作频率。尽管模拟和数字电路能够使射频前端的大部分实现跨频操作，但缺乏能在如此宽频范围内实现频率重构的实用天线。以往的刚性天线要么是高辐射效率的窄带结构，要么是低辐射效率的宽带结构。本研究提出了一种柔软、可拉伸、紧凑且全向的液态金属复合天线系统，在跨宽频带切换至不同频率时仍可保持高辐射效率。在硬件方面，优化了一种可伸展的多分支液态金属基天线几何结构，使其在跨宽频范围切换时仍能保持高效率。在软件方面，集成了一种控制算法，可确保天线自动配置以获得最佳接收信号强度。该天线设计在两个可独立驱动的分支上实现了33%的应变极限，从而进一步实现了1-5 GHz范围内的可切换工作频率。实验表征结果表明，与目前先进的刚性和柔性天线相比，PASTA系统在工作频率范围内可将辐射损耗降低10–20 dB。

### 第二部分 AI 大师评价

该研究旨在解决宽频率范围内可重构天线辐射效率不足的问题，提出了一种气动驱动、液态金属复合的软性天线设计方案。其通过硬件几何结构优化和软件控制算法结合，实现了自动频率配置与高效信号接收。在1–5 GHz宽频范围内保持高辐射效率并显著降低能量损耗，展示了材料与智能控制融合的创新性。该方案为下一代自适应射频系统提供了潜在方向，但在长期稳定性和复杂环境下的可靠性方面仍需进一步验证。

---

## 2. 面向生物医学应用的全纳米酶级联反应：从自级联纳米酶到固定化级联纳米酶

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388484)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41388484
**DOI：** 10.1002/advs.202519656

### 第一部分 原文与翻译

**英文原标题：** All Nanozyme-Based Cascade Reactions for Biomedical Applications: from Self-Cascading Nanozyme to Immobilized Cascade Nanozyme.

> **英文摘要：**
> As artificial substitutes for natural enzymes, nanozymes possess advantages such as high catalytic activity, low cost, excellent stability, and suitability for large-scale production. Inspired by the cascade reactions in biological systems, constructing cascade nanozyme systems with step-saving and high efficiency has been recognized as a key approach to enhancing the functional performance of nanozymes. With the discovery of more nanomaterials with various enzyme-like activities, especially the unique multi-enzyme activity of nanozymes, unprecedented opportunities have arisen for advancing biomimetic design to a higher level. Furthermore, aided by advanced tools such as theoretical calculations, the structural design and functional tuning of nanozymes have gradually become customizable and intelligent, significantly promoting their application in specific tasks ranging from biosensing to therapy. This review introduces the evolution of all-nanozyme cascade reaction systems from a self-cascading nanozyme system to immobilized nanozyme-based cascade catalytic system, and introduces key mechanistic insights and commonly used research methods to clarify their catalytic characteristics and design principles. A detailed classification of all-nanozyme cascade reaction systems is provided, and an analytical survey of recent applications of all-nanozyme cascade reaction systems in biosensing and therapy is covered. Finally, this review discusses the challenges that all-nanozyme cascade reaction systems may face in their application.

> **中文摘要：**
> 作为天然酶的人工替代物，纳米酶具有高催化活性、低成本、优异的稳定性以及适用于大规模生产等优势。受生物体系中级联反应的启发，构建具有节省步骤和高效率的级联纳米酶系统被认为是提升纳米酶功能性能的关键途径。随着越来越多具备不同类酶活性的纳米材料被发现，尤其是纳米酶所特有的多酶活性，为推动仿生设计迈向更高层次带来了前所未有的机遇。此外，在理论计算等先进工具的辅助下，纳米酶的结构设计与功能调控正逐渐实现可定制化与智能化，显著促进了其在从生物传感到治疗等特定任务中的应用。本综述介绍了全纳米酶级联反应体系从自级联纳米酶系统向固定化纳米酶基础的级联催化系统的演化，并阐述了关键的机理见解及常用研究方法，以明确其催化特性与设计原理。文中对全纳米酶级联反应体系进行了详细分类，并分析了其在生物传感与治疗中的最新应用。最后，本综述讨论了全纳米酶级联反应体系在应用中可能面临的挑战。

### 第二部分 AI 大师评价

本文系统梳理了全纳米酶级联反应体系的发展脉络，从自级联纳米酶到固定化级联纳米酶的转变揭示了设计理念的深化与性能优化。作者强调多酶活性纳米材料的发现以及理论计算等先进方法在可控设计中的关键作用，突出了纳米酶在生物传感与治疗领域的广阔前景。该综述兼具机制解析与方法总结，为未来实现智能化、模块化纳米酶催化体系提供了理论参考，但在临床应用与标准化评价方面仍需进一步研究。

---

## 3. OPTRACE：基于光学成像引导的小鼠脑内细胞移植与追踪技术

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388478)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41388478
**DOI：** 10.1002/advs.202514183

### 第一部分 原文与翻译

**英文原标题：** OPTRACE: Optical Imaging-Guided Transplantation and Tracking of Cells in the Mouse Brain.

> **英文摘要：**
> Intracerebral cell transplantation holds promise for treating stroke and neurological disorders, yet challenges in precise delivery and post-engraftment monitoring impede progress. This work introduces OPTRACE (OPtical imaging-guided Transplantation and tRAcking of CElls), a two-step optical framework integrating real-time visualization during transplantation with longitudinal post-transplantation in vivo cell tracking. Leveraging cost-effective translucent glass micropipettes and two innovative predictive mathematical modeling-the retention-depth model (predicts retained fraction versus injection depth) and the hypoperfusion-volume model (predicts hypoperfused fraction versus graft volume)-that this work fits to data (depth-retention R = 0.91; volume-growth R = 0.78)-OPTRACE optimizes delivery parameters to maximize engraftment and minimize hypoxia. A novel pulse-elevation injection technique further enhances the precision of superficial cortical retention. Following transplantation, multicolor labeling combined with two-photon fluorescence microscopy permits longitudinal single-cell tracking, revealing host microglial responses, and altered neuronal calcium signaling at the graft interface. OPTRACE provides micrometer precision, longitudinal dynamics and quantitative insights of cells during and after transplantation, accelerating mechanistic understanding and therapeutic development for regenerative cell therapies.

> **中文摘要：**
> 脑内细胞移植为中风和神经系统疾病的治疗带来了希望，但在精准递送和移植后监测方面的挑战仍阻碍了其发展。本研究提出了 OPTRACE（基于光学成像引导的细胞移植与追踪，OPtical imaging-guided Transplantation and tRAcking of CElls）技术，这是一种双步骤的光学成像框架，将移植过程中的实时可视化与移植后的活体细胞纵向追踪结合在一起。通过使用成本效益高的半透明玻璃显微注射管，以及两个创新的预测性数学模型——保留深度模型（预测注射深度与保留比例的关系）和低灌注体积模型（预测移植物体积与低灌注比例的关系）——并将这些模型与实验数据拟合（深度-保留相关系数 R = 0.91；体积-生长相关系数 R = 0.78），OPTRACE 优化了递送参数，以最大化细胞存活并最小化缺氧现象。一种新颖的脉冲提升注射技术进一步提高了浅层皮质区域中细胞保留的精确度。移植完成后，研究结合多色标记和双光子荧光显微成像，实现了细胞级别的长期追踪，揭示了宿主小胶质细胞的免疫反应及移植物边界处神经元钙信号的变化。OPTRACE 提供了微米级精度、纵向动态观察能力以及细胞在移植过程中的定量洞察，加速了对细胞再生治疗机制的理解与新疗法的开发。

### 第二部分 AI 大师评价

该研究旨在开发一种将光学成像与细胞移植相结合的新型技术体系，以提升脑内移植操作的精准性和后续细胞追踪能力。研究通过设计保留深度和低灌注模型，实现了对移植参数的定量优化，并创新性地引入脉冲提升注射法提升浅层皮质的保留效果。利用多色标记与双光子显微技术，研究者实现了细胞级长期动态成像，揭示了宿主免疫反应与神经信号变化。总体上，该研究在细胞治疗监测技术方面具有重要创新性，但在临床可转化性和深部脑区应用的拓展上仍需进一步验证。

---

## 4. 喉鳞状细胞癌（LSCC）非侵入性早期诊断揭示 HOXD10 基因单甲基化位点的高性能潜力：一项病例对照研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388430)
**期刊：** Clinical epigenetics
**PMID：** 41388430
**DOI：** 10.1186/s13148-025-02036-2

### 第一部分 原文与翻译

**英文原标题：** Noninvasive early diagnosis of laryngeal squamous cell carcinoma (LSCC) revealing the high-performance potential of the HOXD10 gene monomethylated locus: a case-control study.

> **英文摘要：**
> Laryngeal squamous cell carcinomas (LSCCs) was a frequent malignancy in upper aerodigestive tract. The lack of non-invasive biomarkers for early diagnosis has led to unfavorable prognosis. We firstly identified methylation biomarkers from TCGA and GEO databases. We further validated the diagnostic performance by utilizing blood samples obtained from 43 LSCCs and 50 normal controls (NCs). The HOXD10 cg10364040 was hypermethylated in tumors compared with NCs (P < 0.01), with an area under the curve (AUC) greater than 0.90 in each public database. In clinical validation phase, HOXD10 cg10364040 methylation was able to discriminate LSCCs from NCs with high accuracy (AUC = 0.767, sensitivity: 72.1%, specificity: 82.0%), and exhibited greater sensitivity (85.0%) and specificity (86.0%) in stage I patients than in NCs (AUC = 0.864). In summary, we firstly identified cg10364040 as a novel diagnosis biomarker of LSCC and confirmed it as a noninvasive biomarker in clinical.

> **中文摘要：**
> 喉鳞状细胞癌（LSCC）是上消化呼吸道常见的恶性肿瘤。缺乏用于早期诊断的非侵入性生物标志物导致预后不良。我们首先从 TCGA 和 GEO 数据库中筛选出甲基化生物标志物。随后，我们利用来自 43 例 LSCC 患者和 50 名正常对照（NC）的血样，进一步验证其诊断性能。与正常对照相比，HOXD10 cg10364040 在肿瘤中表现出高甲基化（P < 0.01），且在各公共数据库中的曲线下面积（AUC）均大于 0.90。在临床验证阶段，HOXD10 cg10364040 甲基化能够以较高准确度区分 LSCC 与正常对照（AUC = 0.767，灵敏度：72.1%，特异度：82.0%），并在 I 期患者中表现出更高的灵敏度（85.0%）和特异度（86.0%）（AUC = 0.864）。总之，我们首次鉴定出 cg10364040 为 LSCC 的新型诊断生物标志物，并在临床中证实其作为非侵入性生物标志物的可行性。

### 第二部分 AI 大师评价

本研究旨在通过甲基化组学分析发现用于喉鳞状细胞癌（LSCC）早期无创诊断的新型生物标志物。研究者结合 TCGA 与 GEO 公共数据库筛选出 HOXD10 cg10364040 位点，并使用患者血样进行验证，结果显示其在区分 LSCC 与正常人群中具有较高的诊断准确性。该位点在 I 期病例中依然保持优异的灵敏度与特异度，显示其早筛潜力。研究创新地提出 HOXD10 单甲基化位点的临床应用价值，但样本量较小和单中心验证限制了其推广性。

---

## 5. 用于强化肿瘤治疗的细菌工程：从表面修饰到合成遗传回路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388424)
**期刊：** Journal of hematology & oncology
**PMID：** 41388424
**DOI：** 10.1186/s13045-025-01766-3

### 第一部分 原文与翻译

**英文原标题：** Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits.

> **英文摘要：**
> Bacterial therapy represents a promising strategy for cancer treatment, in which tumor regression can be achieved through bacteria-mediated immunotherapy. The mechanisms involve disrupting cellular metabolism, inducing apoptosis, delivering therapeutic agents, and enhancing anticancer immune responses. Naturally occurring bacteria possess inherent advantages in biocompatibility and self-propulsion. Facultative anaerobic species, such as Salmonella, can increase tumor accumulation by more than tenfold through the enhanced permeability and retention (EPR) effect. However, the application of native bacterial therapy is limited by its toxicity and unstable colonization in vivo at disease sites. The negatively charged bacterial surface and abundant functional groups enable surface modifications through ionic interactions or covalent bonding. These approaches include modifying lipopolysaccharides and capsules that trigger in vivo toxicity, or coating bacteria with exogenous nanomaterials to achieve detoxification and construct drug delivery platforms. Furthermore, gene editing and synthetic genetic circuit strategies allow the precise engineering of bacteria to improve tumor targeting, reduce pathogenicity, and endow them with novel anticancer functions. This review discusses the routes of bacterial administration, surface engineering strategies, synthetic circuit design, and clinical translation in bacteria-mediated cancer immunotherapy. It comprehensively summarizes the historical progress, advantages, and distinctive features of bacterial therapy, with a particular emphasis on recent advances in synthetic gene circuit design. Finally, the review highlights the clinical translation prospects and existing challenges of bacteria-mediated tumor therapy, aiming to ensure biosafety, prevent unintended immune responses, and promote large-scale clinical applications in cancer treatment.

> **中文摘要：**
> 细菌治疗代表了一种有前景的癌症治疗策略，其中肿瘤退缩可以通过细菌介导的免疫治疗实现。其机制涉及破坏细胞代谢、诱导细胞凋亡、递送治疗剂以及增强抗癌免疫反应。天然存在的细菌在生物相容性和自我推进方面具有内在优势。兼性厌氧菌种，如沙门菌，可通过增强的通透性与滞留（EPR）效应，使其在肿瘤中的富集提高超过十倍。然而，天然细菌治疗的应用受到其毒性及疾病部位体内定植不稳定性的限制。细菌表面的负电荷及丰富的官能团使其可通过离子相互作用或共价键形成实现表面修饰。这些方法包括修饰可引发体内毒性的脂多糖和荚膜，或通过外源纳米材料包覆细菌以实现解毒并构建药物递送平台。此外，基因编辑和合成遗传回路策略能够精确地改造细菌，以改善肿瘤靶向性、降低致病性，并赋予其新的抗癌功能。本综述讨论了细菌给药途径、表面工程策略、合成遗传回路设计及其在细菌介导癌症免疫治疗中的临床转化。本文全面总结了细菌治疗的历史进展、优势与独特特征，特别强调了合成基因回路设计的最新发展。最后，综述指出了细菌介导肿瘤治疗的临床转化前景和现存挑战，旨在确保生物安全性、防止意外免疫反应，并促进其在癌症治疗中的大规模临床应用。

### 第二部分 AI 大师评价

该综述系统阐述了细菌介导的肿瘤免疫治疗的机制与工程化策略，覆盖了表面修饰、基因编辑及合成遗传回路等领域。文章突出细菌在生物相容性、自我定位与药物递送方面的独特优势，并分析了天然菌株毒性与定植稳定性的瓶颈。其创新性体现在整合纳米材料包覆与合成回路设计，为实现高效且安全的抗肿瘤细菌提供了新思路。然而，体内毒性控制及临床可扩展性仍是未来亟需突破的关键问题。

---

## 6. NKG2D特异性CAR-巨噬细胞通过协同的先天与适应性免疫作用驱动肝细胞癌的持久缓解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388305)
**期刊：** Molecular cancer
**PMID：** 41388305
**DOI：** 10.1186/s12943-025-02538-w

### 第一部分 原文与翻译

**英文原标题：** Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.

> **英文摘要：**
> BACKGROUND: Hepatocellular carcinoma (HCC) immunotherapy is limited by antigenic heterogeneity and an immunosuppressive microenvironment. This study engineered chimeric antigen receptor macrophages (CAR-Ms) targeting stress-inducible NKG2D ligands (NKG2DLs), broadly overexpressed in HCC, to enhance phagocytic clearance and remodel immunity.
> 
> METHODS: NKG2DL expression in HCC and association with survival were analyzed. CAR-Ms were constructed by fusing the NKG2D extracellular domain to FcγRI signaling. In vitro assays assessed phagocytosis, cytokine secretion, signaling, and T cell interactions. Therapeutic efficacy was evaluated in immunocompetent mice bearing subcutaneous, orthotopic, or metastatic HCC models, with or without anti-PD-L1. Tumor progression, immunity, and survival were analyzed via bioluminescence imaging, flow cytometry, histopathology, and serum biochemistry. Statistics analyses were performed using t-tests, ANOVA, and log-rank tests.
> 
> RESULTS: NKG2DLs were significantly upregulated in human HCC and correlated with poor prognosis. CAR-Ms selectively engulfed NKG2DL⁺ tumor cells, polarized to an M1 phenotype, and activated PI3K-AKT and cGAS-STING pathways, driving phagocytosis and pro-inflammatory cytokines secretion. They enhanced T cell chemokines (Cxcl10, Ccl5) and antigen presentation, boosting T cell recruitment and activation in vitro. In subcutaneous models, CAR-Ms suppressed tumor growth, reprogrammed tumor-associated myeloid cells toward M1, and induced durable immune memory (100% tumor rejection upon rechallenge), with T cell activation. In orthotopic models, CAR-M monotherapy induced complete regression by week 5 and 100% survival, with elevated CD8⁺ T cells and CAR-M specifically homing to liver tumors. CAR-Ms suppressed metastasis in peritoneal/pulmonary models. Combining CAR-Ms with PD-L1 blockade accelerated tumor clearance and survival versus monotherapies, enhancing T cell cytotoxicity. Safety assessments showed no significant organ toxicity based on histopathology and serum biochemistry.
> 
> CONCLUSIONS: NKG2D-directed CAR-Ms eliminate HCC through integrated innate phagocytosis, adaptive immune activation, and myeloid reprogramming, overcoming key therapeutic barriers. Combination with anti-PD-L1 enhances therapeutic efficacy by leveraging innate-adaptive crosstalk, providing a promising approach for HCC immunotherapy.

> **中文摘要：**
> 背景：肝细胞癌（HCC）的免疫治疗受到抗原异质性和免疫抑制性微环境的限制。本研究设计了针对应激诱导型NKG2D配体（NKG2DLs）的嵌合抗原受体巨噬细胞（CAR-Ms），这些配体在HCC中普遍过表达，旨在增强吞噬清除能力并重塑免疫反应。
> 
> 方法：分析了HCC中NKG2DL的表达及其与生存的关系。通过将NKG2D的细胞外结构域与FcγRI信号结构融合构建CAR-Ms。体外实验评估了吞噬作用、细胞因子分泌、信号通路活化及与T细胞的相互作用。通过带有皮下、原位或转移性HCC模型的免疫健全小鼠，分别在是否联合抗PD-L1治疗的情况下，评估其治疗效果。采用生物发光成像、流式细胞术、组织病理学和血清生化分析肿瘤进展、免疫状态及生存情况。统计分析采用t检验、方差分析及log-rank检验。
> 
> 结果：在人HCC中，NKG2DL显著上调，并与不良预后相关。CAR-Ms能选择性吞噬NKG2DL⁺肿瘤细胞，极化为M1型表型，并激活PI3K-AKT和cGAS-STING信号通路，促进吞噬作用和促炎性细胞因子分泌。CAR-Ms还增强了T细胞趋化因子（Cxcl10、Ccl5）表达及抗原呈递，体外促进T细胞募集与激活。在皮下肿瘤模型中，CAR-Ms抑制肿瘤生长，重编程肿瘤相关髓系细胞向M1型转化，并诱导持久免疫记忆（再次挑战后100%肿瘤排斥），伴随T细胞活化。在原位模型中，CAR-M单药治疗于第5周实现完全肿瘤回归并获得100%生存率，伴随CD8⁺ T细胞升高及CAR-M特异性归巢至肝脏肿瘤部位。在腹膜及肺转移模型中，CAR-Ms抑制了转移。联合CAR-M与PD-L1阻断较单药治疗更快清除肿瘤并延长生存，增强T细胞细胞毒性。安全性评估显示，依据组织病理和血清生化指标，未见明显器官毒性。
> 
> 结论：NKG2D导向的CAR-M通过整合先天吞噬作用、适应性免疫激活与髓系重编程，有效清除HCC并克服关键治疗障碍。与抗PD-L1联合应用通过促进先天-适应性免疫串联显著提升疗效，为HCC免疫治疗提供了有前景的策略。

### 第二部分 AI 大师评价

该研究旨在通过NKG2D特异性CAR-巨噬细胞实现对肝细胞癌的高效免疫清除，突破HCC免疫治疗中抗原异质性和免疫抑制的瓶颈。研究系统探讨了CAR-M的构建、分子信号机制、免疫重编程效应及其与T细胞协同作用。结果显示CAR-M不仅能直接吞噬肿瘤，还能激活T细胞免疫记忆，与PD-L1阻断协同增强抗肿瘤效应。该研究创新性地将先天与适应性免疫联动用于HCC治疗，虽体内验证充分，但仍需进一步临床评估其安全性与持久疗效。

---

## 7. 作者更正：揭示与半胱氨酸缺乏相关的快速体重下降机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388205)
**期刊：** Nature
**PMID：** 41388205
**DOI：** 10.1038/s41586-025-09780-8

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Unravelling cysteine-deficiency-associated rapid weight loss.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为一篇作者更正说明，表明原始研究在探讨半胱氨酸缺乏与快速体重下降之间的关系中可能存在修订或勘误。尽管正文摘要缺失，但主题暗示研究聚焦于代谢调控与氨基酸营养之间的关联机制。此类更正对确保科研成果的准确性与学术透明度具有重要意义，也提示研究人员需在实验设计与数据解释中保持严格标准。

---

## 8. 作者更正：癌症相关的 SLC43A2 改变了 T 细胞的蛋氨酸代谢和组蛋白甲基化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388204)
**期刊：** Nature
**PMID：** 41388204
**DOI：** 10.1038/s41586-025-09845-8

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Cancer SLC43A2 alters T cell methionine metabolism and histone methylation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 摘要不可用。

### 第二部分 AI 大师评价

这篇文献为原始研究的作者更正声明，涉及癌症细胞中转运蛋白 SLC43A2 对 T 细胞蛋氨酸代谢及组蛋白甲基化的调控作用。虽然正文措辞较简短，但其主题反映了代谢通路与免疫调控之间的重要交叉点。该更正确保了研究数据及结论的准确性，也体现出作者对科研严谨性的重视。整体上，此修正为后续相关免疫代谢研究提供了可靠的参考基线。

---

## 9. 靶向急性髓系白血病中 RUNX1 移码突变的 T 细胞受体研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388195)
**期刊：** Leukemia
**PMID：** 41388195
**DOI：** 10.1038/s41375-025-02817-x

### 第一部分 原文与翻译

**英文原标题：** A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.

> **英文摘要：**
> Runt-related transcription factor 1 (RUNX1) is a key regulator of hematopoietic differentiation. RUNX1 mutations in acute myeloid leukemia (AML) are associated with poor prognosis. One-third are frameshift mutations encoding an oncogenic protein with an elongated C-terminus translated in an alternative reading frame. Here, we investigated whether the alternative reading frame of oncogenic RUNX1 can be targeted by immunotherapy. We introduced a construct with a RUNX1 frameshift mutation into B-cell lines with common HLA class I alleles and identified 13 neopeptides by immunopeptidomics. To investigate whether these peptides are neoantigens, peptide-MHC tetramers were used to screen healthy individuals for RUNX1 neoantigen-specific CD8 T cells. T-cell clones were isolated against 5 neoantigens in 4 HLA alleles. Two neoantigens were recognized on an HLA-B*07:02-positive AML cell line with an endogenous RUNX1 frameshift mutation. The T-cell receptors (TCRs) of these clones were sequenced, and analyzed after transfer into CD8 T cells. One TCR induced effective killing of RUNX1-mutated AML cells in vitro and in immunodeficient mice. TCR-engineered T cells also killed patient-derived AML cells, including leukemic stem cells. In conclusion, we showed that RUNX1 frameshift mutations can be effectively targeted, demonstrating the potential relevance of TCR-based immunotherapy to treat patients with RUNX1-mutated AML.

> **中文摘要：**
> Runt相关转录因子1（RUNX1）是造血分化的重要调控因子。急性髓系白血病（AML）中的RUNX1突变与预后不良相关。其中约三分之一为移码突变，可编码一种C端延长并在替代阅读框中翻译的致癌蛋白。在本研究中，我们探讨了肿瘤性RUNX1的替代阅读框能否作为免疫治疗靶点。我们将含RUNX1移码突变的构建体导入具有常见HLA-I类等位基因的B细胞系中，并通过免疫肽组学鉴定出13种新生肽。为确定这些肽是否为新抗原，我们利用肽-MHC四聚体在健康人群中筛选RUNX1新抗原特异性的CD8 T细胞。针对4种HLA等位基因共分离出识别5种新抗原的T细胞克隆。其中有两种新抗原被携带内源性RUNX1移码突变且为HLA-B*07:02阳性的AML细胞系识别。我们对这些克隆的T细胞受体（TCR）进行测序，并在其转入CD8 T细胞后进行分析。其中一个TCR可在体外及免疫缺陷小鼠体内有效杀伤RUNX1突变的AML细胞。TCR工程化T细胞亦可杀伤来源于患者的AML细胞，包括白血病干细胞。综上所述，我们证明了RUNX1移码突变可被有效靶向，显示了基于TCR的免疫治疗用于治疗RUNX1突变型AML患者的潜在价值。

### 第二部分 AI 大师评价

该研究聚焦于急性髓系白血病中RUNX1移码突变，探索其是否可成为TCR介导免疫治疗的新靶点。研究者通过免疫肽组学鉴定新生肽，并成功分离识别多种HLA等位基因新抗原的CD8 T细胞克隆。进一步验证表明特定TCR可有效杀伤RUNX1突变的AML细胞，包括患者来源的白血病干细胞。这项工作为靶向特定移码突变的个体化免疫疗法提供了关键实验依据，其创新性在于首次实现对RUNX1移码新抗原的功能验证，但未来仍需在临床有效性与安全性上进一步评估。

---

## 10. 肠道细菌来源的鞘脂改变对口服霍乱疫苗抗原的先天免疫反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388019)
**期刊：** Nature communications
**PMID：** 41388019
**DOI：** 10.1038/s41467-025-67388-y

### 第一部分 原文与翻译

**英文原标题：** Gut bacteria-derived sphingolipids alter innate immune responses to oral cholera vaccine antigens.

> **英文摘要：**
> The degree of protection conferred after receiving an oral cholera vaccine (OCV) varies based on age, prior exposure to Vibrio cholerae, and unknown factors. Recent evidence suggests that the microbiota may mediate some of the unexplained differences in oral vaccine responses. Here, we use metagenomic sequencing of the fecal microbiota at the time of vaccination and relate microbial features to immune responses after OCV using a reference-independent gene-level method. We find that the presence of sphingolipid-producing bacteria is associated with the development of protective immune responses after OCV. We test these associations by stimulating human macrophages with Bacteroides xylanisolvens metabolites and find that sphingolipid-containing extracts increase innate immune responses to OCV antigens. Our findings demonstrate a new analytic method for translating metagenomic sequencing data into strain-specific results associated with a biological outcome, and in validating this tool, we identify that microbe-derived sphingolipids impact immune responses to OCV antigens.

> **中文摘要：**
> 口服霍乱疫苗（OCV）所赋予的保护程度会因年龄、既往霍乱弧菌暴露史以及未知因素而异。最新证据表明，肠道微生物群可能介导了部分难以解释的口服疫苗反应差异。在本研究中，我们在接种时对粪便微生物群进行宏基因组测序，并使用一种无参考、以基因水平为单位的方法，将微生物特征与OCV后的免疫反应相关联。我们发现，具有鞘脂生成能力的细菌的存在与OCV后保护性免疫反应的形成相关。我们通过用木聚糖崩解拟杆菌（Bacteroides xylanisolvens）的代谢产物刺激人源巨噬细胞来验证这种关联，结果发现含鞘脂的提取物可增强对OCV抗原的先天免疫反应。我们的研究展示了一种新的分析方法，可将宏基因组测序数据转化为与生物学结果相关的菌株特异性信息。在验证此工具的过程中，我们确定了微生物来源的鞘脂会影响对OCV抗原的免疫反应。

### 第二部分 AI 大师评价

该研究探讨了肠道菌群代谢产物鞘脂如何影响口服霍乱疫苗的免疫效果。研究者结合宏基因组测序与功能验证实验，揭示了鞘脂产生菌与保护性免疫反应之间的正相关。通过代谢物刺激实验，他们进一步证明了鞘脂可增强先天免疫反应。该工作在方法上创新性地实现了基于宏基因组数据的功能推断，为微生物调控疫苗应答的机制研究提供了新思路，但样本规模及临床验证仍需进一步扩展。

---

## 11. 知识引导的病理基础模型自适应有效提升跨域泛化能力和人口公平性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387953)
**期刊：** Nature communications
**PMID：** 41387953
**DOI：** 10.1038/s41467-025-66300-y

### 第一部分 原文与翻译

**英文原标题：** Knowledge-guided adaptation of pathology foundation models effectively improves cross-domain generalization and demographic fairness.

> **英文摘要：**
> Foundation models in computational pathology suffer from site-specific and demographic biases, which compromise their generalizability and fairness. We introduce FLEX, a framework that employs a task-specific information bottleneck, guided by visual and textual domain knowledge, to disentangle robust pathological features from these artifacts. Using three large cohorts (The Cancer Genome Atlas, Clinical Proteomic Tumor Analysis Consortium, and an in-house dataset) across 16 clinical tasks, totaling over 9,900 slides, we demonstrate that FLEX achieves superior zero-shot generalization to unseen external cohorts, significantly outperforming baselines and narrowing the performance gap between seen and unseen domains. A comprehensive fairness analysis confirms that FLEX also effectively mitigates disparities across demographic groups. Furthermore, its versatility and scalability are proven through compatibility with various foundation models and multiple-instance learning architectures. Our work establishes FLEX as a promising solution for developing more generalizable and equitable pathology AI for diverse clinical settings.

> **中文摘要：**
> 计算病理学中的基础模型受到特定机构和人口学偏倚的影响，从而削弱了其泛化性和公平性。我们提出了一个名为 FLEX 的框架，该框架利用由视觉和文本领域知识引导的任务特定信息瓶颈，从这些伪影中分离出稳定的病理特征。通过在三大队列（癌症基因组图谱、临床蛋白质组肿瘤分析联盟以及一个内部数据集）上涵盖16项临床任务、共计9,900余张切片的实验，我们证明了 FLEX 在对未知外部队列的零样本泛化方面表现优越，显著优于基线模型，并缩小了已知与未知域之间的性能差距。全面的公平性分析进一步证实，FLEX 也能有效减少不同人口群体间的差异。此外，其兼容性和可扩展性通过与多种基础模型和多实例学习架构的适配得到验证。我们的研究确立了 FLEX 作为一种有前景的方案，可用于开发更具泛化性与公平性的病理人工智能系统，以适应多样化的临床场景。

### 第二部分 AI 大师评价

该研究聚焦于计算病理基础模型在跨域泛化和人口公平性方面的挑战，提出了融合领域知识的自适应框架 FLEX，通过信息瓶颈机制提炼稳健的病理特征。在多任务、多数据集的验证中，FLEX 展现出显著优于传统模型的跨域性能与公平性提升。该方法具有良好的兼容性和可扩展性，为构建更通用且公平的病理 AI 系统提供了新思路。然而，其实际部署仍需在更多真实临床环境中进一步验证。

---

## 12. 靶向ATR在膀胱癌中通过RAD51介导的代偿性DNA修复提供多层次治疗策略。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387887)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41387887
**DOI：** 10.1186/s13046-025-03603-4

### 第一部分 原文与翻译

**英文原标题：** Targeting ATR offers multifaceted treatment strategies involving RAD51-mediated compensatory DNA repair in bladder cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究聚焦ATR在膀胱癌中的关键作用，探讨以ATR为靶点的多维治疗策略及其与RAD51介导的DNA修复机制之间的关系。尽管正文摘要缺失，但从题目可推测作者可能在揭示ATR抑制引发的DNA损伤应答以及其通过RAD51途径的补偿性修复机制上有新的发现。该研究有望为膀胱癌精准治疗提供新的分子靶点，同时也可能揭示耐药形成的潜在路径。然而，缺乏摘要和数据使其具体实验设计与验证结果尚待进一步确认。

---

## 13. 更正：氨基酸转运体LAT1（SLC7A5）通过L-色氨酸/QPRT/NAD通路促进三阴性乳腺癌进展中的代谢重塑。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387876)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41387876
**DOI：** 10.1186/s13046-025-03611-4

### 第一部分 原文与翻译

**英文原标题：** Correction: Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD pathway.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该文为对先前研究的更正，主要涉及LAT1（SLC7A5）在三阴性乳腺癌代谢重塑中的作用。原研究揭示LAT1通过调控L-色氨酸/QPRT/NAD代谢通路促进癌细胞生长与进展，提示其作为潜在代谢靶点具有重要意义。本次更正可能涉及数据或描述性修订，显示作者对研究准确性的重视。尽管摘要缺失，但标题信息已表明研究在肿瘤代谢网络解析中的创新性价值。

---

## 14. 常见疾病中循环蛋白质组的遗传图谱揭示潜在致病蛋白并提升风险预测能力

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387722)
**期刊：** Nature communications
**PMID：** 41387722
**DOI：** 10.1038/s41467-025-67238-x

### 第一部分 原文与翻译

**英文原标题：** Genetic profiling of the circulating proteome in common diseases suggests causal proteins and improves risk prediction.

> **英文摘要：**
> Elucidating the genetic regulation of protein expression in specific disease states is important for understanding how genetic variation impact disease pathology. To this end, we conduct a large-scale genome-proteome-wide pQTL analysis on 2901 plasma proteins among 7626 healthy individuals and 28,064 patients across 42 disease statuses. We find 25,987 independent pQTL associations across 2224 regions, and investigate similarities and differences in their regulatory effects across various diseases and health states. We find that pQTL identified in specific diseases are more likely to be disease risk variants. We then integrate the association findings with Mendelian randomisation to identify 110 high-confidence causal proteins associated with 21 diseases, including Apolipoprotein(a) for cardiovascular diseases and angiotensin-converting enzyme for type 2 diabetes. Finally, we develop risk prediction models by integrating pQTL-derived polygenic risk scores and causal-protein-derived protein risk scores, which demonstrate good performance in discriminating populations at high risk for 21 disease types. These results indicate that disease state partly determines the impact of genetic variation on protein expression, implicating disease-related and disease-discordant pQTL associations as regulators of disease progression.

> **中文摘要：**
> 阐明蛋白表达在特定疾病状态下的遗传调控，对于理解遗传变异如何影响疾病病理具有重要意义。为此，我们在7626名健康个体和28,064名来自42种疾病状态的患者中，对2901种血浆蛋白进行了大规模全基因组-蛋白质组关联（pQTL）分析。我们共发现25,987个独立的pQTL关联，分布于2224个基因组区域，并探讨了它们在不同疾病及健康状态下调控效应的相似性与差异。我们发现，在特定疾病中识别到的pQTL更可能为疾病风险变异。随后，我们将关联结果与孟德尔随机化分析相结合，鉴定出110种与21种疾病相关的高置信度致因蛋白，其中包括与心血管疾病相关的载脂蛋白(a)及与2型糖尿病相关的血管紧张素转换酶。最后，我们构建了风险预测模型，将pQTL导出的多基因风险评分与因果蛋白导出的蛋白风险评分进行整合，该模型在区分21种疾病类型的高风险人群中表现出良好性能。这些结果表明，疾病状态在一定程度上决定了遗传变异对蛋白表达的影响，并暗示疾病相关及疾病不一致的pQTL关联可能作为疾病进展的调控因子。

### 第二部分 AI 大师评价

本研究通过跨越42种疾病状态的大规模基因组-蛋白质组关联分析，系统揭示了遗传变异对血浆蛋白表达的调控特征。研究利用健康与疾病状态的比较，发现特定疾病相关的pQTL更可能为风险变异，并通过孟德尔随机化确认了若干潜在致因蛋白。将pQTL与蛋白水平风险模型结合有效提升了疾病风险预测能力。该研究创新性地把基因-蛋白信息与临床风险建模相融合，为精准医学中的分子风险评估提供了新策略，但仍需在更广泛的族群中验证其可推广性。

---

## 15. 癌症诊断患者中心理困扰与死亡率关联的中介因素。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387699)
**期刊：** Nature communications
**PMID：** 41387699
**DOI：** 10.1038/s41467-025-66059-2

### 第一部分 原文与翻译

**英文原标题：** Mediators of the association between psychological distress and mortality in people diagnosed with cancer.

> **英文摘要：**
> The biological and behavioural mechanisms linking psychological distress to excess mortality in people living with and beyond cancer (LWBC) remain poorly understood. In this multi-cohort study, we examine the associations between psychological distress and both cancer-specific and all-cause mortality in individuals living with and beyond cancer (LWBC), and assess the potential mediating roles of inflammation and health behaviours. The primary analysis includes 13,349 adults from the UK Biobank (2006-2021), with replication in 5739 participants from the Finnish Public Sector study (2000-2018). Psychological distress is associated with an increased risk of all-cause mortality (pooled adjusted risk ratio (RR), 1.54; 95% confidence interval (CI), 1.37-1.74) and cancer mortality (pooled RR, 1.57; 95% CI, 1.37-1.79). Systemic inflammation explains up to 18.6% of these associations, whereas diet, alcohol consumption, and body mass index do not mediate these relationships. Evidence for mediation by other health behaviours is inconsistent. While adjustment for cancer stage attenuates the distress-mortality link by up to 25%, psychological distress remains a robust predictor of both all-cause and cancer mortality. These findings suggest that psychological distress is an independent predictor of mortality risk in people with LWBC, partially attributable to elevated levels of systemic inflammation.

> **中文摘要：**
> 将心理困扰与癌症患者的过度死亡联系起来的生物学和行为学机制仍然知之甚少。在这项多队列研究中，我们考察了在癌症存活及康复人群中（LWBC），心理困扰与癌症特异性死亡率及全因死亡率的关联，并评估炎症及健康行为的潜在中介作用。主要分析纳入了来自英国生物样本库（2006–2021）的13,349名成年人，并在芬兰公共部门研究（2000–2018）的5,739名参与者中进行了重复验证。结果显示，心理困扰与全因死亡风险增加相关（综合调整风险比（RR）为1.54；95%置信区间（CI）为1.37–1.74）以及癌症死亡风险增加（综合RR为1.57；95% CI为1.37–1.79）。全身炎症可解释这些关联中高达18.6%的部分，而饮食、酒精摄入及体重指数并不在其中起中介作用。其他健康行为的中介证据则不一致。虽然校正癌症分期可使心理困扰与死亡之间的联系减弱约25%，但心理困扰仍是全因及癌症死亡率的稳健预测因子。这些发现表明，心理困扰是癌症存活人群死亡风险的独立预测因素，部分可归因于系统性炎症水平的升高。

### 第二部分 AI 大师评价

该研究利用英国生物样本库与芬兰公共部门两项大型队列数据，系统分析了心理困扰与癌症特异性及全因死亡的关系，并探讨炎症与健康行为的中介作用。结果表明，心理困扰独立增加死亡风险，部分可由系统性炎症解释，而生活方式因素作用有限。研究在方法学上具有较强的验证性和跨队列一致性，但仍受癌症阶段调整及潜在混杂因素限制。整体上，为理解心理健康与癌症预后的生物行为机制提供了坚实证据。

---

## 16. USP29 和 SMURF1 协同调控 FSP1 介导的铁死亡抑制，从而促进胃癌化疗耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387682)
**期刊：** Nature communications
**PMID：** 41387682
**DOI：** 10.1038/s41467-025-66319-1

### 第一部分 原文与翻译

**英文原标题：** USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.

> **英文摘要：**
> Gastric cancer (GC) ranks as the third leading cause of cancer-related mortality. Chemoresistance poses a major obstacle to successful treatment for GC patients. Here, we demonstrate that ferroptosis suppressor protein 1 (FSP1) enables chemoresistance in GC by inhibiting ferroptosis, resulting in diminished chemotherapy response and reduced patient survival rate. USP29 and SMURF1 are subsequently discovered as the deubiquitinase and E3 ligase of FSP1, respectively, orchestrating the ubiquitination of FSP1 to modulate ferroptosis and chemoresistance in GC. In the ubiquitination process, SMURF1 is observed to interact with and polyubiquitinate FSP1 within K63/K193 sites. Notably, pharmacological inhibition of FSP1 by iFSP1 is shown to synergize with chemotherapeutic agents across chemoresistant cellular and mouse models. Our findings thus underscore the pivotal role of the USP29 and SMURF1 in regulating GC chemoresistance via FSP1-mediated ferroptosis suppression. FSP1 inhibition may represent a promising therapeutic avenue to overcome chemoresistance in GC.

> **中文摘要：**
> 胃癌（GC）是癌症相关死亡的第三大原因。化疗耐药是影响胃癌患者治疗成功的主要障碍。本研究表明，铁死亡抑制蛋白1（FSP1）通过抑制铁死亡，促进胃癌细胞的化疗耐药，导致化疗反应减弱及患者生存率下降。进一步发现，USP29 和 SMURF1 分别作为 FSP1 的去泛素化酶和 E3 泛素连接酶，共同调控 FSP1 的泛素化修饰，从而影响铁死亡和化疗耐药过程。在此泛素化过程中，观察到 SMURF1 可与 FSP1 相互作用，并在 K63/K193 位点促进其多泛素化。值得注意的是，药理学抑制剂 iFSP1 对 FSP1 的抑制作用能与化疗药物产生协同效应，在耐药细胞及小鼠模型中均表现出增强的抗癌效果。研究结果强调了 USP29 与 SMURF1 通过 FSP1 介导的铁死亡抑制在胃癌化疗耐药调控中的关键作用。抑制 FSP1 可能为克服胃癌化疗耐药提供一种有前景的治疗策略。

### 第二部分 AI 大师评价

该研究聚焦于铁死亡抑制机制在胃癌化疗耐药中的作用，揭示了 USP29 与 SMURF1 通过调控 FSP1 泛素化过程共同抑制铁死亡，从而推动耐药形成。研究采用细胞与动物模型，系统阐明了分子层面的调控关系，并验证了药物抑制 FSP1 的联合治疗潜力。其创新性在于首次界定了 USP29-SMURF1-FSP1 轴在胃癌化疗耐药机制中的作用，为靶向铁死亡通路逆转耐药提供新思路。但后续仍需开展临床验证以评估该机制的治疗可行性与安全性。

---

## 17. 葡萄膜黑色素瘤驱动基因突变的早期遗传演化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387680)
**期刊：** Nature communications
**PMID：** 41387680
**DOI：** 10.1038/s41467-025-66428-x

### 第一部分 原文与翻译

**英文原标题：** Early genetic evolution of driver mutations in uveal melanoma.

> **英文摘要：**
> Uveal melanoma (UM) is an aggressive eye cancer that frequently results in metastatic death despite successful primary tumor treatment. Subclinical micrometastasis is thought to occur early, when tumors are small and difficult to distinguish from benign nevi. However, the early genetic evolution of UM is poorly understood, and biomarkers for malignant transformation are lacking. Here, we perform integrated genetic profiling of 1140 primary UMs, including 131 small tumors. A clinically available 15-gene expression profile (15-GEP) prospectively validated by our group is more accurate than driver mutations for predicting patient survival. Small tumors are significantly more likely to be in earlier stages of genetic evolution than larger tumors. Further, the 15-GEP support vector machine discriminant score predicts small tumors undergoing transformation from low-risk Class 1 to high-risk Class 2 profile. These results shed light on the early genetic evolution of UM and move us closer to a molecular definition of malignant transformation in this cancer type.

> **中文摘要：**
> 葡萄膜黑色素瘤（UM）是一种侵袭性眼部癌症，尽管原发肿瘤治疗成功，却常常导致转移性死亡。据信，亚临床微转移在肿瘤尚小时便已发生，此时肿瘤难以与良性痣区分。然而，UM的早期遗传演化尚不清楚，缺乏恶性转化的生物标志物。本研究对1140例原发性UM进行综合遗传谱分析，其中包括131个小体积肿瘤。我们课题组前瞻性验证的临床可用15基因表达谱（15-GEP）在预测患者生存方面较驱动突变更为准确。结果显示，小肿瘤显著更可能处于遗传演化的早期阶段。进一步分析表明，15-GEP支持向量机判别得分可预测小肿瘤从低风险的1类向高风险的2类谱型转化。这些结果揭示了UM早期遗传演化的特征，并使我们更接近于该癌种恶性转化的分子学定义。

### 第二部分 AI 大师评价

该研究旨在揭示葡萄膜黑色素瘤从早期发展到恶性阶段的遗传演化规律。研究团队对超过一千例原发性病例进行了大规模整合基因分析，并验证了15基因表达谱在预后预测中的优越性。结果指出小肿瘤处于更早的遗传演化阶段，并能通过机器学习模型区分潜在转化风险。该研究为建立UM恶性转化的分子标准提供了关键线索，但仍需在纵向样本与功能验证方面进一步深入。

---

## 18. 一种多模态知识增强的全视野病理学基础模型

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387679)
**期刊：** Nature communications
**PMID：** 41387679
**DOI：** 10.1038/s41467-025-66220-x

### 第一部分 原文与翻译

**英文原标题：** A multimodal knowledge-enhanced whole-slide pathology foundation model.

> **英文摘要：**
> Computational pathology has advanced through foundation models, yet faces challenges in multimodal integration and capturing whole-slide context. Current approaches typically utilize either vision-only or image-caption data, overlooking distinct insights from pathology reports and gene expression profiles. Additionally, most models focus on patch-level analysis, failing to capture comprehensive whole-slide patterns. Here we present mSTAR (Multimodal Self-TAught PRetraining), the pathology foundation model that incorporates three modalities: pathology slides, expert-created reports, and gene expression data, within a unified framework. Our dataset includes 26,169 slide-level modality pairs across 32 cancer types, comprising over 116 million patch images. This approach injects multimodal whole-slide context into patch representations, expanding modeling from single to multiple modalities and from patch-level to slide-level analysis. Across oncological benchmark spanning 97 tasks, mSTAR outperforms previous state-of-the-art models, particularly in molecular prediction and multimodal tasks, revealing that multimodal integration yields greater improvements than simply expanding vision-only datasets.

> **中文摘要：**
> 计算病理学通过基础模型取得了重大进展，但在多模态整合和捕捉全视野上下文方面仍面临挑战。当前方法通常仅利用视觉数据或图像-描述数据，忽略了病理报告和基因表达特征所提供的独特信息。此外，大多数模型专注于图像块级分析，未能捕捉完整的全视野模式。在本研究中，我们提出了 mSTAR（多模态自学习预训练）病理学基础模型，该模型在统一框架内融合了三种模态：病理切片、专家撰写的病理报告以及基因表达数据。我们的数据集涵盖32种癌症类型，共计26,169个切片级模态配对，包含超过1.16亿张图像块。该方法将多模态的全视野上下文信息注入图像块表示中，将建模范围从单模态拓展到多模态，并从图像块级扩展至切片级分析。在涵盖97项肿瘤学基准任务的评估中，mSTAR显著优于以往的最先进模型，尤其在分子预测和多模态任务中表现突出，揭示了多模态整合能够带来比单纯扩展视觉数据集更显著的性能提升。

### 第二部分 AI 大师评价

该研究旨在构建一个多模态整合的病理学基础模型mSTAR，通过融合病理切片、病理报告与基因表达数据，克服传统视觉模型在全视野和多模态理解上的局限。作者基于大规模多癌种数据集完成预训练，实现了从图像块到整张切片、从单模态到多模态的跃升。实验证明mSTAR在多个肿瘤学任务中超过现有方法，尤其在分子预测与多模态分析中卓越。其创新性在于将跨模态信息深度统一于病理表示学习架构中，但在数据获取与跨机构泛化方面仍需进一步验证。

---

## 19. 基于结构设计的大环肽以生成针对G蛋白偶联受体的功能性抗体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387675)
**期刊：** Nature communications
**PMID：** 41387675
**DOI：** 10.1038/s41467-025-66030-1

### 第一部分 原文与翻译

**英文原标题：** Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors.

> **英文摘要：**
> G protein-coupled receptors (GPCRs) are critical to a variety of pathophysiological processes, making them attractive targets for the development of drugs or relevant diagnostic tools. Although GPCRs have been successfully targeted with small molecules, the production of reliable anti-GPCR antibodies remains a major challenge. To address this issue, we develop a strategy using macrocyclic peptides designed to mimic the three-dimensional structure of GPCR extracellular loops as immunogens and use the chicken, which is genetically distant from mammals, as an immunization host to produce antigen-specific antibodies. The high-affinity neurotensin receptor type 1 (NTS1), overexpressed in many types of human cancer and associated with poor prognosis, is used as a target. Rational design of macrocyclic epitope mimics and linker selection are achieved using modeling and predictive analysis software tools based on available NTS1 crystal structures. This study particularly highlights the critical role of the linker in peptide macrocyclization, which determines whether antibodies can exert antagonistic activity. Overall, this strategy represents a valuable asset to produce effective spatial anti-GPCR antibodies and holds promise for diagnostic and therapeutic applications.

> **中文摘要：**
> G蛋白偶联受体（GPCRs）在多种病理生理过程中起关键作用，使其成为药物开发或相关诊断工具的理想靶点。尽管GPCR已被小分子成功靶向，但制备具有可靠性能的抗GPCR抗体仍是重大挑战。为解决这一问题，我们开发了一种策略，利用设计用于模仿GPCR胞外环三维结构的大环肽作为免疫原，并选择与哺乳动物遗传距离较远的鸡作为免疫宿主，以产生抗原特异性抗体。我们选取高亲和力的神经降压素受体1型（NTS1）为靶点，该受体在多种人类癌症中过度表达并与不良预后相关。基于NTS1已知晶体结构，借助建模与预测分析软件工具实现了大环表位模拟物及连接臂的合理设计与选择。本研究尤其强调了连接臂在肽环化过程中的关键作用，它决定了所得抗体是否具备拮抗活性。总体而言，该策略为制备具有空间构象识别能力的高效抗GPCR抗体提供了有价值的手段，并在诊断与治疗应用中具有潜在前景。

### 第二部分 AI 大师评价

该研究旨在通过结构导向设计的大环肽免疫策略，突破抗GPCR抗体制备的关键瓶颈。研究者利用NTS1晶体结构模型设计出表位模拟肽，并结合连接臂优化实现具有功能活性的抗体生成。工作创新性地强调了连接臂在环化设计中的决定性作用，为结构抗原模拟的免疫学应用提供了新思路。该研究方法学严谨，设计合理，但仍需在更多GPCR靶点上验证普适性与效能。

---

## 20. WWP2通过介导p21的泛素化与降解抑制肝细胞癌细胞衰老。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387673)
**期刊：** Cell death & disease
**PMID：** 41387673
**DOI：** 10.1038/s41419-025-08318-0

### 第一部分 原文与翻译

**英文原标题：** WWP2-induced inhibition of hepatocellular carcinoma cellular senescence via the ubiquitination and degradation of p21.

> **英文摘要：**
> Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. The E3 ubiquitin ligase WWP2 has emerged as a critical regulator of tumor pathogenesis through its modulation of substrate ubiquitination. However, its specific mechanistic role in HCC remains poorly understood. In this study, we found that WWP2 was significantly up-regulated in HCC patients and associated with poor prognosis. Lentivirus-mediated knockdown of WWP2 induced cellular senescence and suppressed proliferation in HCC cell lines. Mechanistically, co-immunoprecipitation and ubiquitination assays identified WWP2 as a novel E3 ubiquitin ligase for p21 that promotes its K48-linked ubiquitination and subsequent proteasomal degradation, consequently accelerating cellular senescence and restraining HCC progression. Notably, we further discovered that CMTM6 directly interacts with WWP2, thereby stabilizing p21 by preventing its WWP2-mediated ubiquitination. Accordingly, the senescence and proliferation arrest induced by WWP2 deficiency were partially reversed by CMTM6 knockdown but enhanced by concurrent CMTM6 overexpression. This functional interplay was corroborated in vivo, as WWP2 depletion enhanced tumor cell senescence and suppressed tumor growth, an effect that was partially rescued by concurrent CMTM6 knockdown. Taken together, our findings establish the WWP2-CMTM6-p21 axis as a pivotal regulatory mechanism of cellular senescence in HCC and shed new light on senescence-related therapeutic strategies for HCC.

> **中文摘要：**
> 肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一。E3泛素连接酶WWP2通过调控底物的泛素化已成为肿瘤发生机制中的关键调节因子。然而，其在HCC中的具体作用机制尚不明确。在本研究中，我们发现WWP2在HCC患者中显著上调，并与预后不良相关。通过慢病毒介导的WWP2敲低实验显示，WWP2缺失可诱导细胞衰老并抑制HCC细胞系的增殖。从机制上看，共免疫沉淀及泛素化实验确认WWP2是p21的新型E3泛素连接酶，可促进其K48位点连接的泛素化及随后的蛋白酶体降解，从而加速细胞衰老并抑制HCC的发展。值得注意的是，我们进一步发现CMTM6可直接与WWP2相互作用，通过阻止WWP2介导的p21泛素化来稳定p21蛋白。相应地，CMTM6敲低可部分逆转由WWP2缺失引起的衰老与增殖停滞，而CMTM6过表达则进一步增强该效应。这种功能性相互作用在体内实验中得到验证：WWP2缺失促进肿瘤细胞衰老并抑制肿瘤生长，而同时敲低CMTM6可部分恢复这一效应。综上所述，我们的研究揭示了WWP2-CMTM6-p21轴在HCC细胞衰老调控中的关键作用，并为HCC衰老相关治疗策略提供了新的见解。

### 第二部分 AI 大师评价

该研究系统阐明了E3泛素连接酶WWP2在调控肝细胞癌细胞衰老中的新机制。作者通过分子与细胞水平实验发现，WWP2通过促进p21的K48连接型泛素化和降解，抑制细胞衰老并促进HCC进展；而CMTM6可通过与WWP2互作稳定p21，形成关键的WWP2-CMTM6-p21调控轴。研究在体内外均获得了功能验证，揭示了肿瘤衰老与蛋白稳态交互的新层面。该发现为HCC衰老靶向治疗提供了潜在新方向，但仍需在临床样本和动物模型中进一步评估其可行性与安全性。

---

## 21. 癌症筛查必须更加精准。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387644)
**期刊：** Nature medicine
**PMID：** 41387644
**DOI：** 10.1038/s41591-025-04148-x

### 第一部分 原文与翻译

**英文原标题：** Cancer screening must become more precise.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文章标题强调了癌症筛查领域需要进一步提高精准性，反映出现今医学界对早期检测策略优化的迫切需求。虽然缺乏摘要内容，但可推测作者可能探讨了传统筛查方案的局限以及精准医学、人工智能或分子诊断等新方法的潜力。本文的核心创新在于呼吁以科学数据和个体化评估来提升筛查效益，以减少过度筛查与漏诊。其局限在于缺乏具体的方法论与实践验证细节。

---

## 22. 由核糖体竞争和翻译扰动驱动的碰撞诱导性核糖体降解

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387539)
**期刊：** Nature communications
**PMID：** 41387539
**DOI：** 10.1038/s41467-025-66026-x

### 第一部分 原文与翻译

**英文原标题：** Collision-induced ribosome degradation driven by ribosome competition and translational perturbations.

> **英文摘要：**
> Individual stalling of catalytically inactive ribosomes at the start codon triggers ubiquitination of ribosomal protein uS3 and subsequent 18S rRNA decay. While collisions between ribosomes during translation elongation represent a more widespread form of translation perturbation, their impact on ribosome stability remains unknown. Here, we clarify a bifurcation in ubiquitination-mediated ribosome turnover, identifying a collision-induced branch of uS3 ubiquitination and small subunit destabilization in yeast. This pathway eliminates not only non-functional ribosomes but also translationally active ones with a prokaryotic-like decoding center, driven by competition with wild-type ribosomes due to differing translation rates. We further show that endogenous ribosomal subunit stoichiometry shifts toward a small-subunit-shortage state via ubiquitination upon perturbed translation triggered by the anti-cancer drug cisplatin and the growth phase transition. These findings reveal a mechanism by which ribosome dynamics generally affects ribosome stability, implicating ribosome dysfunction, heterogeneity, and stress-related translational disturbances in small subunit degradation.

> **中文摘要：**
> 单个在起始密码子处催化失活的核糖体停滞会触发核糖体蛋白uS3的泛素化以及随后18S rRNA的降解。虽然在翻译延伸过程中核糖体之间的碰撞代表了一种更普遍的翻译扰动形式，但其对核糖体稳定性的影响仍不清楚。在此，我们阐明了由泛素化介导的核糖体周转过程中的分叉机制，并在酿酒酵母中鉴定出一个由碰撞诱导的uS3泛素化及小亚基不稳定化分支。该通路不仅清除无功能的核糖体，还消除由于翻译速率差异而与野生型核糖体竞争、具有类原核解码中心的活性翻译核糖体。我们进一步表明，当抗癌药物顺铂或生长阶段转换引起翻译受扰时，内源性核糖体亚基化学计量比会通过泛素化向小亚基短缺状态转变。这些发现揭示了核糖体动力学普遍影响核糖体稳定性的机制，提示核糖体功能障碍、异质性以及应激相关的翻译扰动在小亚基降解中的作用。

### 第二部分 AI 大师评价

本研究揭示了核糖体碰撞如何通过泛素化通路诱导小亚基降解，拓展了对翻译应激与核糖体稳态调控的理解。作者在酿酒酵母模型中解析了泛素化介导的核糖体周转分支，发现该通路不仅针对失效核糖体，也可清除受速率竞争影响的活性核糖体。研究利用顺铂诱导翻译扰动与生长阶段切换等生理情境验证了机制的普遍性。该工作创新之处在于将核糖体动力学与结构稳定性联系起来，但在机制的保守性及细胞类型特异性验证方面仍需进一步探讨。

---

## 23. LRRC59与核转运蛋白协同抑制核膜修复机制以维护基因组完整性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387506)
**期刊：** Nature communications
**PMID：** 41387506
**DOI：** 10.1038/s41467-025-65994-4

### 第一部分 原文与翻译

**英文原标题：** LRRC59 cooperates with nuclear transporters to restrain the nuclear envelope repair machinery and safeguard genome integrity.

> **英文摘要：**
> Nuclear envelope (NE) rupture is a hallmark of cancer cells, and persistent NE damage drives genome instability and inflammation. NE repair relies on activation of the endosomal sorting complex required for transport (ESCRT)-III repair machinery by the LEMD2-CHMP7 compartmentalization sensor, but little is known beyond these core factors. Here, we use convergent proximity proteomics to inventorise proteins mobilized to the NE upon assembly of LEMD2-CHMP7 and activation of ESCRT-III. Within this NE repairome, we identify LRRC59 as a critical regulator of LEMD2 accumulation at NE ruptures. We find that LRRC59, together with the nuclear transporters KPNB1 and XPO1, restricts the assembly of LEMD2-CHMP7 complexes to the site of rupture. Disruption of this regulatory axis escalates LEMD2-CHMP7 spreading across the NE, driving torsional DNA damage in ruptured nuclei and micronuclei. Thus, our work identifies a central regulatory layer of NE repair centered on LRRC59 and KPNB1. We propose that altered LRRC59 levels and deregulated nuclear transport coordinately compromise NE repair, driving genome instability and cancer development.

> **中文摘要：**
> 核膜（NE）破裂是癌细胞的标志性特征，而持续的核膜损伤会驱动基因组不稳定性和炎症反应。核膜修复依赖于由LEMD2-CHMP7区隔感应器激活的转运所需囊泡内体分选复合物（ESCRT）-III修复机制，但在这些核心因子之外的机制知之甚少。在本研究中，我们利用收敛邻近蛋白质组学，对在LEMD2-CHMP7组装及ESCRT-III激活时动员至核膜的蛋白进行了系统编目。在这一核膜修复蛋白组中，我们鉴定出LRRC59是调控LEMD2在核膜破裂处积累的关键因子。我们发现，LRRC59与核转运蛋白KPNB1和XPO1协同作用，将LEMD2-CHMP7复合物的组装限制于破裂部位。该调控轴的破坏会导致LEMD2-CHMP7在核膜上的扩散增强，从而在破裂核和微核中诱发扭转性DNA损伤。因此，我们的研究揭示了一个以LRRC59和KPNB1为中心的核膜修复核心调控层。我们提出，LRRC59水平的异常及核转运的失调可协同削弱核膜修复能力，从而推动基因组不稳定性和癌症发展。

### 第二部分 AI 大师评价

该研究聚焦于核膜破裂后的修复调控机制，利用邻近蛋白质组学揭示了LRRC59与核转运因子KPNB1、XPO1协同控制LEMD2-CHMP7复合物定位的关键作用。结果表明LRRC59是维持核膜修复精确性、保护基因组完整性的核心因子。研究创新地提出了LRRC59-核转运调控轴对核膜修复范围及DNA损伤防御的调节模型。其发现为理解癌细胞基因组不稳定性提供了新视角，同时也可能成为未来干预核膜损伤相关疾病的新靶点。

---

## 24. 基质刚度通过整合素–核骨架轴维持膀胱癌干性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387479)
**期刊：** Cell death & disease
**PMID：** 41387479
**DOI：** 10.1038/s41419-025-08222-7

### 第一部分 原文与翻译

**英文原标题：** Matrix stiffness maintains bladder cancer stemness via integrin-nuclear skeleton axis.

> **英文摘要：**
> Tumors have a unique niche system that plays an important role in their occurrence and development. At present, there is increasing interest in the biomechanical properties of niches. The increased stemness of cancer cells is closely related to bladder cancer progression and recurrence. However, how biomechanical properties in the niche regulate bladder cancer stemness remains unclear. Here, we show that as bladder cancer progresses, matrix stiffness increases, and tumor stemness increases. Mechanistically, high matrix stiffness mediates β-catenin nuclear translocation by increasing the nuclear pore size. On the other hand, it promotes the expression of the nuclear cytoskeletal protein Lamin A/C, inhibits the nuclear export of β-catenin, and finally, it upregulates the Wnt pathway to increase the stemness of cancer cells. These findings reveal a role for matrix stiffness in the regulation of stemness in bladder cancer cells and suggest that targeting matrix stiffness may be an effective strategy to delay bladder cancer progression.

> **中文摘要：**
> 肿瘤具有独特的微环境系统，在其发生和发展中起着重要作用。目前，人们对肿瘤微环境的生物力学特性越来越关注。癌细胞干性增强与膀胱癌的进展和复发密切相关。然而，微环境中的生物力学特性如何调控膀胱癌干性仍不清楚。在本研究中，我们发现随着膀胱癌的进展，基质刚度增加，肿瘤干性也随之增强。从机制上看，高基质刚度通过增大核孔径介导β-连环蛋白的核转位。另一方面，它促进核骨架蛋白Lamin A/C的表达，抑制β-连环蛋白的核输出，最终通过上调Wnt信号通路增强癌细胞的干性。这些发现揭示了基质刚度在膀胱癌细胞干性调控中的作用，并提示靶向基质刚度可能是延缓膀胱癌进展的有效策略。

### 第二部分 AI 大师评价

该研究聚焦于肿瘤微环境的力学属性，探讨基质刚度如何通过整合素–核骨架轴影响膀胱癌细胞干性。作者揭示高基质刚度可通过调节核孔结构和核骨架蛋白Lamin A/C表达促进β-连环蛋白核内滞留，引发Wnt通路激活，从而维持癌细胞干性。此研究以内环境力学与信号传导相互作用为核心，提供了新的病理机制视角。其创新在于将力学信号与核骨架调控联系起来，但仍需在体内研究验证其临床可行性。

---

## 25. 940例从未吸烟者肺癌的微生物组分析显示缺乏临床相关性关联。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387456)
**期刊：** Nature communications
**PMID：** 41387456
**DOI：** 10.1038/s41467-025-66780-y

### 第一部分 原文与翻译

**英文原标题：** Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.

> **英文摘要：**
> In spite of the growing interest in the microbiome in human cancer, there are currently only small-scale lung cancer microbiome studies conducted directly on tissue. As part of the Sherlock-Lung study, we studied the microbiomes of 940 lung cancers (4090 samples) in never smokers (LCINS) directly from lung tissue using three data types: 16S rRNA gene sequencing (16S), whole-genome sequencing (WGS) with paired blood, and RNA-seq. We observe very low biomass and few microbiome associations in LCINS using 16S and WGS tissue. Using RNA-seq, we observe more total microbial reads, and decreased relative abundance of several commensal bacteria at the genus and species levels in tumors relative to paired normal lung tissue. Among all datasets, we see no consistent associations between the lung tissue microbiome, or circulating bacterial DNA, and any available demographic and clinical features, including age, sex, genetic ancestry, second-hand tobacco smoking exposure, LCINS histology, stage, and overall survival. We also observe no microbiome associations with any human genomic alterations within the same samples. Every null result should be interpreted with caution given the possibility of future methodological breakthroughs. However, all together, using multiple data types in nearly 1000 patients, we find no substantive role for the lung cancer microbiome in treatment-naïve LCINS.

> **中文摘要：**
> 尽管人们对肿瘤相关微生物组的兴趣日益增长，目前仅有少数基于组织的肺癌微生物组小规模研究。作为 Sherlock-Lung 研究的一部分，我们利用三种数据类型——16S rRNA 基因测序（16S）、配对血液的全基因组测序（WGS）以及 RNA 测序（RNA-seq），直接从从未吸烟者肺癌（LCINS）的肺组织中分析了940例（共4090个样本）的微生物组。我们在使用16S和WGS组织数据时观察到LCINS样本中微生物含量极低，且关联性有限。通过RNA-seq，我们发现总体微生物序列读数更多，并且与配对的正常肺组织相比，肿瘤组织中若干共生菌在属和种水平上的相对丰度下降。在所有数据集中，我们未发现肺组织微生物组或循环细菌DNA与任何已知人口学和临床特征（包括年龄、性别、遗传祖源、二手烟暴露、LCINS组织学类型、分期及总体生存）之间存在一致的关联。此外，我们也未观察到微生物组与同一样本中任何人类基因组改变的相关性。鉴于未来方法学进展的可能性，每一个“无显著结果”都应谨慎解读。然而，综合近千例患者的多数据类型分析，我们认为在未经治疗的LCINS中，肺癌微生物组并无实质性作用。

### 第二部分 AI 大师评价

该研究基于Sherlock-Lung项目，利用16S、WGS及RNA测序三种数据类型对近千例从未吸烟者肺癌组织进行微生物组分析。结果显示总体微生物生物量极低，且无与临床特征、基因变异或预后显著相关的微生物模式。研究的创新性在于样本规模大且数据多维，但结论相对谨慎，表明肺组织微生物组在未治疗LCINS中的生物学作用有限。此结论为未来探索肺癌微生物学机制与方法学改进提供了重要参考。

---

## 26. 小窝力觉感应与 RhoA-GEFs 的时空耦合调控细胞极性与定向迁移

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387450)
**期刊：** Nature communications
**PMID：** 41387450
**DOI：** 10.1038/s41467-025-67090-z

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporal coupling of caveolae mechanosensing and RhoA-GEFs regulates cell polarity and directional migration.

> **英文摘要：**
> Migrating cells dynamically adapt their morphogenetic programs in response to microenvironmental changes, requiring coordinated spatiotemporal integration of mechanical and biochemical signals. The plasma membrane, through membrane tension and actin dynamics modulation, is essential for cell motility. Caveolae, small plasma membrane invaginations, act as mechanosensors to buffer tension changes under mechanical stress. Recent evidence suggests a role for caveolae in cell migration. Here, we demonstrate that breast cancer cells exhibit a front-rear asymmetry in caveolae and caveolin-1 scaffolds, which is regulated by membrane tension and is crucial for persistent migration and cell directionality. RhoA-driven cell contraction relies on the spatiotemporally coordinated assembly of caveolae and recruitment of RhoA-GEFs at the cell rear. These results are supported by a physical model establishing a feedback loop between local membrane tension and contractility, through caveolae formation and disruption. Our findings underscore the importance of caveolae mechanosensing in regulating RhoA activation and guiding cell migration.

> **中文摘要：**
> 迁移细胞会根据微环境变化动态调整其形态发生程序，这需要机械信号与生化信号的时空协调整合。质膜通过调节膜张力和肌动蛋白动力学，对细胞运动至关重要。小窝是质膜上微小的内陷结构，作为力学感应器，在机械应力下缓冲张力变化。最新证据显示，小窝在细胞迁移中发挥作用。本研究表明，乳腺癌细胞在小窝及 caveolin-1 支架中呈现前后非对称分布，这种非对称性受膜张力调控，并且对持续迁移和细胞方向性至关重要。由 RhoA 驱动的细胞收缩依赖于小窝的时空协调组装及 RhoA-GEFs 在细胞后缘的募集。这些结果得到一个物理模型的支持，该模型通过小窝的形成与破裂建立了局部膜张力与收缩性之间的反馈环路。我们的研究结果强调，小窝的力觉感应在调节 RhoA 活化及引导细胞迁移中具有重要作用。

### 第二部分 AI 大师评价

本研究聚焦于小窝及其相关信号复合物在细胞迁移过程中的力学感应功能。作者通过实验与物理模型相结合的方法，揭示了小窝形成、膜张力与 RhoA-GEFs 时空耦合之间的反馈调控机制。研究发现，小窝的前后非对称分布是维持细胞极性和定向迁移的关键。该工作在细胞力学生物学领域具有创新性，为理解癌细胞迁移机制提供了新的力学视角，但仍需进一步探讨不同细胞类型中的普适性及其生理意义。

---

## 27. 联合结核病与 HIV 治疗在共感染期间可控制结核病再激活，但不能抑制慢性免疫激活。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387448)
**期刊：** Nature communications
**PMID：** 41387448
**DOI：** 10.1038/s41467-025-67188-4

### 第一部分 原文与翻译

**英文原标题：** Concurrent TB and HIV therapies control TB reactivation during co-infection but not chronic immune activation.

> **英文摘要：**
> Most HIV-negative individuals exposed to Mycobacterium tuberculosis (Mtb) control infection as latent TB infection (LTBI), but HIV co-infection greatly increases progression to tuberculosis (TB), the leading cause of death in people living with HIV (PLHIV). Although combination antiretroviral therapy (cART) reduces LTBI reactivation, immune control of Mtb is not fully restored, as shown by persistent TB incidence in PLHIV on cART. In macaques, skewed pulmonary effector memory CD4⁺ T-cell (T) responses and new TB lesions persist despite cART. We hypothesize that concurrent anti-TB therapy with cART would improve bacterial control and immune restoration compared to cART alone. Using rhesus macaques (RM) with LTBI and Simian Immunodeficiency Virus (SIV) co-infection, we tested three months of weekly isoniazid and rifapentine (3HP) plus daily cART. Concurrent cART+3HP improves clinical and microbiological outcomes but fails to fully restore lung CD4⁺ T-cell immunity. Treated RMs retain caseous granulomas with high FDG uptake and incomplete CD4⁺ T-cell reconstitution, marked by persistent activation, exhaustion, and inflammation. CD4⁺ T cells remain depleted. Concurrent therapy induces Type I IFN signatures and enhances Mtb-specific T/T-but reduces TNFα-responses. These findings reveal persistent pulmonary immune defects underlying TB risk in HIV co-infection and identify potential targets for host-directed adjunctive therapies.

> **中文摘要：**
> 多数暴露于结核分枝杆菌（Mtb）的 HIV 阴性个体能将感染控制为潜伏性结核感染（LTBI），但 HIV 共感染显著增加了进展为活动性结核病（TB）的风险，而结核病仍是 HIV 感染者（PLHIV）死亡的主要原因。尽管联合抗逆转录病毒治疗（cART）可降低 LTBI 再激活，但 Mtb 的免疫控制并未完全恢复，这可由接受 cART 治疗的 PLHIV 中持续发生的结核病例得到证明。在猕猴模型中，即使接受 cART，肺部效应记忆 CD4⁺ T 细胞反应仍然偏斜，并持续出现新的结核病灶。我们假设，与单用 cART 相比，同时给予抗结核治疗可改善细菌控制和免疫重建。使用存在 LTBI 与猿免疫缺陷病毒（SIV）共感染的恒河猴（RM），我们测试了为期三个月的每周异烟肼与利福喷汀（3HP）联合每日 cART 的方案。联合 cART+3HP 改善了临床和微生物学结局，但未能完全恢复肺部 CD4⁺ T 细胞免疫功能。接受治疗的恒河猴仍保留具有高 FDG 摄取的干酪样肉芽肿，且 CD4⁺ T 细胞重建不完全，表现为持续的激活、耗竭与炎症。CD4⁺ T 细胞仍处于减少状态。联合治疗诱导了 I 型干扰素（IFN）特征，并增强了 Mtb 特异性 T/T 反应，但降低了 TNFα 反应。这些发现揭示了 HIV 共感染中支撑结核风险的持续性肺部免疫缺陷，并指出了潜在的宿主定向辅助治疗靶点。

### 第二部分 AI 大师评价

本研究通过恒河猴 LTBI 与 SIV 共感染模型，系统评估了同步实施抗结核治疗与 cART 联合方案的效果。结果显示，3HP+cART 可显著改善临床及微生物学控制，但肺部 CD4⁺ T 细胞免疫恢复不完全，残留活性炎症与免疫耗竭。研究揭示了在 HIV 共感染背景下结核持续风险的免疫学基础，并指示 I 型干扰素信号可能参与失衡。该工作为宿主靶向的辅助疗法提供了重要线索，但其临床转化仍需进一步验证。

---

## 28. 作者更正：Alectinib 联合 Bevacizumab 作为 ALK 重排非小细胞肺癌的一线治疗（ALEK-B）：一项单臂、II 期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387445)
**期刊：** Nature communications
**PMID：** 41387445
**DOI：** 10.1038/s41467-025-67648-x

### 第一部分 原文与翻译

**英文原标题：** Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本篇文章为作者更正声明，涉及一项关于 Alectinib 联合 Bevacizumab 在 ALK 重排非小细胞肺癌中作为一线治疗的单臂 II 期临床试验。该研究旨在评价此联合方案的疗效与安全性。虽然此文并未提供新的实验结果，但反映了作者对数据或表述准确性的重视。作为更正类论文，其创新性有限，但对确保研究质量与可靠性具有重要意义。

---

## 29. G-CSF/NAMPT 信号通路驱动中性粒细胞功能障碍并增强癌症患者对细菌感染的易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387444)
**期刊：** Nature communications
**PMID：** 41387444
**DOI：** 10.1038/s41467-025-67471-4

### 第一部分 原文与翻译

**英文原标题：** G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients.

> **英文摘要：**
> Despite advancements in cancer therapies, bacterial complications remain a major challenge, delaying treatment and worsening outcomes. While immunosuppressive therapies and prolonged hospitalizations contribute, they do not fully explain the elevated infection risk in cancer patients. Here we show that tumors producing high levels of granulocyte colony-stimulating factor (G-CSF) promote the persistence of Gram-negative pathogens in head and neck squamous cell carcinoma due to neutrophil reprogramming. Mechanistically, we identify tumor-driven activation of the G-CSF / nicotinamide phosphoribosyltransferase (NAMPT) signaling axis in neutrophil progenitors, resulting in impaired antibacterial functions, such as phagocytosis and neutrophil extracellular traps formation, and development of tissue-damaging neutrophil subsets. This disrupts lung tissue integrity and facilitates bacterial persistence. Importantly, targeting the G-CSF/NAMPT pathway prevents the generation of dysfunctional neutrophils and improves bacterial clearance in vivo. Our findings reveal tumor-induced, NAMPT-dependent neutrophil reprogramming as a central driver of compromised antimicrobial defenses in cancer. Therapeutic strategies aimed at modulating G-CSF/NAMPT signaling could enhance infection control and survival for cancer patients.

> **中文摘要：**
> 尽管癌症治疗取得了诸多进展，细菌并发症仍然是一个主要挑战，导致治疗延迟并使病情恶化。虽然免疫抑制疗法和长期住院有一定影响，但它们并不能完全解释癌症患者感染风险升高的原因。在本研究中，我们发现分泌高水平粒细胞集落刺激因子（G-CSF）的肿瘤可通过重编程中性粒细胞，促进头颈部鳞状细胞癌中革兰阴性病原体的持续存在。从机制上看，我们鉴定出肿瘤驱动的 G-CSF/烟酰胺磷酸核糖转移酶（NAMPT）信号轴在中性粒细胞前体中的激活，导致抗菌功能受损，包括吞噬作用和中性粒细胞胞外陷阱形成的缺陷，以及产生具组织损伤效应的中性粒细胞亚群。这一过程破坏了肺组织完整性，并促进细菌的持续存在。值得注意的是，靶向 G-CSF/NAMPT 通路可阻止功能失调中性粒细胞的形成，并在体内改善细菌清除。我们的研究揭示了肿瘤诱导的、依赖 NAMPT 的中性粒细胞重编程是癌症中抗菌防御受损的核心驱动因素。针对 G-CSF/NAMPT 信号通路的调控性治疗策略可能增强癌症患者的感染控制能力并改善生存。

### 第二部分 AI 大师评价

本研究聚焦于癌症患者感染易感性增加的分子机制，揭示 G-CSF/NAMPT 信号通路在中性粒细胞功能重编程中的关键作用。作者通过机制性实验阐明了肿瘤驱动的信号激活如何削弱中性粒细胞的抗菌效应并导致组织损伤。研究显示，阻断该通路可恢复中性粒细胞功能并增强体内细菌清除，提示其潜在治疗价值。该工作为理解肿瘤相关免疫失衡及其感染后果提供了新视角，但仍需进一步研究其在不同肿瘤类型和临床环境中的适用性。

---

## 30. 饮食诱导的RKIP下调破坏PC/PE-内质网稳态以驱动代谢功能障碍相关脂肪性肝病（MASLD）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387436)
**期刊：** Nature communications
**PMID：** 41387436
**DOI：** 10.1038/s41467-025-65982-8

### 第一部分 原文与翻译

**英文原标题：** Diet-induced RKIP downregulation disrupts PC/PE-ER homeostasis to drive MASLD.

> **英文摘要：**
> High-fat diet (HFD) is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD), yet the molecular pathways that connect dietary fats to liver dysfunction remain unclear. Here, we discover that hepatic downregulation of Raf kinase inhibitory protein (RKIP) in MASLD patients and male mice is linked to fatty acid uptake, which causes endoplasmic reticulum (ER)-associated degradation of RKIP by inhibiting its S-palmitoylation. Via facilitating the mA-modified RNA binding of YTHDF1, RKIP is required for the efficient translation of PEMT, an essential enzyme in maintaining phosphatidylcholine (PC) / phosphatidylethanolamine (PE) ratio and ER homeostasis. Hepatocyte-specific RKIP depletion in male mice exacerbates the PC/PE imbalance and ER stress, resulting in lipid droplets accumulation and MASLD progression. Notably, RKIP correlates positively with PEMT protein but inversely with MASLD development. These findings uncover a cellular mechanism of HFD-RKIP-PEMT that underlies diet-induced liver metabolic disease and propose RKIP as a target for MASLD prevention.

> **中文摘要：**
> 高脂饮食（HFD）是代谢功能障碍相关脂肪性肝病（MASLD）的危险因素，然而将膳食脂肪与肝功能障碍联系起来的分子通路仍不清楚。本研究发现，在MASLD患者和雄性小鼠中，肝脏Raf激酶抑制蛋白（RKIP）的下调与脂肪酸摄取相关，这种下调通过抑制RKIP的S-棕榈酰化导致其内质网（ER）相关降解。通过促进YTHDF1与m6A修饰RNA的结合，RKIP对于磷脂酶甲基转移酶（PEMT）的高效翻译至关重要，而PEMT是维持磷脂酰胆碱（PC）/磷脂酰乙醇胺（PE）比例及内质网稳态的关键酶。雄性小鼠肝细胞特异性敲除RKIP会加剧PC/PE比例失衡和内质网应激，从而导致脂滴积累并促进MASLD进展。值得注意的是，RKIP与PEMT蛋白呈正相关，而与MASLD的发生发展呈负相关。这些发现揭示了HFD-RKIP-PEMT轴在饮食诱导肝脏代谢性疾病中的细胞机制，并提出RKIP为MASLD预防的潜在靶点。

### 第二部分 AI 大师评价

该研究旨在揭示高脂饮食诱导的代谢性脂肪肝疾病中关键分子RKIP的调控机制。通过在人类样本和小鼠模型中的多层实验，作者阐明了HFD通过抑制RKIP的S-棕榈酰化导致其内质网相关降解，从而影响PEMT翻译，破坏磷脂稳态及内质网功能。研究提供了HFD-RKIP-PEMT信号轴的新机制，揭示了饮食与肝脂代谢异常之间的关键联系。该工作具有显著的创新性，但仍需验证其性别差异及长期干预的可逆性。

---

## 31. 由内源性鸟嘌呤损伤引发的组织特异性突变形成受 Polκ 和 DNA 修复的抑制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387429)
**期刊：** Nature communications
**PMID：** 41387429
**DOI：** 10.1038/s41467-025-67072-1

### 第一部分 原文与翻译

**英文原标题：** Tissue-specific mutagenesis from endogenous guanine damage is suppressed by Polκ and DNA repair.

> **英文摘要：**
> Knowledge of mutational patterns has expanded significantly, but linking these patterns to specific molecular mechanisms or sources of endogenous DNA damage remains challenging. Translesion synthesis (TLS) is a key determinant of mutagenesis, yet the endogenous lesions that require TLS and how TLS polymerases shape mammalian mutational landscapes are unclear. Here, we characterize somatic mutational patterns across mouse tissues deficient in the TLS polymerase Polκ and find that Polκ suppresses a distinct tissue-specific mutational signature in the liver and kidney. This signature, enriched for C > A/G/T mutations with strong transcriptional-strand bias, indicates that Polκ performs error-free bypass of endogenous guanine adducts. Nucleotide excision repair (NER) acts in parallel, mitigating some of this damage. Targeted adductomics and biochemical analyses identify endogenous N-dG lesions requiring Polκ-mediated bypass, while untargeted adductomics reveal new guanine lesions that engage NER. These findings uncover the nature of endogenous DNA damage and the coordinated roles of repair and tolerance pathways that limit mutagenesis in tissues.

> **中文摘要：**
> 对突变模式的认识已显著扩展，但将这些模式与特定的分子机制或内源性 DNA 损伤来源建立明确联系仍具挑战性。跨损伤合成（TLS）是诱变的关键决定因素，但仍不清楚哪些内源性损伤需要 TLS，以及 TLS 聚合酶如何塑造哺乳动物的突变景观。在本研究中，我们分析了缺乏 TLS 聚合酶 Polκ 的小鼠组织中的体细胞突变模式，发现 Polκ 在肝脏和肾脏中抑制了一种明显的组织特异性突变特征。该突变特征富含具有强烈转录链偏向的 C > A/G/T 型突变，表明 Polκ 能够对内源性鸟嘌呤加合物进行无错绕过。核苷酸切除修复（NER）则以平行方式作用，缓解部分损伤。靶向加合体组学和生化分析鉴定了需要由 Polκ 介导绕过的内源性 N-dG 损伤，而非靶向加合体组学则揭示了可被 NER 识别的新型鸟嘌呤损伤。这些发现揭示了内源性 DNA 损伤的性质，以及修复与耐受途径在限制组织突变形成中的协同作用。

### 第二部分 AI 大师评价

本研究旨在揭示内源性鸟嘌呤损伤导致的组织特异性突变形成机制，通过在小鼠中敲除 Polκ 聚合酶，系统分析不同组织的突变模式。研究发现 Polκ 可有效抑制肝脏和肾脏中特定类型的突变，说明其在内源性 DNA 损伤绕过中的关键作用。结合靶向与非靶向加合体组学，研究明确了 NER 与 Polκ 在修复与容忍损伤中的协同关系。该工作创新性地将分子机制与突变特征关联，为理解体内诱变限制机制提供了新的实验证据。

---

## 32. 肝特异性对氧磷酶-1通过代谢重编程缓解肝细胞癌中调节性T细胞驱动的免疫抑制。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387425)
**期刊：** Nature communications
**PMID：** 41387425
**DOI：** 10.1038/s41467-025-66168-y

### 第一部分 原文与翻译

**英文原标题：** Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma.

> **英文摘要：**
> Paraoxonase-1 (PON1) is specifically expressed in the liver and has crucial effects on various liver diseases. The functions and underlying mechanisms of PON1 in hepatocellular carcinoma (HCC) remain unclear. Here, we demonstrate that PON1 serves as a metabolic regulator to counteract regulatory T (Treg) cell-mediated immunosuppression, thereby suppressing HCC progression. Mechanistically, PON1 promotes Von Hippel-Lindau protein (VHL)-mediated ubiquitination and degradation of hypoxia-inducible factor alpha (HIF-1α), leading to attenuated lactic acid production and limited Treg cell accumulation in the HCC microenvironment. In clinical settings, higher PON1 expression is correlated with a better prognosis in patients with HCC. Recombinant PON1 protein (rPON1) effectively impeded tumor growth. Furthermore, enhancing Pon1 expression with quercetin sensitized HCC to anti-programmed death-1(PD-1) therapy in murine HCC. Our findings elucidate a role of PON1 in orchestrating lactic acid production to relieve immunosuppression and suppress HCC, paving the way for targeting PON1 as a therapeutic strategy.

> **中文摘要：**
> 对氧磷酶-1（PON1）在肝脏中具有特异性表达，并在多种肝病中发挥关键作用。PON1在肝细胞癌（HCC）中的功能及其潜在机制仍不清楚。本研究表明，PON1作为一种代谢调节因子，能够抵抗调节性T（Treg）细胞介导的免疫抑制，从而抑制HCC的进展。在机制层面，PON1促进了von Hippel-Lindau蛋白（VHL）介导的低氧诱导因子α（HIF-1α）的泛素化与降解，导致乳酸生成减少，并限制了HCC微环境中Treg细胞的积聚。在临床样本中，较高的PON1表达与HCC患者的更好预后相关。重组PON1蛋白（rPON1）能有效抑制肿瘤生长。此外，用槲皮素增强Pon1表达可使小鼠HCC对抗程序性死亡-1（PD-1）治疗更为敏感。本研究阐明了PON1通过调控乳酸生成缓解免疫抑制并抑制HCC发生发展的作用，为以PON1为靶点的治疗策略提供了新的方向。

### 第二部分 AI 大师评价

该研究旨在揭示肝脏特异性蛋白PON1在肝细胞癌免疫代谢调控中的作用与机制。研究者发现，PON1通过促进VHL介导的HIF-1α降解，减少乳酸产生，从而削弱Treg细胞主导的免疫抑制并抑制肿瘤进展。实验包括分子机制验证、动物模型干预及临床样本关联分析，结果显示PON1可能成为HCC新的治疗靶点。其创新性在于揭示了代谢重编程与免疫调节间的联系，但需进一步验证其在人类临床中的安全性与可行性。

---

## 33. 长链非编码RNA UGDH-AS1 在三阴性乳腺癌中编码一种抑制NK细胞功能的微肽。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387419)
**期刊：** Nature communications
**PMID：** 41387419
**DOI：** 10.1038/s41467-025-66266-x

### 第一部分 原文与翻译

**英文原标题：** The long non-coding RNA UGDH-AS1 encodes an NK-cell-inhibiting micropeptide in triple-negative breast cancers.

> **英文摘要：**
> NK cells are important for the anti-tumour immune response for their potential to kill MHC class I-deficient tumor cells, but they often become dysfunctional in the immune-hostile tumour microenvironment. Here, using single-cell RNA sequencing, we identify an NK cell subpopulation that is specific to triple-negative breast cancers (TNBC) subtype, characterised by the expression of the long non-coding RNA UGDH-AS1. In these NK cells, UGDH-AS1 encodes the micropeptide, NKSM, which renders these NK cells dysfunctional due to the loss of their activation program, which leads to cancer progression. Conditional NKSM knock-in into NK cells of mice results in NK cell deactivation and increased growth of transplanted tumours. Targeted NKSM therapy effectively reduces tumor growth in TNBC mouse models. We find that UGDH-AS1 NK cells are shaped by the tumor microenvironment (TME). Following upregulation by the TGF-β signaling pathway, NKSM binds to Myc, inhibiting its ERK1/2-mediated phosphorylation at Serine 62 and thus reducing its stability. Decreased Myc activity results in deregulation of T-bet, a key protein involved in NK cell function, which leads to NK cell deactivation. Our study thus provides mechanistic insight int NK cell dysfunctionality in TNBC and lays down the proof of principle for an NK-cell-targeting TNBC immunotherapy.

> **中文摘要：**
> NK细胞由于能够杀伤缺乏MHC I类分子的肿瘤细胞，在抗肿瘤免疫反应中起着重要作用，但在免疫抑制型肿瘤微环境中，它们常常发生功能障碍。本研究通过单细胞RNA测序，鉴定出一种特异于三阴性乳腺癌（TNBC）亚型的NK细胞亚群，其特征是长链非编码RNA UGDH-AS1的高表达。在这些NK细胞中，UGDH-AS1编码一种名为NKSM的微肽，该微肽使NK细胞因激活程序丧失而功能失活，从而促进肿瘤进展。将NKSM条件性导入小鼠NK细胞会导致NK细胞去活化，并促进移植肿瘤的生长。针对NKSM的靶向治疗在TNBC小鼠模型中可有效抑制肿瘤生长。我们发现UGDH-AS1阳性的NK细胞受到肿瘤微环境（TME）的塑造。经TGF-β信号通路上调后，NKSM与Myc结合，抑制其通过ERK1/2介导的Serine 62位点磷酸化，从而降低Myc的稳定性。Myc活性降低导致关键NK细胞功能蛋白T-bet的失调，最终引发NK细胞去活化。本研究揭示了TNBC中NK细胞功能障碍的分子机制，并为开发靶向NK细胞的TNBC免疫治疗提供了概念验证。

### 第二部分 AI 大师评价

该研究聚焦于三阴性乳腺癌中NK细胞的功能障碍机制，利用单细胞转录组学发现长链非编码RNA UGDH-AS1可编码微肽NKSM，从而抑制NK细胞功能。研究通过小鼠模型和分子实验证实NKSM通过影响Myc磷酸化及T-bet调控，导致NK细胞失活和肿瘤进展。针对NKSM的靶向治疗在动物模型中表现出抑瘤潜力。该工作揭示了非编码RNA可通过微肽介导免疫调控的新模式，为NK细胞导向的TNBC免疫治疗提供了新思路，但对临床转化的可行性仍需后续验证。

---

## 34. 组蛋白乙酰化稳态动力调控细胞存活与凋亡。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387415)
**期刊：** Nature communications
**PMID：** 41387415
**DOI：** 10.1038/s41467-025-66405-4

### 第一部分 原文与翻译

**英文原标题：** Histone acetylation homeodynamics navigates cell survival and apoptosis.

> **英文摘要：**
> The balance between inhibitor of apoptosis proteins (IAPs) and pro-apoptotic proteins (PAPs) tightly and precisely regulates cellular homeostasis. However, the epigenetic mechanism by which this balance is maintained in vivo remains largely unknown. Here we show that in various Drosophila tissues, the homeodynamics of H3K14ac/H3K27ac/H4K8ac on the promoters/enhancers of E93 and PAPs (rpr/hid), modulated by P300-CtBP/HDAC3, directs the decision between cell survival and the activation of hormone-induced developmental apoptosis. Concurrently, the homeodynamics of H3K14ac/H3K27ac/H4K8ac in IAPs (Diap1) promoters, modulated by Tip60/P300-CtBP/HDAC3, sustains cellular homeostasis by antagonizing the activities of PAPs. Notably, the epigenetic mechanism revealed in Drosophila is partially conserved in mammals. Moreover, disrupting the histone acetylation homeodynamics attenuates tumorigenesis through altering the balances between IAPs and PAPs in Drosophila and mice. In conclusion, histone acetylation homeodynamics navigates cell survival and apoptosis, suggesting potential epigenetic targets for the treatment of diseases or tumors caused by the imbalance between IAPs and PAPs.

> **中文摘要：**
> 细胞凋亡抑制蛋白（IAPs）与促凋亡蛋白（PAPs）之间的平衡严密而精准地调控着细胞稳态。然而，在体内维持这一平衡的表观遗传机制仍然在很大程度上未知。在本研究中，我们发现，在多种果蝇组织中，P300-CtBP/HDAC3 调控的 E93 与 PAPs（rpr/hid）启动子/增强子上的 H3K14ac、H3K27ac、H4K8ac 的稳态动力决定了细胞存活与激素诱导发育性凋亡之间的命运选择。同时，Tip60/P300-CtBP/HDAC3 调控的 IAP（Diap1）启动子中 H3K14ac、H3K27ac、H4K8ac 的稳态动力通过拮抗 PAPs 的活性来维持细胞稳态。值得注意的是，在果蝇中揭示的这一表观遗传机制在哺乳动物中部分保守。此外，破坏组蛋白乙酰化的稳态动力可通过改变 IAPs 与 PAPs 之间的平衡，削弱果蝇和小鼠的肿瘤发生。综上所述，组蛋白乙酰化的稳态动力调控细胞的存活与凋亡，提示由 IAPs 与 PAPs 失衡引起的疾病或肿瘤可能存在潜在的表观遗传治疗靶点。

### 第二部分 AI 大师评价

本研究揭示了组蛋白乙酰化稳态动力在细胞命运抉择中的关键作用，建立了 IAPs 与 PAPs 平衡的表观遗传调控框架。作者通过果蝇模型系统性解析了 H3K14ac、H3K27ac 与 H4K8ac 的动态变化及其调控酶网络，并验证了该机制在哺乳动物中的部分保守性。研究发现乙酰化稳态的破坏可减弱肿瘤形成，为肿瘤和发育性疾病提供了新的表观遗传干预思路。其创新点在于提出“乙酰化稳态动力学”这一概念，但机制精细调控的分子细节仍需进一步验证。

---

## 35. 葡萄膜黑色素瘤可靶向的表观遗传脆弱性鉴定

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387414)
**期刊：** Cell death & disease
**PMID：** 41387414
**DOI：** 10.1038/s41419-025-08295-4

### 第一部分 原文与翻译

**英文原标题：** Identification of targetable epigenetic vulnerabilities for uveal melanoma.

> **英文摘要：**
> Uveal melanoma (UM) is the most common adult primary intraocular malignancy, with a strong predilection for hepatic metastasis, occurring in approximately 50% of cases. Metastatic UM is highly resistant to therapy and is almost invariably fatal. The strongest genetic driver of UM metastasis is loss of function of the tumor suppressor BRCA-associated protein 1 (BAP1), which leads to widespread epigenetic dysregulation. To identify novel therapeutic strategies, we investigated whether targeting the epigenome of UM could reveal new vulnerabilities. We performed a high-throughput compound screen using a curated epigenetic inhibitor library and identified BET (bromodomain and extra-terminal domain) inhibition as a particularly promising approach. While previous clinical trials with BET inhibitors for UM treatment have failed, we found substantial heterogeneity in the efficacy of different BET inhibitors in UM. Notably, the BET inhibitor mivebresib (ABBV-075) significantly improved survival rates by 50% in a metastatic UM xenograft mouse model and prevented detectable metastases in the bones, spinal cord, and brain. Transcriptomic analysis revealed a strong overlap between BET and histone deacetylase (HDAC) inhibition, an approach currently under clinical evaluation for UM treatment. BET and HDAC inhibitors reversed gene expression signatures associated with high metastatic risk and induced a neuron-like phenotype in UM cells. These findings establish BET inhibition as a potent and previously underappreciated vulnerability for metastatic UM.

> **中文摘要：**
> 葡萄膜黑色素瘤（UM）是最常见的成人原发性眼内恶性肿瘤，具有明显的肝脏转移倾向，约发生于50%的病例中。转移性UM对治疗高度耐受，并几乎总是致命的。UM转移最强的基因驱动因素是肿瘤抑制因子BRCA相关蛋白1（BAP1）的功能缺失，这导致了广泛的表观遗传失调。为了寻找新的治疗策略，我们探讨了通过靶向UM的表观基因组是否可以揭示新的脆弱性。我们利用一个经精心筛选的表观遗传抑制剂库进行了高通量化合物筛选，并鉴定出BET（溴结构域和额外末端结构域）抑制作为一种特别有前景的方法。尽管以往针对UM的BET抑制剂临床试验未获成功，我们发现不同BET抑制剂在UM中的疗效存在显著异质性。值得注意的是，BET抑制剂mivebresib（ABBV-075）在转移性UM异种移植小鼠模型中显著提高了50%的生存率，并防止了骨骼、脊髓和脑中可检测到的转移。转录组分析显示BET抑制与组蛋白去乙酰化酶（HDAC）抑制之间具有高度重叠的效应，后者目前正在UM治疗的临床研究中。BET和HDAC抑制剂逆转了与高转移风险相关的基因表达特征，并诱导UM细胞呈现神经元样表型。这些发现确立了BET抑制作为转移性UM中一种强效且此前被低估的治疗脆弱性。

### 第二部分 AI 大师评价

该研究旨在揭示葡萄膜黑色素瘤（UM）的可靶向表观遗传弱点，通过高通量筛选发现BET抑制具有显著潜力。作者证明BET抑制剂mivebresib在体内可显著延长生存并抑制多部位转移，同时与HDAC抑制表现出类似的转录重编程效应。该研究不仅提供了新的治疗靶点，还揭示了UM表观遗传调控的关键机制。其创新性在于通过药物筛选和表观组学整合发现新的治疗脆弱性，但仍需进一步验证临床可行性与长期安全性。

---

## 36. 通过浓度依赖性荧光寿命变化成像线粒体膜电位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387403)
**期刊：** Nature communications
**PMID：** 41387403
**DOI：** 10.1038/s41467-025-66042-x

### 第一部分 原文与翻译

**英文原标题：** Imaging mitochondrial membrane potential via concentration-dependent fluorescence lifetime changes.

> **英文摘要：**
> Mitochondria are central to cellular metabolism. Various fluorescence tools have been developed for imaging the mitochondrial environment. Yet, new reporters and imaging methods for directly reading the mitochondrial status are needed for high spatial-temporal resolution imaging. Here, we introduce PK Mito Deep Red (PKMDR), a low-phototoxicity mitochondrial probe for time-lapse imaging, whose fluorescence lifetime serves as a sensitive indicator of mitochondrial membrane potential (Δψ). The positively charged PKMDR accumulates within mitochondria under a higher Δψ, leading to concentration-induced quenching and a measurable decrease in fluorescence lifetime. Since mitochondrial respiration primarily regulates Δψ, PKMDR's fluorescence lifetime effectively reports on the status of oxidative phosphorylation. Using PKMDR with fluorescence lifetime imaging microscopy (FLIM), we visualize heterogeneous Δψ across individual cells, organoids, and tissues over time. This method reliably reveals the heterogeneity between metabolically active peripheral mitochondria and relatively inactive perinuclear mitochondria in various cell types. Overall, PKMDR-FLIM is a robust tool for directly visualizing Δψ with high spatiotemporal resolution.

> **中文摘要：**
> 线粒体是细胞代谢的核心。已经开发出多种荧光工具用于成像线粒体环境。然而，为了实现高时空分辨率成像，仍需要新的报告分子和成像方法以直接读取线粒体状态。在本研究中，我们介绍了 PK Mito Deep Red（PKMDR），这是一种用于时间序列成像的低光毒性线粒体探针，其荧光寿命可作为线粒体膜电位（Δψ）的敏感指示器。带正电的 PKMDR 在较高 Δψ 状态下积聚于线粒体内，导致浓度诱导的猝灭效应，并产生可测的荧光寿命降低。由于线粒体呼吸主要调控 Δψ，因此 PKMDR 的荧光寿命能够有效反映氧化磷酸化的状态。利用结合荧光寿命成像显微镜（FLIM）的 PKMDR，我们能够随时间可视化单细胞、类器官及组织中 Δψ 的异质性。该方法可靠揭示了不同类型细胞中代谢活跃的外周线粒体与相对不活跃的核周线粒体之间的差异。总体而言，PKMDR-FLIM 是一种能够以高时空分辨率直接可视化 Δψ 的稳健工具。

### 第二部分 AI 大师评价

该研究提出了一种基于荧光寿命变化的新型线粒体膜电位成像探针 PKMDR，能够通过低光毒性方式实现动态、高分辨率的线粒体功能监测。其机制利用Δψ依赖的探针富集和猝灭效应，将荧光寿命与氧化磷酸化状态直接关联。作者利用 FLIM 技术展示了单细胞及组织水平上线粒体膜电位的空间异质性。该方法在细胞代谢动力学研究中具有显著创新性，但在临床应用和复杂组织成像中的适用性仍需进一步验证。

---

## 37. 一种基于TtAgo驱动的自催化电路：具有热增强动力学的一锅式核酸检测体系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387325)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387325
**DOI：** 10.1002/advs.202521671

### 第一部分 原文与翻译

**英文原标题：** A TtAgo-Driven Autocatalytic Circuit with Thermal-Enhanced Kinetics for One-Pot Nucleic Acid Detection.

> **英文摘要：**
> Catalytic DNA circuits hold significant promise for nucleic-acid-based diagnostics, yet they remain hindered by slow reaction kinetics and the non-universal nature of one-pot approaches. Here, a universal catalytic DNA circuits termed TACTIC (Thermus thermophilus Argonaute (TtAgo) protein-driven autocatalytic circuit) is developed for one-pot detection of DNA and RNA in multiple clinical samples. TACTIC employs the heat-activated cleavage activity of TtAgo to accelerate reaction kinetics of rolling circle amplification (RCA) by producing an efficient circular template with Gibbs free energy approaching zero at 70. Combined with TtAgo cleavage-mediated explosive regeneration and accumulation of target mimics, an autocatalytic positive-feedback circuit is successfully constructed for universal and sensitive detection of nucleic acid biomarkers. Efficient TACTIC is developed by increasing 381% amplification efficiency and achieved detection sensitivity at the attomolar (aM) level. TACTIC enables rapid one-pot detection of bacterial DNA, mutant mRNA, and four extracellular vesicle-derived miRNAs (EV miRNAs) within 30 min. Integrated with machine learning, the distinct expression patterns of four EV miRNAs across different biofluids are accurately profiled, and machine learning-driven diagnostic and staging models for breast cancer are established within a clinical cohort. TACTIC offers new insights for advancing higher-order catalytic circuits and expanding the toolbox for accurate nucleic acid detection.

> **中文摘要：**
> 催化性DNA电路在基于核酸的诊断中具有巨大的应用潜力，但其发展仍受限于反应动力学缓慢以及一锅式方法的非通用性。本文构建了一种通用的催化性DNA电路，命名为TACTIC（由嗜热栖热菌Argonaute（TtAgo）蛋白驱动的自催化电路），可用于在多种临床样本中进行一锅式DNA和RNA检测。TACTIC利用TtAgo的热活化切割活性，通过生成在70°C下吉布斯自由能趋近于零的高效环状模板，加速了滚环扩增（RCA）的反应动力学。结合TtAgo切割介导的爆发性靶标模拟再生与积累，成功构建了一个自催化正反馈电路，实现了核酸生物标志物的通用且高灵敏检测。优化后的TACTIC系统将放大效率提高了381%，检测灵敏度达到了阿托摩尔（aM）水平。TACTIC可在30分钟内实现对细菌DNA、突变型mRNA，以及四种外泌体来源miRNA（EV miRNAs）的一锅式快速检测。结合机器学习分析，本研究准确描绘了四种EV miRNA在不同生物流体中的差异表达模式，并在临床队列中建立了基于机器学习的乳腺癌诊断及分期模型。TACTIC为高阶催化电路的发展和精确核酸检测工具箱的扩展提供了新的见解。

### 第二部分 AI 大师评价

该研究提出了一种由TtAgo蛋白驱动的自催化核酸检测系统TACTIC，创新性地利用热激活切割加速滚环扩增反应，从而强化了反应动力学与检测灵敏度。TACTIC不仅实现了DNA与RNA的一锅式快速检测，还结合机器学习进行临床样本分析，展示出良好的普适性和临床转化潜力。其核心创新在于热依赖的自催化机制与生物信息建模的整合。然而，体系在复杂临床样本中长期稳定性及多靶并行检测能力仍需进一步研究。

---

## 38. 基于HSP70互作组介导的蛋白水解靶向嵌合体（HSP70-PROTAC）的铁死亡驱动型癌症治疗策略

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387312)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387312
**DOI：** 10.1002/advs.202513655

### 第一部分 原文与翻译

**英文原标题：** HSP70 Interactome-Mediated Proteolysis Targeting Chimera (HSP70-PROTAC) for Ferroptosis-Driven Cancer Treatment.

> **英文摘要：**
> Targeted protein degradation (TPD) represents a transformative therapeutic paradigm that harnesses the cellular degradation machinery to pharmacologically eliminate disease-causing proteins with aberrant expression. This work here reports the first design of an HSP70 interactome-mediated proteolysis targeting chimera (HSP70-PROTAC) for the degradation of the intracellular therapeutically relevant proteins via dual processes of ubiquitin-proteasomal degradation (UPS) and chaperone-mediated autophagy (CMA). By hijacking the highly expressed heat shock cognate protein (Hsc70) isoform complex in tumor tissues to glutathione peroxidase 4 (GPX4) protein, this work successfully develops an HSP70-PROTAC molecule GDAz-3 that potently and rapidly eliminates GPX4 in HT1080 cells, thereby triggering ferroptosis with high selectivity. Correspondingly, GDAz-3 exhibits a remarkable tumor-inhibitory effect in the HT1080 xenograft tumor mouse model without obvious toxicity. In addition, this work demonstrates the versatility of HSP70-based PROTACs by effectively degrading additional endogenous bromodomain-containing protein 4 (BRD4) in cancer cells. More importantly, the degradation of GPX4 mediated by GDAz-3 occurs with comparable efficiency in CRBN/VHL-knockdown cells and 786-O cells intrinsically lacking VHL expression, which facilitates expanding the application scope and overcoming drug resistance of traditional PROTAC. These findings suggest that HSP70-PROTAC is a novel and feasible strategy for the future development of TPD technology.

> **中文摘要：**
> 靶向蛋白降解（TPD）代表了一种变革性的治疗范式，它利用细胞自身的降解机制，以药理学方式消除异常表达的致病蛋白。本研究首次报道了一种基于HSP70互作组介导的蛋白水解靶向嵌合体（HSP70-PROTAC）的设计，用于通过泛素-蛋白酶体降解（UPS）和伴侣介导自噬（CMA）双重途径降解细胞内具有治疗意义的蛋白。通过劫持肿瘤组织中高表达的热休克同源蛋白（Hsc70）同工型复合物至谷胱甘肽过氧化物酶4（GPX4）蛋白，本研究成功开发出HSP70-PROTAC分子GDAz-3，可在HT1080细胞中高效且迅速地消除GPX4，从而以高度选择性触发铁死亡。相应地，GDAz-3在HT1080异种移植肿瘤小鼠模型中表现出显著的抑瘤效果，且未见明显毒性。此外，本研究通过有效降解癌细胞中另一种内源性溴结构域蛋白BRD4，进一步展示了基于HSP70的PROTAC的多样性。更为重要的是，GDAz-3介导的GPX4降解在CRBN/VHL敲低细胞以及本身缺乏VHL表达的786-O细胞中具有相当的效率，这有助于扩展其应用范围并克服传统PROTAC的耐药问题。这些发现表明，HSP70-PROTAC是一种新颖且可行的策略，可为未来TPD技术的发展提供新方向。

### 第二部分 AI 大师评价

本研究提出了一种创新性的HSP70互作组介导的PROTAC策略，实现了通过伴侣蛋白介导途径与UPS双重机制的靶向蛋白降解。研究开发的分子GDAz-3可特异性、高效地消除GPX4，诱导肿瘤细胞铁死亡，并在动物模型中表现出优异的抗肿瘤活性和较低毒性。该工作突破了传统PROTAC依赖CRBN或VHL的限制，展现出更广泛的适用性和潜在的耐药克服能力。整体而言，该研究在TPD技术领域具有显著的创新性与应用前景，但机制通路的精确调控及临床转化仍需进一步验证。

---

## 39. 多功能纳米免疫刺激剂：突破免疫抑制性微环境的抗肿瘤免疫治疗研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387306)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387306
**DOI：** 10.1002/advs.202517480

### 第一部分 原文与翻译

**英文原标题：** Multifunctional Nano Immunostimulant: Overcoming Immunosuppressive Microenvironment for Antitumor Immunotherapy.

> **英文摘要：**
> Antitumor immunotherapy has become a pillar therapy by activating the immune system to recognize and attack tumor cells. Yet its efficacy is limited by the immunosuppressive tumor microenvironment (TME) and related mechanisms like hypoxia, high glutathione (GSH) expression, and immune evasion. Due to TME complexity and tumor heterogeneity, monotherapy struggles to modulate immunosuppressive factors for potent results. To solve this, this work develops a multifunctional immune stimulator (3IZH), which can simultaneously boost immunity, downregulate GSH, and alleviate hypoxia. In weakly acidic TME, it releases photosensitizer (3ICy5) and Fe ions. Fe ions consume GSH and relieve hypoxia via redox reactions and hydrogen peroxide decomposition. 3ICy5 accumulates in the endoplasmic reticulum (ER), produces ROS, induces severe ER stress and DAMPs release, triggering immunogenic cell death (ICD). Fe ions and ROS also reduce glutathione peroxidase 4 (GPX4), causing ferroptosis. ICD and ferroptosis activate T cell infiltration to restructure TME. Combined with HIF-1α inhibitor digoxin, 3IZH further reduces HIF-1α resistance, enhances immune cell infiltration, and shows satisfying efficacy in bilateral tumor-bearing mice. The regulatory effect of the immune-suppressive TME, the remarkable therapeutic effect, as well as the safety profile, together indicate the potential of the multifunctional immune stimulator design strategy.

> **中文摘要：**
> 抗肿瘤免疫治疗通过激活免疫系统识别并攻击肿瘤细胞，已成为治疗的重要支柱。然而，其疗效受到免疫抑制性肿瘤微环境（TME）及其相关机制（如缺氧、高谷胱甘肽（GSH）表达和免疫逃逸）的限制。由于TME的复杂性和肿瘤的异质性，单一治疗难以有效调节免疫抑制因素以取得强效疗效。为解决这一问题，本研究开发了一种多功能免疫刺激剂（3IZH），能够同时增强免疫反应、下调GSH水平并缓解缺氧。在弱酸性TME中，该体系可释放光敏剂（3ICy5）和Fe离子。Fe离子通过氧化还原反应和过氧化氢分解消耗GSH并缓解缺氧。3ICy5在内质网（ER）内富集，产生活性氧（ROS），引发严重ER应激和损伤相关分子模式（DAMPs）的释放，从而触发免疫原性细胞死亡（ICD）。Fe离子和ROS还可降低谷胱甘肽过氧化物酶4（GPX4）的表达，导致铁死亡。ICD与铁死亡可促进T细胞浸润，重塑TME。结合HIF-1α抑制剂地高辛，3IZH进一步减弱HIF-1α介导的耐药性，增强免疫细胞浸润，并在双侧荷瘤小鼠模型中展示出令人满意的疗效。其对免疫抑制性TME的调控作用、显著的治疗效果以及良好的安全性共同表明，该多功能免疫刺激剂设计策略具有潜在应用前景。

### 第二部分 AI 大师评价

该研究旨在通过设计多功能纳米免疫刺激剂（3IZH）克服肿瘤免疫抑制微环境的限制，从而提升抗肿瘤免疫疗效。作者综合利用光敏剂、Fe离子及HIF-1α抑制剂的协同作用，实现了免疫激活、缺氧缓解和铁死亡诱导的多重效应。结果显示该体系显著促进T细胞浸润和TME重塑，在动物模型中展现出优异疗效与安全性。研究创新性地整合光免疫、铁死亡及微环境调控策略，为多功能免疫治疗平台提供了新思路。其局限在于仍需在临床前和长期安全性层面进行进一步验证。

---

## 40. KDM6B/SLC10A2 轴通过 ERK/AP-1 信号通路抑制结直肠癌中 MDSCs 的募集

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387297)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387297
**DOI：** 10.1002/advs.202514086

### 第一部分 原文与翻译

**英文原标题：** The KDM6B/SLC10A2 Axis Suppresses MDSCs Recruitment via ERK/AP-1 Signaling in Colorectal Cancer.

> **英文摘要：**
> Colorectal cancer (CRC) progression is regulated by an immunosuppressive tumor microenvironment, but the epigenetic mechanisms governing this milieu remain unclear. This study identifies the histone demethylase KDM6B as a key regulator of myeloid-derived suppressor cells (MDSCs) recruitment in CRC. Intestinal epithelial-specific KDM6B deletion promotes tumor growth by increasing MDSCs-mediated immunosuppression. Mechanistically, KDM6B directly transcriptionally activates solute carrier family 10 member 2 (SLC10A2), whereas its loss increased H3K27me3 repression at the SLC10A2 promoter, activating the ERK/AP-1 pathway and subsequent CXCL/CXCR2-dependent MDSC recruitment. Clinically, KDM6B expression positively correlated with SLC10A2 levels and inversely correlated with MDSC infiltration in human CRC specimens. More importantly, KDM6B knockdown conferred resistance to anti-PD-1 therapy in CRC, whereas its overexpression synergized with anti-PD-1 therapy. In conclusion, this study establishes the KDM6B-SLC10A2 axis as a novel epigenetic immune checkpoint, highlighting its potential as a therapeutic target for reprogramming the immunosuppressive microenvironment in CRC.

> **中文摘要：**
> 结直肠癌（CRC）的进展受免疫抑制性肿瘤微环境调控，但控制这一环境的表观遗传机制仍不清楚。本研究鉴定出组蛋白去甲基化酶 KDM6B 是调节 CRC 中髓源抑制性细胞（MDSCs）募集的关键因子。肠上皮特异性缺失 KDM6B 会通过增强 MDSCs 介导的免疫抑制促进肿瘤生长。在机制上，KDM6B 直接转录激活溶质载体家族 10 成员 2（SLC10A2），而其缺失则增加 SLC10A2 启动子处的 H3K27me3 抑制，从而激活 ERK/AP-1 通路及随后 CXCL/CXCR2 依赖的 MDSC 招募。在临床上，KDM6B 表达与 SLC10A2 水平呈正相关，而与人类 CRC 标本中 MDSC 浸润呈负相关。更重要的是，敲低 KDM6B 会使 CRC 对抗 PD-1 治疗产生耐受性，而其过表达可与抗 PD-1 治疗产生协同作用。综上所述，本研究确立了 KDM6B-SLC10A2 轴作为新的表观遗传免疫检查点，突出了其在重塑 CRC 免疫抑制微环境中的治疗潜力。

### 第二部分 AI 大师评价

本研究揭示了 KDM6B/SLC10A2 轴在结直肠癌中通过 ERK/AP-1 信号途径调控 MDSCs 招募的表观遗传机制。研究采用基因敲除与过表达模型，结合临床样本分析，全面阐明了 KDM6B 对肿瘤免疫微环境的调控作用。结果显示该轴不仅影响免疫细胞浸润，还与抗 PD-1 免疫治疗反应密切相关。该发现为 CRC 的免疫治疗提供了新的表观遗传靶点，但仍需临床研究验证其转化应用价值。

---

## 41. 用于大规模细胞间相互作用研究的单靶配对系统（StarPair）

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387244)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387244
**DOI：** 10.1002/advs.202513951

### 第一部分 原文与翻译

**英文原标题：** Single-Target Pairing System (StarPair) for Large-Scale Interrogation of Cell-Cell Interactions.

> **英文摘要：**
> Coordination of cell populations through intercellular interactions is essential to the formation and function of living organisms. However, technologies enabling systematic dissection of cell-cell communications or manipulation of cell-cell interactions at the single-cell resolution remain largely out of reach. To solve this, a single-target pairing system, termed StarPair, is proposed, for the high-throughput and high-precision combination of desired single targets in droplets. How target buoyancy, target concentration, sorting parameters, droplet flow rates, and electric stimulation collectively determine the single-target pairing performance is comprehensively explored. Upon optimization of these parameters, pairing efficiencies over 95% can be achieved with an operation frequency reaching one million single-target pairs per 9.5 h for two-target assembly. Leveraging StarPair, the immune cell-cancer cell interactions are assessed between 4 × 10 cell pairs and the NK-92MI cells with high secretion capability are further enriched. It is envisioned that StarPair will open new perspectives for characterizing and manipulating cell-cell interactions at scale.

> **中文摘要：**
> 通过细胞间相互作用对细胞群体进行协调，是生物体形成与功能实现的关键。然而，能够在单细胞分辨率下系统剖析细胞间通讯或操纵细胞相互作用的技术仍然十分有限。为解决这一问题，研究者提出了一种称为 StarPair 的单靶配对系统，用于在液滴中以高通量和高精度实现所需单一靶标的组合。研究系统地探讨了靶标浮力、靶标浓度、分选参数、液滴流速以及电刺激等因素如何共同决定单靶配对性能。经过这些参数的优化后，配对效率可超过 95%，并能在两靶组装模式下以每 9.5 小时生成一百万个单靶配对的操作频率运行。利用 StarPair，研究评估了免疫细胞与癌细胞之间的相互作用（约 4 × 10 对细胞），并进一步富集了具有高分泌能力的 NK‑92MI 细胞。预计 StarPair 将为大规模刻画和操控细胞间相互作用开辟新的研究视角。

### 第二部分 AI 大师评价

本研究旨在开发一种高通量、高精度的单靶配对系统 StarPair，用于探究细胞间相互作用机制。其通过优化液滴流控、电刺激等关键参数，实现了超过 95% 的配对效率和百万级单元级别的操作通量。该技术成功应用于免疫细胞与癌细胞相互作用分析，并可筛选出高功能细胞群体。StarPair 的出现显著拓展了单细胞层面分析与操控细胞通讯的能力，然而其在更复杂细胞类型或体内环境中的可适用性仍需进一步验证。

---

## 42. 结直肠癌细胞的武器：RNF32 促使 SPP1 巨噬细胞促进肝转移，并被吲哚-3-乙酸所靶向

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387204)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387204
**DOI：** 10.1002/advs.202519735

### 第一部分 原文与翻译

**英文原标题：** Colorectal Cancer Cell's Weapon: RNF32 Engages SPP1 Macrophages to Foster Liver Metastasis, Targeted by Indole-3-Acetic Acid.

> **英文摘要：**
> Colorectal cancer liver metastasis (CRLM) involves complex molecular mechanisms. By integrating The Cancer Genome Atlas (TCGA) data and employing Cox regression, Weighted Gene Co-expression Network Analysis (WGCNA), and single-cell RNA sequencing, this study identifies RNF32 as a key gene linking poor prognosis to metastasis. Functional assays demonstrate that RNF32 promotes tumor cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) in vitro, and drives tumor growth and liver metastasis in vivo. Mechanistically, RNF32 catalyzes K48-linked ubiquitination at the K60 site of GSK3β, stabilizing β-catenin and activating the Wnt signaling pathway, thereby upregulating CCL2. Mass cytometry and other experiments further reveal that RNF32 recruits SPP1 macrophages via CCL2 to remodel the metastatic niche, a process dependent on the CCR2/FABP1/PPARG axis. Macrophage depletion abrogates metastasis, while the FABP1 inhibitor orlistat reverses SPP1 upregulation in macrophages. Moreover, SPP1 macrophages interact with tumor cell CD44, synergizing with RNF32 to enhance cancer stemness via Wnt signaling. Importantly, virtual screening identifies indole-3-acetic acid (IAA) as an RNF32 inhibitor that suppresses liver metastasis and reverses immunosuppression in vivo. This study establishes RNF32 as a dual-functional driver of metastasis and proposes IAA as a promising therapeutic agent, offering new hope for targeting both tumor-intrinsic EMT and the immune microenvironment in CRC liver metastasis.

> **中文摘要：**
> 结直肠癌肝转移（CRLM）涉及复杂的分子机制。通过整合癌症基因组图谱（TCGA）数据，并采用 Cox 回归、加权基因共表达网络分析（WGCNA）以及单细胞 RNA 测序，本研究确定 RNF32 是连接预后不良与转移的关键基因。功能实验表明，RNF32 可在体外促进肿瘤细胞增殖、侵袭及上皮-间质转化（EMT），并在体内驱动肿瘤生长和肝转移。在机制上，RNF32 在 GSK3β 的 K60 位点催化 K48 连接型泛素化，从而稳定 β-连环蛋白并激活 Wnt 信号通路，进而上调 CCL2。质谱细胞术及其他实验进一步揭示，RNF32 通过 CCL2 招募 SPP1 巨噬细胞以重塑转移性微环境，这一过程依赖于 CCR2/FABP1/PPARG 轴。消除巨噬细胞可阻断转移，而 FABP1 抑制剂奥利司他可逆转巨噬细胞中 SPP1 的上调。此外，SPP1 巨噬细胞与肿瘤细胞 CD44 相互作用，并与 RNF32 协同，通过 Wnt 信号增强癌症干性。重要的是，虚拟筛选鉴定出吲哚-3-乙酸（IAA）为 RNF32 抑制剂，可在体内抑制肝转移并逆转免疫抑制。本研究确立了 RNF32 作为促进转移的双功能驱动因子，并提出 IAA 作为一种有前景的治疗药物，为靶向肿瘤内在 EMT 与免疫微环境的结直肠癌肝转移提供了新的希望。

### 第二部分 AI 大师评价

本研究通过整合多组学数据与单细胞测序，系统揭示了 RNF32 在结直肠癌肝转移中的核心驱动作用及其免疫微环境调控机制。研究以 TCGA 数据筛选关键基因，并通过体内外功能实验验证 RNF32 促进肿瘤进展和重塑免疫生态的作用链条。创新性地发现 RNF32 通过调控 GSK3β 泛素化激活 Wnt 信号，并通过 CCL2 介导 SPP1 巨噬细胞募集。此外，研究利用虚拟筛选鉴定出 RNF32 抑制剂吲哚-3-乙酸，为结直肠癌转移的靶向治疗提供了新策略。局限性在于其临床验证仍待进一步开展。

---

## 43. 卤海鞘灵B：一种来源于海洋海鞘的新型萜类化合物，通过靶向细胞周期调控因子UBE2C抑制肿瘤生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387196)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387196
**DOI：** 10.1002/advs.202515652

### 第一部分 原文与翻译

**英文原标题：** Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C.

> **英文摘要：**
> Screening and identification of novel small-molecule have proven to be effective strategies in addressing the growing threat of cancer to human health. In this study, a novel natural terpenoid compound, Halorotetin B, is identified from the edible ascidian Halocynthia roretzi. Halorotetin B is shown to significantly inhibit tumor growth both in vitro and in vivo. Mechanistically, the E2 ubiquitin-conjugating enzyme C (UBE2C) is identified as a direct binding target of Halorotetin B through a combination of the peptide-centric local stability assay and the omics-based target enrichment and ranking. Further investigations reveal that Halorotetin B binding to UBE2C induced M phase cell cycle arrest by inhibiting the ubiquitin-mediated degradation of key cell cycle regulators, including cyclin B1 and securin, ultimately leading to tumor cell senescence. These findings suggest that Halorotetin B, as a novel cell cycle inhibitor targeting UBE2C, holds strong potential for development into ascidian-derived therapeutics for cancer treatment.

> **中文摘要：**
> 新型小分子化合物的筛选与鉴定已被证明是应对癌症对人类健康日益增长威胁的有效策略。在本研究中，从可食用海鞘——食用海鞘（Halocynthia roretzi）中鉴定出一种新型天然萜类化合物——卤海鞘灵B。研究结果显示，卤海鞘灵B在体外和体内均可显著抑制肿瘤生长。在作用机制方面，通过结合基于肽的局部稳定性检测与组学靶点富集及排序方法，发现E2泛素结合酶C（UBE2C）是卤海鞘灵B的直接结合靶点。进一步研究表明，卤海鞘灵B与UBE2C结合后，通过抑制包括Cyclin B1和Securin在内的关键细胞周期调节因子的泛素介导降解，诱导细胞周期在M期阻滞，最终导致肿瘤细胞衰老。这些发现表明，作为一种靶向UBE2C的新型细胞周期抑制剂，卤海鞘灵B具有发展为源自海鞘的抗癌治疗药物的巨大潜力。

### 第二部分 AI 大师评价

本研究通过天然产物筛选发现了来源于海鞘的全新萜类化合物卤海鞘灵B，并首次揭示其通过直接靶向UBE2C抑制肿瘤细胞生长的分子机制。该化合物通过干扰细胞周期蛋白的泛素化降解，诱导M期阻滞和细胞衰老，是潜在的UBE2C靶向抑制剂。在研究设计上，作者结合了组学富集、靶点稳定性分析与生物验证，方法系统且多层验证充分。尽管结果具有较高创新性，但其药代动力学与临床适用性仍有待进一步研究。

---

## 44. 移植前联合GLP-1受体激动剂与SGLT2抑制剂治疗对肥胖及2型糖尿病器官移植候选者全因死亡率的影响：一项目标试验模拟研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387113)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387113
**DOI：** 10.1002/advs.202518813

### 第一部分 原文与翻译

**英文原标题：** Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.

> **英文摘要：**
> Evidence on pre-transplant metabolic therapy remains limited. We evaluated whether concurrent glucagon-like peptide-1 receptor agonist (GLP-1 RA) plus sodium-glucose cotransporter 2 inhibitor (SGLT2i) use before solid-organ transplantation is was associated with post-transplant outcomes in adults with obesity and type 2 diabetes. A target trial is emulated using de-identified electronic health records from TriNetX US. Dual therapy is compared with GLP-1 RA, SGLT2i, and usual care using 1:1 propensity-score matching. The primary outcome is all-cause mortality at 12 months; kidney graft failure, rejection, complications, and infections are secondary. Sensitivity analyses included the global network, landmark, extensions at 24 and 36 months. Three matched cohorts are constructed, dual versus GLP-1 RA (n = 4718 pairs), dual versus SGLT2i (n = 4282), and dual versus usual care (n = 3787). At 12 months, dual therapy is associated with lower mortality versus GLP-1 RA (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.57-0.85), SGLT2i (0.59, 0.48-0.72), and usual care (0.52, 0.43-0.64). Infection endpoints are neutral or lower. Estimates are consistent across sensitivity analyses. In transplant candidates with obesity and type 2 diabetes, pre-transplant GLP-1 RA+SGLT2i use is associated with lower mortality than monotherapy or usual care. Prospective evaluation is warranted.

> **中文摘要：**
> 关于移植前代谢治疗的证据仍然有限。本研究评估了在肥胖和2型糖尿病成人中，固体器官移植前同时使用胰高糖素样肽-1受体激动剂（GLP-1 RA）联合钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）是否与移植后的结局相关。研究利用来自美国TriNetX数据库的去标识电子健康记录，模拟了一项目标试验。采用1:1倾向评分匹配，将双重治疗组与GLP-1 RA组、SGLT2i组及常规治疗组进行比较。主要结局为12个月全因死亡率；次要结局包括肾移植物衰竭、排斥反应、并发症及感染。敏感性分析包括全球网络分析、里程碑分析及在24个月与36个月的延伸分析。共建立了三组匹配队列：双重治疗对比GLP-1 RA组（n=4718对）、双重治疗对比SGLT2i组（n=4282对）、双重治疗对比常规治疗组（n=3787对）。在12个月时，双重治疗的死亡率较GLP-1 RA组（危险比[HR] 0.69，95%置信区间[CI] 0.57–0.85）、SGLT2i组（HR 0.59，CI 0.48–0.72）和常规治疗组（HR 0.52，CI 0.43–0.64）均显著降低。感染相关终点呈中性或更低。敏感性分析结果一致。在肥胖及2型糖尿病的移植候选者中，移植前联合使用GLP-1 RA与SGLT2i与较低的死亡率相关，相较单药或常规治疗更具优势。未来需进行前瞻性研究验证。

### 第二部分 AI 大师评价

本研究通过目标试验模拟方法，系统评估了肥胖及2型糖尿病器官移植候选者中，移植前联合GLP-1 RA与SGLT2i治疗的潜在获益。利用大规模真实世界电子健康记录并进行严格的倾向评分匹配，研究显示双重代谢治疗显著降低12个月全因死亡率，相较单药及常规治疗更具生存优势。结果在多重敏感性分析中保持一致，提示其可能的稳健性。该研究创新性地将代谢合并策略引入移植前治疗领域，但由于为模拟性回顾研究，因果推断仍需前瞻性临床试验证实。

---

## 45. 用于膀胱癌多机制协同免疫治疗的近红外激活多米诺级联催化纳米酶反应器

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387105)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387105
**DOI：** 10.1002/advs.202513913

### 第一部分 原文与翻译

**英文原标题：** NIR-Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi-Mechanism Synergistic Immunotherapy in Bladder Cancer.

> **英文摘要：**
> Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off-target effects, and insufficient efficacy. To address these challenges, this study designs a thermo-responsive hydrogel (PNH) that encapsulates chitosan (CS)-coated Fe/Mn bimetallic nanozymes (FMCC) together with cholesterol oxidase (ChOx). FMCC displays multiple enzyme-mimicking activities, including peroxidase (POD), catalase (CAT), and glutathione oxidase (GSHox). ChOx amplifies this catalytic cascade, enhancing reactive oxygen species (ROS) production and inducing ferroptosis-mediated tumor cell death. The CS coating improves mucosal adhesion and tissue permeability, thereby facilitating intravesical delivery. Upon near-infrared (NIR) irradiation, FMCC generates heat that liquefies the hydrogel, enabling spatiotemporally controlled drug release and providing mild photothermal therapy (MPTT). This photothermal effect acts synergistically with ferroptosis induction and immune modulation, concurrently minimizing damage to normal tissues. In parallel, ChOx disrupts cholesterol-rich membrane rafts and promotes pro-inflammatory M1 macrophage polarization. Released Mn ions further potentiate immune activation by stimulating the cGAS-STING pathway, driving IFN-β and IL-6 secretion, dendritic cell maturation, and T cell infiltration. Together, this nanozyme-hydrogel system integrates tissue penetration, metabolic disruption, and immune stimulation, representing a promising strategy for localized bladder cancer therapy.

> **中文摘要：**
> 目前，膀胱癌术后膀胱灌注治疗受限于组织渗透性差、脱靶效应明显及疗效不足。为解决这些问题，本研究设计了一种热响应型水凝胶（PNH），其共封装了壳聚糖（CS）包覆的铁/锰双金属纳米酶（FMCC）以及胆固醇氧化酶（ChOx）。FMCC表现出多种酶仿活性，包括过氧化物酶（POD）、过氧化氢酶（CAT）及谷胱甘肽氧化酶（GSHox）活性。ChOx放大了该催化级联反应，增强活性氧（ROS）的产生，引发铁死亡介导的肿瘤细胞死亡。CS包覆层提高了黏膜黏附性和组织渗透性，从而促进了膀胱内给药。受近红外（NIR）照射后，FMCC产热使水凝胶液化，实现了时空可控的药物释放，并提供了温和的光热治疗（MPTT）。该光热效应与铁死亡诱导及免疫调节协同作用，同时最大限度地减少了正常组织损伤。同时，ChOx可破坏富含胆固醇的膜筏，并促进促炎性M1型巨噬细胞极化。释放的锰离子进一步通过激活cGAS-STING通路增强免疫应答，驱动IFN-β和IL-6分泌、树突状细胞成熟以及T细胞浸润。总体而言，该纳米酶-水凝胶系统整合了组织渗透、代谢干扰和免疫刺激功能，表现出一种有前景的局部膀胱癌治疗策略。

### 第二部分 AI 大师评价

该研究针对膀胱癌术后局部治疗效果有限的问题，创新性地构建了可近红外激活的热响应纳米酶-水凝胶系统，通过多模式协同（光热、铁死亡与免疫激活）实现精准、时空可控的抗肿瘤效应。系统整合了胆固醇氧化酶催化级联、Mn离子免疫增强以及壳聚糖改性以提高组织渗透性，体现出良好的工程设计与免疫治疗融合理念。该策略在调控肿瘤代谢、改善免疫微环境方面显示出显著潜力，但未来仍需评估其长期安全性与体内转化应用可行性。

---

## 46. 用于表征细胞外囊泡表面蛋白及其细胞相互作用者的内源性蛋白探针的开发

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387095)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41387095
**DOI：** 10.1002/advs.202511414

### 第一部分 原文与翻译

**英文原标题：** Development of Endogenous Protein Probes for Characterizing Surface Proteins and Cellular Interactors of Extracellular Vesicles.

> **英文摘要：**
> Extracellular vesicle (EV) surface proteins, derived from producer cells and their surrounding environment, represent a valuable source of biomarkers and participate in a plethora of biological functions, including intercellular communication. However, current methods struggle to distinguish core EV surface proteins from adsorbed corona proteins or map the EV-cell interplay. Here, a genetically encoded proximity labelling probe is presented that displays engineered ascorbate peroxidase, APEX2, on the surface of EVs via fusion to EV-sorting scaffold proteins. This enables the biotinylation of producer-cell-derived surface proteins, corona proteins, and interactors in vitro. After the enrichment by streptavidin bead pulldowns, subpopulation-specific, biotinylated surfaceome and interactome are comprehensively characterized using mass spectrometry-based proteomics. Thus, a genetic tool is introduced for the high-fidelity mapping of the surfaceome and cellular interactome of EVs in vitro. This approach offers a robust framework for dissecting EV biology and has broad applications in biomarker discovery and EV-based therapeutics.

> **中文摘要：**
> 细胞外囊泡（EV）的表面蛋白来源于产生细胞及其周围的环境，是重要的生物标志物来源，并参与包括细胞间通讯在内的多种生物学功能。然而，现有方法难以区分EV核心表面蛋白与吸附的冠层蛋白，或者解析EV与细胞之间的相互作用。在此，研究者提出了一种遗传编码的邻近标记探针，通过将工程化的抗坏血酸过氧化物酶APEX2与EV分选支架蛋白融合，从而在EV表面展示该酶。该方法可在体外实现对来源于产生细胞的表面蛋白、冠层蛋白及其相互作用者的生物素化。经链霉亲和素磁珠富集后，利用基于质谱的蛋白质组学技术，可全面表征亚群特异性的生物素化表面组和相互作用组。因此，该研究引入了一种可在体外对EV表面组和细胞相互作用组进行高保真映射的遗传学工具。该方法为解析EV生物学提供了坚实的研究框架，并在生物标志物发现及基于EV的治疗研究中具有广阔的应用前景。

### 第二部分 AI 大师评价

本研究旨在开发一种基于遗传编码的APEX2邻近标记探针，用于精确描绘细胞外囊泡（EV）的表面蛋白和与细胞相互作用的蛋白网络。通过在EV表面展示APEX2并实现对表面及相互作用蛋白的生物素化，研究者成功实现了对EV特异性表面组与交互组的系统分析。该方法创新性地解决了冠层蛋白干扰与表面蛋白区分的难题，为EV生物学研究奠定了新技术基础。其优点在于高特异性与可操作性，但未来仍需在体内系统中验证其适用性和通用性。

---

## 47. 异常脂质代谢重塑鼻咽癌骨转移的免疫图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41386974)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41386974
**DOI：** 10.1136/jitc-2025-012134

### 第一部分 原文与翻译

**英文原标题：** Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma.

> **英文摘要：**
> BACKGROUND: Bone metastasis (BM) drives therapeutic resistance and mortality in nasopharyngeal carcinoma (NPC). Tumor metabolites are crucial for NPC metastasis; however, the mechanisms by which these metabolites synergistically alter the immune microenvironment to promote BM remain unclear.
> 
> METHODS: In this study, limited immune infiltration was observed in the NPC BM tumor microenvironment. Multiomics analysis has identified sphingosine kinase 1 (SPHK1) as a pivotal mediator driving BM and immune evasion in NPC, orchestrating the production of 1-phosphorylated sphingosine (S1P), which is critical for NPC pathogenesis.
> 
> RESULTS: The aberrant buildup of lipid metabolites, along with immune microenvironment shifts, serves as a critical driver of NPC BM. Mechanistically, S1P enhanced osteoclast recruitment via S1PR3 binding and activated the Hippo pathway, worsening bone colonization and facilitating immune evasion by expanding the exhausted CD8 T cell population.
> 
> CONCLUSIONS: The synergy between the SPHK1 inhibitor PF543 and anti-programmed cell death protein 1 therapy amplified treatment effectiveness beyond standalone approaches. Overall, the SPHK1/S1P pathway advances NPC growth and aids in suppressing immune defense. Regulation of lipid metabolism may be a therapeutic target against BM in NPC and may improve the effectiveness of immunotherapy.

> **中文摘要：**
> 背景：骨转移（BM）导致鼻咽癌（NPC）的治疗耐药性和死亡率升高。肿瘤代谢产物在NPC转移过程中起关键作用；然而，这些代谢产物如何协同改变免疫微环境以促进骨转移的机制仍不清楚。
> 
> 方法：本研究发现，在NPC骨转移的肿瘤微环境中，免疫细胞浸润受限。多组学分析确定鞘氨醇激酶1（SPHK1）是驱动NPC骨转移及免疫逃逸的关键介质，它调控1-磷酸鞘氨醇（S1P）的生成，而S1P对NPC发病机制至关重要。
> 
> 结果：脂质代谢产物的异常积累伴随免疫微环境的改变，共同成为NPC骨转移的重要驱动力。从机制上看，S1P通过与S1PR3结合增强破骨细胞募集，并激活Hippo通路，从而加剧骨定植并通过扩增衰竭型CD8 T细胞群促进免疫逃逸。
> 
> 结论：SPHK1抑制剂PF543与抗程序性死亡蛋白1（PD-1）治疗的联合应用产生协同效应，显著提高治疗效果，优于单一治疗。总体而言，SPHK1/S1P通路促进NPC生长并抑制免疫防御。调控脂质代谢可能成为针对NPC骨转移的潜在治疗靶点，并有望提升免疫治疗的疗效。

### 第二部分 AI 大师评价

本研究针对鼻咽癌骨转移的免疫微环境调控机制进行了系统性探索，揭示了脂质代谢异常通过SPHK1/S1P轴驱动免疫逃逸与骨定植的重要作用。研究采用多组学方法，明确SPHK1在调控鞘氨醇信号及影响T细胞功能中的核心地位，并验证了SPHK1抑制剂联合免疫检查点阻断治疗的潜在协同效应。该工作为鼻咽癌转移治疗提供了新的代谢-免疫交互靶点，但仍需进一步临床实验证实其转化价值。

---

## 48. DC原位激活疫苗联合CD137激动剂通过cDC1介导的肿瘤抗原特异性CD8 T细胞反应诱导持久的抗肿瘤免疫反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41386973)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41386973
**DOI：** 10.1136/jitc-2025-011665

### 第一部分 原文与翻译

**英文原标题：** In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8 T cell responses.

> **英文摘要：**
> BACKGROUND: Intratumoral vaccines offer a promising avenue in cancer immunotherapy by harnessing the tumor microenvironment to stimulate immune responses. However, challenges persist in maximizing their effectiveness and addressing immune suppression within tumors.
> 
> METHODS: Conventional in situ vaccine (CisVac) and α-CD137 antibody were administered in implanted mouse models of lung and colon cancer to evaluate therapeutic efficacy. The initiation mechanism of CD8 T cells was determined using antibody blockade and transgenic mouse models. Single-cell RNA sequencing was used to further characterize the activation mechanism of T cells.
> 
> RESULTS: Our findings indicate that this synergistic approach markedly inhibits tumor growth while eliciting a robust antitumor immune response, characterized by heightened activation and cytotoxic differentiation of CD8 T cells, as well as the polarization of conventional dendritic cells (cDC1). Mechanistically, it promotes the cDC1-dependent proportion and cytokine production of tumor antigen-specific CD8 T cells, mobilizes and establishes enduring systemic immune memory. Our single-cell transcriptome analyses revealed that the therapy facilitates a functional remodeling of regulatory T cells (Tregs) with upregulated inflammatory genes, potentially attenuating immune suppression. Cell-cell communication analyses highlighted interactions between CD4 Th1-like/Th17 cells and monocytes/DCs through the CD40L-CD40 pathway, indicating potential intercellular regulatory mechanisms.
> 
> CONCLUSIONS: Our results highlight the transformative potential of the CisVac/α-CD137 combination in cancer immunotherapy, paving the way for further exploration of its clinical utility and long-term efficacy.

> **中文摘要：**
> 背景：肿瘤内疫苗通过利用肿瘤微环境激发免疫反应，为癌症免疫治疗提供了有前景的途径。然而，如何最大化其疗效并克服肿瘤内免疫抑制仍然是挑战。
> 
> 方法：在移植性肺癌和结肠癌小鼠模型中给予常规原位疫苗（CisVac）和α-CD137抗体，以评估其治疗效果。通过抗体阻断和转基因小鼠模型分析CD8 T细胞的启动机制。采用单细胞RNA测序进一步表征T细胞的激活机制。
> 
> 结果：我们的研究表明，该协同策略显著抑制了肿瘤生长，同时诱导了强烈的抗肿瘤免疫反应，其特征是CD8 T细胞的活化增强和细胞毒性分化，以及常规树突状细胞（cDC1）的极化。从机制上看，该方案可促进cDC1依赖的肿瘤抗原特异性CD8 T细胞比例及其细胞因子产生，动员并建立持久的系统性免疫记忆。单细胞转录组分析显示，该治疗促进了调节性T细胞（Tregs）的功能重塑，其炎症相关基因上调，可能削弱免疫抑制。细胞间通讯分析显示，CD4 Th1样/Th17细胞与单核细胞/DCs通过CD40L-CD40通路进行互作，提示潜在的细胞间调控机制。
> 
> 结论：本研究结果突显了CisVac/α-CD137联合策略在癌症免疫治疗中的变革潜力，为其临床应用及长期疗效的进一步探索奠定基础。

### 第二部分 AI 大师评价

本研究旨在评估原位树突状细胞诱导疫苗与CD137激动剂联合治疗的抗肿瘤免疫效应。作者利用小鼠肿瘤模型和单细胞RNA测序解析其作用机制，发现联合疗法显著增强CD8 T细胞的激活和记忆反应，并促进cDC1依赖的免疫过程，同时减弱Treg相关免疫抑制。该研究揭示了肿瘤内疫苗策略与共刺激信号协同的潜力，具有创新意义，但仍需在临床模型中验证其安全性与持久性。

---

## 49. TIM-3阻断增强造血细胞移植后复发小鼠神经母细胞瘤的体外刺激异基因NK细胞治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41386972)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41386972
**DOI：** 10.1136/jitc-2024-010239

### 第一部分 原文与翻译

**英文原标题：** TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant.

> **英文摘要：**
> BACKGROUND: High-risk neuroblastoma (HR-NBL) is an aggressive tumor of the sympathetic nervous system with high risk of relapse and poor overall survival. Allogeneic hematopoietic cell transplant (allo-HCT) has been used previously in patients with HR-NBL; however, graft-versus-host disease (GVHD) and disease progression have limited clinical application. Ex vivo stimulated allogeneic natural killer (NK) cells represent an approach to enhance the graft-versus-tumor (GVT) effect without exacerbation of GVHD but have not shown efficacy in NBL.
> 
> METHODS: Ex vivo stimulated NK cells from C57BL/6NCr (B6) mice were expanded with soluble interleukin-15 (IL-15) and IL-15 receptor alpha (IL-15Rα) alone or with irradiated CD137L/CD54 aggressive variant of the Neuro-2a murine neuroblastoma cell line (15-4P) at a 1:1 ratio for 10-12 days. Allogeneic NK cells were then analyzed for activation, proliferation, cytokine production, and cytotoxicity against two murine NBL cell lines, Neuro2a and NXS2, in the absence or presence of anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Lethally irradiated B6AJF1 mice received allo-HCT from B6 donors followed by NBL challenge after 7 days to mimic tumor relapse. Select groups received anti-TIM-3 starting on day 9 for every 4 days with/without infusions of 15-4P B6 NK cells on days 14, 21, and 28. In select experiments, T cell and NK cells were selectively depleted to establish contribution to the GVT effect. All groups were analyzed for tumor growth, GVHD and survival.
> 
> RESULTS: Co-culturing NK cells with 15-4P results in 78-fold expansion with increased expression of Kiel-67 (Ki-67) and Natural Killer Group 2, Member D (NKG2D), NKp46, TNF-Related Apoptosis-Inducing Ligand (TRAIL) and TIM-3. 15-4P stimulated allogeneic NK cells showed enhanced cytotoxicity against NBL compared with IL-15 NK cells alone but was limited in part due to high expression of TIM-3 ligands on Neuro-2a compared with NXS2. The addition of TIM-3 blockade further enhanced NK cytotoxicity versus Neuro-2a, with enhanced 15-4P NK cell degranulation, Eomesodermin, TRAIL and Fas Ligand expression observed. In vivo, the combination of 15-4P stimulated allogeneic NK cells and TIM-3 blockade after allo-HCT resulted in prolonged survival against NBL with decreased tumor burden compared with NK cells or anti-TIM-3 alone. Depletion of NK cells, but not T cells, abrogated the GVT effect.
> 
> CONCLUSION: Allo-HCT can be a platform for treating NBL using combination ex vivo stimulated allogeneic NK cell therapy with TIM-3 blockade to enhance the GVT effect without inducing GVHD.

> **中文摘要：**
> 背景：高危神经母细胞瘤（HR-NBL）是一种起源于交感神经系统的侵袭性肿瘤，具有高复发风险和较差的总体生存率。异基因造血细胞移植（allo-HCT）此前已用于HR-NBL患者的治疗，但移植物抗宿主病（GVHD）和疾病进展限制了其临床应用。体外刺激的异基因自然杀伤（NK）细胞被认为是一种在不加重GVHD的情况下增强移植物抗肿瘤（GVT）效应的策略，但在NBL中尚未显示出疗效。
> 
> 方法：从C57BL/6NCr（B6）小鼠中分离的体外刺激NK细胞，与可溶性白细胞介素-15（IL-15）及IL-15受体α（IL-15Rα）单独或与经照射的Neuro-2a小鼠神经母细胞瘤细胞株的攻击性变体（15-4P，表达CD137L/CD54）以1:1比例共培养扩增10–12天。随后分析异基因NK细胞的激活、增殖、细胞因子产生及其对两种小鼠NBL细胞系（Neuro2a和NXS2）的细胞毒性作用，在无或有抗T细胞免疫球蛋白及黏蛋白结构域3（TIM-3）阻断的条件下进行。致死照射的B6AJF1小鼠接受来自B6供体的allo-HCT，并于7天后接受NBL细胞攻击以模拟肿瘤复发。部分实验组从第9天开始每4天给予抗TIM-3，伴或不伴于第14、21和28天输注15-4P刺激的B6 NK细胞。在特定实验中，通过选择性去除T细胞或NK细胞以确定其对GVT效应的贡献。所有组均被分析肿瘤生长、GVHD及生存情况。
> 
> 结果：NK细胞与15-4P共培养后扩增达78倍，并伴随Ki-67、NKG2D、NKp46、TNF相关凋亡诱导配体（TRAIL）及TIM-3的高表达。与单独使用IL-15培养的NK细胞相比，15-4P刺激的异基因NK细胞对NBL的细胞毒性增强，但部分受到Neuro-2a细胞上高表达TIM-3配体的限制。加入TIM-3阻断进一步增强了针对Neuro-2a的NK细胞毒性，同时观察到15-4P NK细胞脱颗粒、Eomesodermin、TRAIL及Fas配体的表达增强。在体内实验中，allo-HCT后联合应用15-4P刺激的异基因NK细胞与TIM-3阻断可显著延长NBL负荷小鼠的存活期，并降低肿瘤负担，相较于单用NK细胞或抗TIM-3治疗。去除NK细胞但非T细胞会消除GVT效应。
> 
> 结论：allo-HCT可作为治疗NBL的平台，结合体外刺激的异基因NK细胞疗法与TIM-3阻断可增强GVT效应而不诱发GVHD。

### 第二部分 AI 大师评价

本研究旨在通过TIM-3阻断增强异基因造血干细胞移植后复发神经母细胞瘤模型的NK细胞治疗效果。研究采用体外共培养扩增NK细胞及TIM-3抑制策略，系统评估其激活状态、细胞毒性与体内抗肿瘤作用。结果显示，TIM-3阻断显著提高了NK细胞的活化及杀瘤能力，延长了移植后小鼠的生存期，而不增加GVHD风险。该研究创新性地验证了TIM-3为异基因NK细胞治疗NBL的关键调控靶点，但主要限于小鼠模型，仍需临床验证。

---

## 50. 用于低氧肿瘤治疗的I型光敏剂闭环混合发现系统

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41386764)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41386764
**DOI：** 10.1002/advs.202515103

### 第一部分 原文与翻译

**英文原标题：** A Closed-Loop Hybrid Discovery System of Type I Photosensitizers for Hypoxic Tumor Therapy.

> **英文摘要：**
> Type I photosensitizers (PSs), which operate effectively under low-oxygen conditions, offer a promising approach to overcome hypoxia-associated challenges in solid tumor therapy. However, their design remains challenging due to the limited number of reported molecules with diverse structures, as well as insufficient understanding of the underlying mechanisms. Herein, a closed-loop hybrid discovery system is developed that combines molecular excited-state calculations with machine learning (ML) to rationally design and predict high-performance Type I PSs for hypoxic tumor therapy. Through a support vector machine (SVM) classification model, 664 potential Type I PSs are identified from a molecular space based on donor-acceptor (D-A) and donor-acceptor-donor (D-A-D) structures. Among these, two candidates, M1 and M2, are synthesized and experimentally verified as Type I PSs, exhibiting aggregate-induced enhancement of Type I reactive oxygen species (ROS) generation. Both in vitro and in vivo studies demonstrated their ability to induce intracellular Type I ROS generation and effectively suppress tumor growth. The work highlights the potential of ML in the design and prediction of Type I PSs for hypoxic tumor therapy.

> **中文摘要：**
> I型光敏剂（PSs）能在低氧条件下有效工作，为克服实体肿瘤治疗中与缺氧相关的挑战提供了有前景的途径。然而，由于目前报道的具有多样结构的分子数量有限，且对其作用机制理解不足，其设计仍具有相当的挑战性。本文开发了一种闭环混合发现系统，将分子激发态计算与机器学习（ML）相结合，用于理性设计和预测适用于低氧肿瘤治疗的高性能I型光敏剂。通过支持向量机（SVM）分类模型，从以供体-受体（D-A）及供体-受体-供体（D-A-D）为构型的分子空间中识别出664种潜在的I型光敏剂。其中，两种候选分子M1和M2被成功合成并在实验上验证为I型光敏剂，表现出聚集诱导的I型活性氧（ROS）产生增强效应。体内和体外研究均表明，它们能有效诱导细胞内I型ROS的生成并抑制肿瘤生长。该研究强调了机器学习在低氧肿瘤治疗I型光敏剂设计与预测中的潜在价值。

### 第二部分 AI 大师评价

该研究旨在利用机器学习与量子化学计算相结合的闭环系统，加速低氧环境下I型光敏剂的发现与优化。研究通过SVM模型在结构筛选中识别出多种潜在分子，并成功合成验证了其中两种具代表性的候选物。结果显示这些分子在聚集状态下具有增强的活性氧生成能力，并能有效抑制肿瘤生长，展示出强大的应用潜力。该方法突出了人工智能助力药物设计的创新性，但仍需在更多结构体系与生物模型中验证其泛化性与稳定性。

---

## 51. 一线治疗后大B细胞淋巴瘤循环肿瘤DNA可测残留病灶的前瞻性验证研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385760)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41385760
**DOI：** 10.1200/JCO-25-01712

### 第一部分 原文与翻译

**英文原标题：** Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.

> **英文摘要：**
> PURPOSE: End-of-treatment (EOT) response evaluation by positron emission tomography (PET) remains suboptimal in patients with large B-cell lymphoma (LBCL), because of its limited positive predictive value (PPV). Circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) detection offers a minimally invasive approach and may improve prognostication. We prospectively evaluated EOT MRD using phased variant enrichment and detection sequencing (PhasED-Seq) in patients with first-line LBCL.
> 
> METHODS: Patients were enrolled in the HOVON-902 prospective cohort and received curative-intent first-line treatment. Phased variants (PVs) were identified and tracked using tumor biopsies or pretreatment plasma. The prognostic significance of EOT ctDNA-MRD status in progression-free survival (PFS) and overall survival (OS) was compared with that of the International Prognostic Index (IPI) and EOT PET-computed tomography (CT).
> 
> RESULTS: PV identification was successful in 134 of 136 (99%) using either tissue or plasma. At EOT, 83% of patients were MRD-negative and 17% of patients were MRD-positive. MRD positivity was strongly associated with inferior outcomes: the 3-year PFS was 17% in MRD-positive versus 85% in MRD-negative patients (hazard ratio [HR], 9.8 [95% CI, 5.1 to 19];  = 9.63 × 10), and the OS was 43% versus 92%, respectively (HR, 7.7 [95% CI, 3.4 to 17.4];  = 1.27 × 10). In multivariate analysis, MRD was an independent prognostic factor when controlling for IPI and EOT PET-CT. MRD positivity had a higher PPV for 2-year PFS than positive PET (68%  56%,  ≤ .001), whereas negative predictive value was similar between negative MRD and PET (89%  88%,  = .71). MRD positivity was associated with a significantly higher relapse risk within both complete metabolic response (CMR) and non-CMR subgroups.
> 
> CONCLUSION: This study validates ultrasensitive ctDNA-MRD detection using PhasED-Seq in a uniformly treated, prospective real-world LBCL cohort. These findings support further evaluation of MRD integration into clinical response assessment.

> **中文摘要：**
> 研究目的：在大B细胞淋巴瘤（LBCL）患者中，由于正电子发射断层扫描（PET）在治疗结束时（EOT）的阳性预测值（PPV）有限，其疗效评估仍不理想。基于循环肿瘤DNA（ctDNA）的可测残留病灶（MRD）检测提供了一种微创的方法，可能改善预后评估。本研究前瞻性地在一线LBCL患者中，采用相位突变富集与检测测序（PhasED-Seq）评估EOT时的MRD状态。
> 
> 方法：患者纳入HOVON-902前瞻性队列，并接受治愈意图的一线治疗。通过肿瘤活检或治疗前血浆识别并追踪相位突变（PVs）。比较EOT ctDNA-MRD状态与国际预后指数（IPI）及EOT PET-CT在无进展生存期（PFS）和总生存期（OS）方面的预后意义。
> 
> 结果：在136例患者中，有134例（99%）通过组织或血浆成功进行PVs识别。在EOT时，83%的患者MRD阴性，17%的患者MRD阳性。MRD阳性与较差的结局显著相关：MRD阳性患者3年PFS为17%，而MRD阴性患者为85%（风险比[HR] 9.8 [95% CI, 5.1–19]）；相应的OS分别为43%和92%（HR 7.7 [95% CI, 3.4–17.4]）。在多变量分析中，MRD在控制IPI和EOT PET-CT后仍为独立的预后因素。MRD阳性对2年PFS的阳性预测值高于PET阳性（68%对56%，P ≤ .001），而阴性预测值在MRD阴性与PET阴性之间相似（89%对88%，P = .71）。无论在完全代谢缓解（CMR）还是非CMR亚组中，MRD阳性均与明显更高的复发风险相关。
> 
> 结论：本研究在均一治疗的真实世界LBCL前瞻性队列中验证了采用PhasED-Seq的超灵敏ctDNA-MRD检测方法。这些结果支持将MRD检测纳入临床疗效评估体系的进一步探索。

### 第二部分 AI 大师评价

该研究旨在前瞻性验证通过PhasED-Seq技术检测循环肿瘤DNA残留病灶在LBCL中的预后价值。研究结果显示，EOT时ctDNA MRD阳性与显著较差的无进展和总生存期相关，并具有较PET更高的阳性预测力。研究利用真实世界的前瞻性队列，验证了ctDNA-MRD作为独立预后指标的临床潜力。其创新性在于应用高灵敏PhasED-Seq检测技术，但仍需更大规模、多中心验证其在治疗决策中的实际应用价值。

---

## 52. Ribociclib联合来曲唑治疗复发性卵巢、输卵管或腹膜低级别浆液性癌女性患者的II期临床试验：GOG合作试验（GOG 3026）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385758)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41385758
**DOI：** 10.1200/JCO-25-01348

### 第一部分 原文与翻译

**英文原标题：** Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

> **英文摘要：**
> PURPOSE: Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)-p16-Rb pathway, features shared with hormone receptor-positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC.
> 
> METHODS: This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety.
> 
> RESULTS: Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed.
> 
> CONCLUSION: Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.

> **中文摘要：**
> 研究目的：卵巢、输卵管或腹膜的低级别浆液性癌（LGSOC）是一种受激素驱动、相对耐化疗且在复发时治疗选择有限的恶性肿瘤。鉴于其常见的雌激素受体（ER）表达以及细胞周期依赖性激酶4和6（CDK4/6）-p16-Rb通路的失调，与激素受体阳性乳腺癌具有相似特征，因此联合内分泌治疗和CDK4/6抑制是一种具有生物学合理性的策略。本II期试验评估了Ribociclib联合来曲唑在复发性LGSOC中的疗效。
> 
> 研究方法：这是一项开放标签、单臂、多中心的II期研究，入组了具有可测量病灶的复发性LGSOC女性患者。患者接受Ribociclib（口服600 mg，每日一次，28天为一周期的第1–21天服用）及来曲唑（口服2.5 mg，每日一次）。主要评价指标为研究者依据RECIST 1.1标准评定的客观缓解率（ORR）。次要终点包括临床获益率（CBR）、无进展生存期（PFS）、总生存期（OS）及安全性。
> 
> 研究结果：共筛查74例患者，51例入组，49例接受治疗。确认的ORR为30.6%（90%置信区间：19.9–43.2%），包括1例完全缓解和14例部分缓解。在获得缓解的患者中，中位缓解持续时间为21.2个月。CBR为84%（90%置信区间：72.5–91.6%）。中位PFS为14.5个月（90%置信区间：10.1–28.8），中位OS为44.5个月（90%置信区间：31.8–未达到）。最常见的≥3级不良事件为中性粒细胞减少（47%），经剂量调整处理。出现3例5级事件（6%），均与治疗无关。由于不良事件导致停药的比例为4%。未观察到剂量限制性毒性。
> 
> 结论：Ribociclib联合来曲唑达到主要终点，在复发性LGSOC中实现了显著的缓解率及持久的疾病控制。其安全性与以往CDK4/6抑制剂研究一致。该联合方案为这一罕见且基因组特征独特的亚型提供了一种可行的治疗选择。

### 第二部分 AI 大师评价

该研究通过II期临床试验验证了Ribociclib联合来曲唑在复发性低级别浆液性癌中的疗效与安全性，证实该方案能实现近三成客观缓解率和超过80%的临床获益率。研究设计为单臂多中心研究，验证了CDK4/6抑制联合内分泌治疗的生物学合理性。主要创新在于将乳腺癌成熟策略应用于罕见女性生殖系统肿瘤，显示出较持久的疾病控制。局限性在于样本量较小、缺乏对照组及长期安全性需进一步验证。

---

## 53. 地诺妥昔单抗β联合替莫唑胺为基础的化疗用于复发与难治性神经母细胞瘤患儿：ITCC-SIOPEN BEACON Immuno II期试验结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385757)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41385757
**DOI：** 10.1200/JCO-25-01868

### 第一部分 原文与翻译

**英文原标题：** Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

> **英文摘要：**
> PURPOSE: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HR-NBL) remain dismal. Here, we investigate addition of the anti-GD2 monoclonal antibody, dinutuximab beta (dB), to temozolomide (T)-based chemotherapy.
> 
> MATERIALS AND METHODS: Patients with RR-HR-NBL were randomly assigned in a 1:2 ratio to receive chemotherapy alone or chemotherapy with dB, given concurrently as a 7-day infusion (10 mg/m/24 h). The trial had a factorial design, with some patients also randomly assigned between chemotherapy regimens (T  T-topotecan [TTo]). Crossover to dB with To/cyclophosphamide was allowed for patients randomly assigned to chemotherapy alone with disease progression (PD). The primary outcome was best objective response (complete or partial) rate (overall response rate [ORR]) during six cycles of treatment. Progression-free (PFS), overall survival (OS), and safety were secondary outcomes.
> 
> RESULTS: Sixty-five patients were randomly assigned to chemotherapy alone (3 T, 19 TTo) or with dB (6 dBT, 37 dBTTo). The median age was 4 years; 28 and 37 patients had refractory and relapsed diseases, respectively. Baseline characteristics were balanced between arms. The ORR was 30.2% (13 of 43) and 18.2% (4 of 22) in dB and non-dB arms, the median PFS was 11.1 months (95% CI, 4.3 to 15.5) for dB patients and 3.8 months (95% CI, 1.9 to 7.9) for non-dB patients, respectively. The median OS was 25.7 months (95% CI, 11.4 to not reached [NR]) for dB patients and 17.1 months (95% CI, 7.6 to 54.6) for non-dB patients (upper 95% CI, NR in dB arm). Thirteen of 22 patients in the non-dB arm crossed over to dB with cyclophosphamide/To because of PD. Neurotoxicity was more common in the dB arm (grade 1 and 2: 26%  9%, grade 3: 2.3%  4.5%), but other toxicities were similar.
> 
> CONCLUSION: Within a randomized phase II setting, results observed with addition of dB to T-based chemotherapy in RR-HR-NB warrant further evaluation.

> **中文摘要：**
> 目的：复发和难治性高危神经母细胞瘤（RR-HR-NBL）患儿的预后仍然不佳。本研究探讨在以替莫唑胺（T）为基础的化疗中加入抗GD2单克隆抗体地诺妥昔单抗β（dB）的疗效。
> 
> 材料与方法：RR-HR-NBL患者按1:2比例随机分配接受单纯化疗或联合dB的化疗，dB以连续输注方式（10 mg/m²/24小时）给药共7天。该试验采用析因设计，部分患者在不同化疗方案（T与T-拓扑替康[TTo]）之间再随机分配。对于随机分配至单纯化疗组且病情进展（PD）的患者，允许交叉接受含dB的环磷酰胺/TTo方案。主要终点为六个治疗周期内的最佳客观缓解率（完全缓解或部分缓解）（总体缓解率[ORR]）。无进展生存期（PFS）、总生存期（OS）及安全性为次要终点。
> 
> 结果：共有65例患者随机分配至单纯化疗组（3例T，19例TTo）或联合dB组（6例dBT，37例dBTTo）。患者中位年龄为4岁；28例为难治性疾病，37例为复发性疾病。基线特征在各组之间平衡。dB组与非dB组的ORR分别为30.2%（43例中的13例）与18.2%（22例中的4例）；中位PFS分别为11.1个月（95% CI，4.3至15.5）与3.8个月（95% CI，1.9至7.9）；中位OS分别为25.7个月（95% CI，11.4至未达到[NR]）与17.1个月（95% CI，7.6至54.6）（dB组上限95% CI为NR）。非dB组中有22例中的13例因PD而交叉至dB联合环磷酰胺/TTo方案。dB组神经毒性发生更常见（1–2级：26% 对 9%，3级：2.3% 对 4.5%），其他毒性相似。
> 
> 结论：在随机的II期试验环境下，将dB加入T为基础的化疗方案治疗RR-HR-NBL所观察到的结果值得进一步研究。

### 第二部分 AI 大师评价

该研究为一项随机II期临床试验，评估将地诺妥昔单抗β加入替莫唑胺为基础的化疗在复发或难治性高危神经母细胞瘤患儿中的疗效与安全性。结果显示，联合dB治疗可提高客观缓解率并延长无进展生存期，尽管总体生存改善有限。dB组神经毒性增加，但总体安全性可接受。该研究创新性地探索了免疫治疗与化疗的联合策略，为RR-HR-NBL患儿提供了潜在的新治疗方向，但样本量较小、长期随访数据有限，仍需进一步验证。

---

## 54. 弥合差距：通过基因组学细化骨髓瘤前驱状态及其进展风险。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385751)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41385751
**DOI：** 10.1200/JCO-25-02305

### 第一部分 原文与翻译

**英文原标题：** Bridging the Gap: Refining Myeloma Precursors and Their Risk of Progression Through Genomics.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究旨在通过基因组学方法更精确地界定骨髓瘤前驱疾病（如惰性骨髓瘤、单克隆免疫球蛋白病等）的分子特征及其向多发性骨髓瘤进展的风险。标题暗示研究可能依托高通量测序或多组学分析，以发现新的风险分层生物标志物。其创新之处在于利用基因组学手段缩小临床风险评估与生物学机制之间的差距。然而，研究可能仍需更大样本量与前瞻性验证以巩固结论的临床适用性。

---

## 55. 用于局部进展期可切除头颈部鳞状细胞癌患者的术前纳武利尤单抗联合卡铂和紫杉醇治疗：一项II期单臂研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385730)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41385730
**DOI：** 10.1158/1078-0432.CCR-25-2807

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.

> **英文摘要：**
> BACKGROUND: In locally-advanced resectable squamous cell carcinoma of the head and neck (SCCHN), patients treated with neoadjuvant chemotherapy with major pathologic response (MPR) or pathologic complete response (pCR) have overall survival (OS) rates superior to those of patients with poorer pathologic responses. To improve efficacy, we added the PD-1 inhibitor, nivolumab, to neoadjuvant chemotherapy and evaluated the combination.
> 
> METHODS: In this single-arm, open-label phase II trial, patients with newly-diagnosed stage III-IV HPV-negative SCCHN in the oral cavity, oropharynx, hypopharynx, and larynx or stage II-III HPV-positive oropharyngeal SCCHN received neoadjuvant carboplatin and paclitaxel (6 weeks) plus nivolumab (every other week) followed by surgery and adjuvant radiotherapy+/-chemotherapy. Primary endpoint was pCR at the primary site.
> 
> RESULTS: Thirty-four patients were enrolled and received neoadjuvant therapy. Thirty-three patients received surgery (R0 resection=100%). Disease sites included the oral cavity (79%), oropharynx (12%), hypopharynx (6%), and larynx (3%). Twenty-eight (85%) patients had stage IVA disease. Median postsurgical follow-up was 35.3 months. Fourteen (41%) patients experienced Grade 3/ 4 treatment-related adverse events. Twenty-seven (82%) patients completed all cycles of neoadjuvant therapy. Twenty-four (73%) patients had at least an MPR at the primary site, and 15(45%) had a pCR. In an unplanned analysis at 3-years, recurrence-free survival and OS were 74% and 83%, respectively.
> 
> CONCLUSIONS: This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally-advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN.

> **中文摘要：**
> 背景：在局部进展期可切除的头颈部鳞状细胞癌（SCCHN）中，接受术前化疗并获得主要病理反应（MPR）或病理完全缓解（pCR）的患者，其总生存率（OS）优于病理反应较差者。为提高疗效，我们在术前化疗方案中加入PD-1抑制剂纳武利尤单抗，并评估该联合治疗的效果。
> 
> 方法：这是一项单臂、开放标签的II期临床试验。入组对象为新诊断的III–IV期HPV阴性口腔、口咽、下咽、喉部SCCHN患者，或II–III期HPV阳性口咽部SCCHN患者。治疗方案为术前卡铂联合紫杉醇（6周）+纳武利尤单抗（每两周一次），随后行手术及辅助放疗±化疗。主要终点为原发灶的pCR率。
> 
> 结果：共有34例患者入组并接受术前治疗；33例患者接受了手术（R0切除率=100%）。病灶分布为口腔79%、口咽12%、下咽6%、喉3%。28例（85%）为IVA期疾病。术后中位随访时间为35.3个月。14例（41%）出现3/4级治疗相关不良事件。27例（82%）完成全部术前治疗周期。24例（73%）在原发灶处达到至少MPR，15例（45%）达到pCR。在3年非计划性分析中，无复发生存率和总生存率分别为74%和83%。
> 
> 结论：本II期试验显示，术前纳武利尤单抗联合卡铂和紫杉醇用于初治、局部进展期、可切除的SCCHN患者具有良好的耐受性，并达到了原发灶pCR这一主要研究终点。针对晚期可切除HPV阴性SCCHN的III期验证性研究是有必要的。

### 第二部分 AI 大师评价

本研究探索了PD-1抑制剂纳武利尤单抗与标准化疗药物卡铂和紫杉醇联合作为术前治疗在局部进展期可切除头颈部鳞癌中的疗效与安全性。结果显示该方案耐受性良好，pCR率达45%，显著高于历史数据，且长期随访的无复发生存和总生存率表现优异。此研究在头颈部肿瘤的围手术期免疫联合策略中具有探索意义，但样本量有限且为单臂设计，需通过III期随机试验进一步验证。

---

## 56. 关于F. Chen的研究论文《通过外泌体“搭载”的纳米脂质体调控与癌相关成纤维细胞表型以阻止转移进展》的更正通知

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385646)
**期刊：** Science advances
**PMID：** 41385646
**DOI：** 10.1126/sciadv.aee0685

### 第一部分 原文与翻译

**英文原标题：** Erratum for the Research Article "Extracellular vesicle-hitchhiking nanoliposomes for cancer-associated fibroblast phenotype modulation impede metastasis progression" by F. Chen

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为更正公告，旨在对F. Chen等人此前发表于《Science Advances》的研究论文进行说明或修订。原研究聚焦于利用外泌体介导的纳米脂质体实现癌相关成纤维细胞表型调控，从而抑制肿瘤转移。尽管该更正未提供新的实验数据，但对维护科研记录的准确性具有重要意义。

---

## 57. 基于液滴的单细胞配对技术用于抗原-受体组合的高通量相互作用映射

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385644)
**期刊：** Science advances
**PMID：** 41385644
**DOI：** 10.1126/sciadv.aeb1515

### 第一部分 原文与翻译

**英文原标题：** Droplet-based single-cell pairing for high-throughput interaction mapping of antigen-receptor combinations.

> **英文摘要：**
> Mapping the interaction potential of different variant combinations of viral antigens and human cell receptors and understanding how viral antigen mutations interact with human genetic polymorphisms are critical for predicting infection susceptibility and informing precision public health strategies. Here, we develop a droplet-based single-cell pairing and library-on-library interaction screening (SPLIS) system for high-throughput profiling of the syncytium-formation landscapes of various spike-angiotensin-converting enzyme 2 (ACE2) variant combinations. This system uses combined droplet sorting and merging to deterministically encapsulate one antigen-presenting sender cell and one receptor-expressing receiver cell into each drop, followed by selection and sequencing of the fused DNA readouts to characterize the syncytium-formation potential of each combination. We applied SPLIS to characterize both fusion-enhancing and -inhibiting variant pairs, comprehensively profiling how ACE2 single-nucleotide polymorphisms modulate susceptibility to emerging severe acute respiratory syndrome coronavirus 2 spike mutations. Our system emerges as a powerful tool to interrogate the interactions between two libraries of variants, offering valuable insights into host susceptibility patterns and viral infectivity trends.

> **中文摘要：**
> 绘制不同病毒抗原与人细胞受体变体组合的相互作用潜能，并理解病毒抗原突变与人类基因多态性之间的交互作用，对于预测感染易感性和指导精准公共卫生策略至关重要。在此，我们开发了一种基于液滴的单细胞配对与库对库相互作用筛选（SPLIS）系统，用于对多种刺突—血管紧张素转化酶2（ACE2）变体组合的融合体形成景观进行高通量分析。该系统结合了液滴排序与融合技术，能够以确定性方式将一个呈递抗原的“发送”细胞和一个表达受体的“接收”细胞包裹于同一液滴中，随后通过选择与测序融合DNA读出，表征每种组合的融合体形成潜能。我们应用SPLIS系统表征了增强和抑制融合的变体配对，全面描绘了ACE2单核苷酸多态性如何调节对新出现的严重急性呼吸综合征冠状病毒2刺突突变的易感性。该系统成为研究双库变体相互作用的有力工具，为理解宿主易感模式与病毒感染性趋势提供了重要洞察。

### 第二部分 AI 大师评价

本研究旨在系统解析病毒抗原与宿主受体变体之间的相互作用网络，通过创新的基于液滴的单细胞配对与库对库筛选技术（SPLIS），实现了高通量的融合体形成能力测定。该方法突破了传统一对一筛选的局限，为同时研究大量突变组合的功能关系提供了强大工具。结果揭示了ACE2多态性对新冠刺突突变感染性的调节作用，具有精准防疫与变异监测应用潜力。尽管仍需在复杂生理环境中进一步验证，其技术平台的可拓展性和精确性显示出显著创新性。

---

## 58. 组蛋白甲基转移酶 DOT1L 维持细胞状态并限制 CD8 T 细胞的细胞毒潜能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385642)
**期刊：** Science advances
**PMID：** 41385642
**DOI：** 10.1126/sciadv.adw1289

### 第一部分 原文与翻译

**英文原标题：** Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells.

> **英文摘要：**
> The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory characteristics but has also been reported to compromise CD8 T cell viability and antitumor reactivity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of  in vitro, CD8 T cells retained in vivo proliferative capacity and antitumor reactivity. Moreover,  knockout CD8 T cells showed increased antigen-specific cytotoxicity toward tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell state with loss of T cell and gain of innate-like features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that in mature CD8 T cells, ablation of DOT1L activity is well tolerated and reprograms them to gain innate-like memory cell characteristics and enhance intrinsic cytotoxic capacity.

> **中文摘要：**
> 组蛋白甲基转移酶 DOT1L 正逐渐成为免疫细胞中的关键表观遗传调控因子。在体内 CD8 T 细胞发育过程中，DOT1L 的缺失会导致记忆特征的获得，但据报道也会损害 CD8 T 细胞的存活性和抗肿瘤反应能力。在本研究中，我们确定了 DOT1L 在成熟小鼠 CD8 T 细胞中的细胞内在作用。在体外条件性删除 DOT1L 后，CD8 T 细胞在体内仍保持增殖能力和抗肿瘤反应。此外，DOT1L 缺失的 CD8 T 细胞在体外对肿瘤细胞表现出更强的抗原特异性细胞毒性。从机制上看，DOT1L 的缺失导致细胞状态的改变，即失去部分 T 细胞特征并获得类似先天免疫样的特征。这些转录变化由 DOT1L 甲基转移酶活性的剂量依赖性丧失所介导。我们的研究结果表明，在成熟的 CD8 T 细胞中，消除 DOT1L 活性是可耐受的，并能够重编程这些细胞，使其获得类似先天样的记忆细胞特征并增强内在细胞毒能力。

### 第二部分 AI 大师评价

该研究聚焦于 DOT1L 在成熟 CD8 T 细胞中的功能，揭示其在调控细胞状态与细胞毒性潜能中的关键作用。研究者通过条件性基因敲除模型，证明 DOT1L 的缺失可增强 CD8 T 细胞的抗原特异性杀伤力，并诱导其表现出先天样记忆特征。从机制上，DOT1L 作为甲基转移酶在转录调控中具有剂量依赖性作用。此研究不仅阐明了 DOT1L 对 CD8 T 细胞可塑性的表观遗传调控机制，也提示其可能成为优化抗肿瘤免疫疗法的新靶点。

---

## 59. BE筛选揭示METTL3 S2去磷酸化通过干扰METTL3-eIF3H相互作用使胃癌细胞对奥沙利铂敏化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385641)
**期刊：** Science advances
**PMID：** 41385641
**DOI：** 10.1126/sciadv.ady7259

### 第一部分 原文与翻译

**英文原标题：** BE screen reveals METTL3 S2 dephosphorylation sensitizes gastric cancer cells to oxaliplatin by interfering METTL3-eIF3H interaction.

> **英文摘要：**
> The resistance to oxaliplatin (OXA)-based chemotherapies may lead to poor prognosis in patients with gastric cancer (GC). Emerging evidence suggests that resistance is closely associated with phosphorylation modifications. In GC cell line AGS, high-throughput base editor screen identified key phosphorylation sites associated with OXA response. Methyltransferase-like 3 (METTL3) S2 emerged as a notable negative hit. Further investigation revealed that dephosphorylation of METTL3 S2 disrupted the METTL3-eukaryotic translation initiation factor 3 subunit H (eIF3H) interaction, thereby suppressing the translation of oncogenes involved in replication stress responses, including bromine domain protein 4 () and serpin family E member 2 (), ultimately enhancing sensitivity to OXA. In addition, clinical investigation showed that METTL3 S2 phosphorylation was highly correlated with the response to GC OXA chemotherapy. In summary, base editor screen provides a versatile approach for exploring the role of phosphorylation sites in cancer chemotherapy. The METTL3-eIF3H interaction may serve as a potential therapeutic target.

> **中文摘要：**
> 奥沙利铂（OXA）为基础的化疗耐药可能导致胃癌（GC）患者的预后不良。新兴证据表明，耐药性与磷酸化修饰密切相关。在GC细胞系AGS中，高通量碱基编辑筛查鉴定出与OXA反应相关的关键磷酸化位点。其中，甲基转移酶样蛋白3（METTL3）的S2位点成为显著的负向命中。进一步研究发现，METTL3 S2的去磷酸化会破坏METTL3与真核翻译起始因子3亚基H（eIF3H）之间的相互作用，从而抑制参与复制应激反应的癌基因（包括溴结构域蛋白4和丝氨酸蛋白酶抑制剂家族E成员2）的翻译，最终增强对OXA的敏感性。此外，临床研究表明，METTL3 S2的磷酸化水平与GC患者OXA化疗反应高度相关。总之，碱基编辑筛查为探索癌症化疗中磷酸化位点的作用提供了一种多功能途径。METTL3-eIF3H相互作用可能成为潜在的治疗靶点。

### 第二部分 AI 大师评价

该研究利用高通量碱基编辑技术在胃癌模型中系统筛查磷酸化位点，揭示了METTL3 S2去磷酸化可通过干扰METTL3-eIF3H复合体从而增强奥沙利铂敏感性。研究不仅阐明了化疗耐药的分子调控机制，还提供了潜在的治疗靶点。临床数据验证了发现的相关性，体现了从基础机制到临床转化的完整路径。创新性在于结合功能基因组学与翻译调控机制，然而未来仍需针对体内模型和患者样本进行更广泛验证。

---

## 60. 光谱指纹诊断：均相系统中生物标志物模式的空间独立分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385635)
**期刊：** Science advances
**PMID：** 41385635
**DOI：** 10.1126/sciadv.aea8943

### 第一部分 原文与翻译

**英文原标题：** Spectral fingerprint diagnosis: Spatially independent analysis of biomarker patterns in homogeneous systems.

> **英文摘要：**
> High-throughput biomarker analysis traditionally relies on spatial distribution features, either naturally occurring or artificially engineered. Achieving multiplex detection in a homogeneous system without spatial distribution remains a challenge. Fluorescence-based polymerase chain reaction (PCR) exemplifies a spatially independent technology for targeted multiplex detection, but it is limited by spectral overlap. Here, we proposed spectral fingerprint PCR (sf-PCR), which leverages three-dimensional fluorescence spectral fingerprints to profile biomarker expression patterns. These fingerprints capture both the position and intensity of fluorescence peaks, increasing information density and offering a breakthrough in spectral overlap. In addition, sf-PCR exhibits linear superimposability and decodability, providing a solid foundation for data interpretability. Using a 10-plex sf-PCR model, we demonstrated sf-PCR's capacity to fundamentally overcome spectral overlap limitations. Furthermore, sf-PCR has demonstrated clinical potential in cancer diagnosis and respiratory pathogen detection. This work underscores the potential of spectral fingerprints to enhance information density and fundamentally resolve challenges in homogeneous system analysis.

> **中文摘要：**
> 高通量生物标志物分析传统上依赖于空间分布特征，这些特征可能是自然存在的，也可能是人工设计的。在没有空间分布的均相系统中实现多重检测仍然是一项挑战。基于荧光的聚合酶链式反应（PCR）是用于靶向多重检测的一种空间独立技术，但受光谱重叠的限制。在本研究中，我们提出了一种光谱指纹PCR（sf-PCR），利用三维荧光光谱指纹来描绘生物标志物的表达模式。这些指纹同时捕捉荧光峰的位置和强度，从而提高信息密度，并在解决光谱重叠问题上取得突破。此外，sf-PCR表现出线性叠加性和可解码性，为数据解释提供了坚实基础。通过使用10重sf-PCR模型，我们展示了sf-PCR在根本上克服光谱重叠限制的能力。此外，sf-PCR在癌症诊断和呼吸道病原体检测中显示出潜在的临床应用价值。本研究强调了光谱指纹在提高信息密度和从根本上解决均相系统分析挑战方面的潜力。

### 第二部分 AI 大师评价

该研究提出了创新性的光谱指纹PCR（sf-PCR）技术，用以在均相体系中实现多重生物标志物检测。其方法通过三维荧光光谱指纹显著提高信息密度，有效突破光谱重叠限制，展示出线性叠加和可解码特性。结果表明该方法在癌症及呼吸道病原检测中具有应用潜力，显示出技术上的重要创新性。尽管其实际临床标准化尚需进一步验证，但为均相系统的高通量分析提供了新的思路。

---

## 61. 室内日晒的分子效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385634)
**期刊：** Science advances
**PMID：** 41385634
**DOI：** 10.1126/sciadv.ady4878

### 第一部分 原文与翻译

**英文原标题：** Molecular effects of indoor tanning.

> **英文摘要：**
> Tanning bed users have a significantly increased risk of melanoma, but it remains unclear how indoor tanning drives melanomagenesis. To better understand the etiology of melanoma associated with tanning bed use, we described the patterns of melanoma in patients with quantifiable tanning bed usage and performed exome sequencing of melanocytes from normal skin of a subset of these patients. Tanning bed users were more likely to have melanoma on body sites with low cumulative levels of sun damage and to have multiple melanomas. The melanocytes in skin from tanning bed users had higher mutation burdens and higher proportions of cells with pathogenic mutations-these differences were most prominent over body sites that experience comparatively less exposure to natural sunlight. We conclude that tanning bed radiation induces melanoma by increasing the mutation burden of melanocytes and by mutagenizing a broader field of melanocytes than are typically exposed to natural sunlight.

> **中文摘要：**
> 使用日光浴床者罹患黑色素瘤的风险显著增加，但室内日晒如何驱动黑色素瘤发生仍不清楚。为更好理解与使用日光浴床相关的黑色素瘤病因，我们描述了拥有可量化日光浴床使用史患者的黑色素瘤特征，并对其中部分患者正常皮肤来源的黑色素细胞进行了外显子组测序。与未使用者相比，日光浴床使用者更可能在累积日晒损伤较低的身体部位发生黑色素瘤，并且更容易出现多发黑色素瘤。来自日光浴床使用者皮肤的黑色素细胞具有更高的突变负荷及更高比例的致病突变细胞——这种差异在相对更少暴露于自然阳光的身体部位最为明显。我们得出结论，日光浴床辐射通过增加黑色素细胞的突变负荷，并在比自然阳光通常暴露更广的范围内诱导黑色素细胞突变，进而促发黑色素瘤的发生。

### 第二部分 AI 大师评价

本研究探讨了室内日晒对黑色素瘤发生的分子机制。通过对具有可量化日光浴床使用史患者的黑色素细胞进行外显子组测序，研究揭示出日光浴床辐射可显著增加突变负荷与致病突变比例，尤其在日晒较少的部位更为明显。该发现为室内日晒所致黑色素瘤的病理机制提供了分子层面的证据。研究的创新性在于首次结合使用行为量化与外显子组分析揭示此关系，但样本量及跨群体可推广性仍需进一步验证。

---

## 62. 一种用于同时检测半胱氨酸、同型半胱氨酸和超氧阴离子的荧光探针

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385627)
**期刊：** Science advances
**PMID：** 41385627
**DOI：** 10.1126/sciadv.adx6659

### 第一部分 原文与翻译

**英文原标题：** A fluorescent probe for concurrent detection of cysteine, homocysteine, and superoxide anion.

> **英文摘要：**
> Redox imbalance is a key factor in the pathogenesis of diseases such as epilepsy and liver injury. Superoxide anion (O), cysteine (Cys), and homocysteine (Hcy) play central roles in maintaining redox homeostasis, and their dysregulation drives oxidative stress and disease progression. Here, we report a multifunctional fluorescent probe, BPC, capable of simultaneously and selectively detecting Cys, Hcy, and O in complex biological environments. BPC shows high sensitivity, selectivity, and biocompatibility, enabling real-time visualization of redox fluctuations in living cells and zebrafish with minimal cytotoxicity. In pentylenetetrazole (PTZ)- and acetaminophen (APAP)-induced models of epilepsy and liver injury, BPC revealed notable alterations in Cys, Hcy, and O levels, providing mechanistic insights into redox dysregulation. Moreover, BPC successfully tracked redox restoration following -acetylcysteine (NAC) treatment. These findings establish BPC as a versatile tool for redox biology and highlight its promise for diagnostic and therapeutic applications.

> **中文摘要：**
> 氧化还原失衡是癫痫和肝损伤等疾病发病机制中的关键因素。超氧阴离子（O）、半胱氨酸（Cys）和同型半胱氨酸（Hcy）在维持氧化还原稳态中起核心作用，它们的失调会促进氧化应激及疾病进展。在本研究中，我们报道了一种多功能荧光探针 BPC，能够在复杂的生物环境中同时且选择性地检测 Cys、Hcy 和 O。BPC 具有高灵敏度、高选择性和良好生物相容性，可在活细胞和斑马鱼中以极低细胞毒性实现氧化还原波动的实时可视化。在戊四氮（PTZ）和对乙酰氨基酚（APAP）诱导的癫痫和肝损伤模型中，BPC 揭示了 Cys、Hcy 和 O 水平的显著变化，为理解氧化还原失调的机制提供了重要线索。此外，BPC 成功地追踪了经 N-乙酰半胱氨酸（NAC）治疗后的氧化还原恢复。这些发现表明，BPC 是氧化还原生物学中的一项多用途工具，并展示了其在诊断和治疗应用中的潜在价值。

### 第二部分 AI 大师评价

本文旨在开发一种可同时检测半胱氨酸、同型半胱氨酸及超氧阴离子的多功能荧光探针 BPC。研究通过体内外模型验证了其高灵敏度、选择性及生物相容性，能够实时监测氧化还原状态变化。实验在癫痫与肝损伤模型中揭示了与氧化还原失衡相关的生理变化，并可追踪药物干预后的恢复过程。该研究在氧化还原生物学研究工具和疾病诊断应用方面具有显著创新性，但仍需在临床复杂环境下进一步验证其实用性。

---

## 63. 细胞外基质驱动鸟苷酸生成并保护胰腺癌细胞免受奥沙利铂诱导的DNA损伤。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385622)
**期刊：** Science advances
**PMID：** 41385622
**DOI：** 10.1126/sciadv.adu2276

### 第一部分 原文与翻译

**英文原标题：** The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage.

> **英文摘要：**
> The excessive production of extracellular matrix (ECM) and the metabolic adaptations in pancreatic ductal adenocarcinoma (PDAC) contribute individually to enhanced chemoresistance, marked tumor progression, and dismal patient survival. However, ECM-driven metabolic alterations that promote chemoresistance in PDAC are so far unexplored. Here, we use in vitro-generated ECM bioscaffolds that recapitulate cell-ECM interactions and induce broad metabolic alterations in PDAC cells. High-throughput integration of multiomics datasets coupled with metabolic tracing showed that the ECM enhances the generation of guanylates in PDAC cells, the accumulation of which alleviates oxaliplatin-induced DNA damage, and boosts PDAC cell proliferation. These events are guided by the guanosine monophosphate (GMP)-producing enzymes inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthase (GMPS), the expression of which correlated with that of matrisomal and DNA repair genes in samples from patients with PDAC. We propose that targeting ECM-driven metabolic processes, such as the enhanced IMPDH activity, may be an effective therapeutic approach for patients with PDAC to bypass the negative side effects of direct targeting of the ECM itself.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）中过度生产的细胞外基质（ECM）及其代谢适应性分别促成了化疗耐药性增强、肿瘤显著进展以及患者生存率低下。然而，目前尚未探究ECM驱动的代谢改变如何促进PDAC的化疗耐药性。在本研究中，我们利用体外生成的ECM生物支架再现了细胞与ECM的相互作用，并诱导了PDAC细胞的广泛代谢重塑。通过高通量整合多组学数据并结合代谢示踪分析，我们发现ECM可增强PDAC细胞中鸟苷酸的生成，这种累积能够减轻奥沙利铂诱导的DNA损伤，并促进PDAC细胞增殖。这些过程受鸟苷酸单磷酸（GMP）生成酶——肌苷酸脱氢酶（IMPDH）和鸟苷酸合成酶（GMPS）——的调控，其基因表达与PDAC患者样本中基质组和DNA修复相关基因的表达呈正相关。我们提出，针对ECM驱动的代谢过程（如增强的IMPDH活性）可能是一种有效的治疗策略，从而避免直接靶向ECM本身所带来的负面副作用。

### 第二部分 AI 大师评价

本研究揭示了细胞外基质（ECM）在胰腺导管腺癌（PDAC）中通过调控鸟苷酸代谢促进化疗耐药的新机制。作者利用体外ECM支架体系与多组学整合分析相结合，发现ECM可提升IMPDH和GMPS介导的GMP合成，从而减轻奥沙利铂造成的DNA损伤，并促进肿瘤细胞增殖。该研究创新地将肿瘤基质生物学与代谢重编程联系起来，为靶向ECM驱动的代谢通路提供了潜在的治疗思路。其局限在于主要基于体外模型，尚需进一步的动物及临床验证。

---

## 64. HR+/HER2- 高增殖性乳腺癌患者中，阿贝西利联合来曲唑新辅助治疗与化疗的比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385615)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41385615
**DOI：** 10.1158/1078-0432.CCR-25-2435

### 第一部分 原文与翻译

**英文原标题：** Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2- Highly Proliferative Breast Cancer.

> **英文摘要：**
> PURPOSE: Neoadjuvant chemotherapy is standard for high-risk HR+/HER2-breast cancer (BC). This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative.
> 
> PATIENTS AND METHODS: The phase II, open-label CARABELA trial randomized HR+/HER2- stage II-III BC patients with Ki-67 ≥20% to receive letrozole/abemaciclib for 12 months or chemotherapy for 6 months. Patients were stratified by menopausal status, TNM stage, and Ki-67 index (<30% vs. ≥30%). The primary endpoint was the rate of residual cancer burden (RCB) 0-I. Secondary endpoints included clinical response rate (CRR) and correlations of Ki-67 and Recurrence Score® (RS) with tumor response. A Bayesian design aimed to assess treatment similarity.
> 
> RESULTS: 200 patients (median age 53 years, 57% postmenopausal, 79% stage II, 77% Ki-67 ≥30%, 58% RS ≥26) were randomized. RCB 0-I was achieved in 13% (letrozole/abemaciclib, 95% Credible Intervals (CrI): 7.4% - 20.5%) vs. 18% (chemotherapy, 95% CrI: 11.5% - 26.4%), failing to show similarity between treatment arms. The CRRs were 78% (letrozole/abemaciclib) vs. 71% (chemotherapy) (P=0.26). Tumors with Ki-67 ≥30% and/or RS results ≥26 showed a trend toward higher RCB 0-I rates with chemotherapy (23% vs. 17%, P=0.52). RCB 0-I rates were similar between treatments for tumors with Ki-67 <30% or RS <26.
> 
> CONCLUSIONS: CARABELA trial results suggest that 12 months of letrozole/abemaciclib may not offer similar efficacy to that of chemotherapy in achieving RCB 0-I. However, in less proliferative tumors (RS <26 or Ki-67 <30%), outcomes were comparable, suggesting that letrozole/abemaciclib could replace (neo)adjuvant chemotherapy in selected patients.

> **中文摘要：**
> 研究目的：新辅助化疗是高风险 HR+/HER2- 乳腺癌（BC）的标准治疗。本研究旨在评估为期 12 个月的来曲唑联合阿贝西利是否可作为替代方案。
> 
> 患者与方法：II 期、开放标签的 CARABELA 试验将 HR+/HER2-、II–III 期且 Ki-67 ≥20% 的乳腺癌患者随机分配至两组，分别接受 12 个月的来曲唑/阿贝西利治疗或 6 个月的化疗。患者按绝经状态、TNM 分期及 Ki-67 指数（<30% vs. ≥30%）进行分层。主要终点为残余癌负荷（RCB）0–I 率。次要终点包括临床缓解率（CRR）以及 Ki-67、复发评分（RS）与肿瘤反应的相关性。采用贝叶斯设计以评估治疗间的相似性。
> 
> 研究结果：共入组 200 例患者（中位年龄 53 岁，57% 绝经后，79% 为 II 期，77% Ki-67 ≥30%，58% RS ≥26）。RCB 0–I 的达成率为来曲唑/阿贝西利组 13%（95% 可信区间：7.4%–20.5%）与化疗组 18%（95% 可信区间：11.5%–26.4%），未能显示两组疗效相似。CRR 分别为来曲唑/阿贝西利组 78%，化疗组 71%（P=0.26）。在 Ki-67 ≥30% 和/或 RS ≥26 的肿瘤中，化疗组 RCB 0–I 率较高（23% vs. 17%，P=0.52）。对于 Ki-67 <30% 或 RS <26 的肿瘤，两组 RCB 0–I 率相似。
> 
> 结论：CARABELA 试验结果表明，为期 12 个月的来曲唑/阿贝西利治疗在实现 RCB 0–I 方面的疗效未能与化疗相当。然而，在低增殖肿瘤（RS <26 或 Ki-67 <30%）中，其疗效可比，提示来曲唑/阿贝西利可能在特定患者中替代（新）辅助化疗。

### 第二部分 AI 大师评价

该研究通过 CARABELA II 期随机对照试验，评估了阿贝西利联合来曲唑在高增殖性 HR+/HER2- 乳腺癌中新辅助治疗中的疗效。研究未能证实其与化疗在减少残余癌负荷方面的等效性，但在低增殖性肿瘤中表现出相似疗效。结果提示，对于 Ki-67 和 RS 较低的患者，该内分泌联合方案有望成为化疗的替代选项。研究创新性体现在将 CDK4/6 抑制剂纳入新辅助内分泌治疗方案，但受样本规模和试验阶段限制，结论仍需进一步验证。

---

## 65. 基于FDG-PET的人乳头瘤病毒相关口咽鳞状细胞癌化放疗选择性减量：一项多中心II期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385605)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41385605
**DOI：** 10.1158/1078-0432.CCR-25-2820

### 第一部分 原文与翻译

**英文原标题：** FDG-PET-based Selective De-escalation of Chemoradiation in Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma: a Multi-center Phase II Trial.

> **英文摘要：**
> PURPOSE: We conducted a phase II multicenter clinical trial to test the hypothesis that FDG-PET based chemoradiation (CRT) dose de-escalation would provide non-inferior loco-regional control compared to historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that HPVctDNA changes during treatment predict loco-regional recurrence (LRR).
> 
> PATIENTS AND METHODS: Patients with Stage I/II p16+ oropharyngeal squamous cell carcinoma were planned to receive radiation 70Gy in 35 fractions with concurrent weekly carboplatin and paclitaxel. All patients underwent FDG-PET at baseline and at RT fraction 10. Patients with ≥50% decrease from baseline to mid-treatment metabolic tumor volume (MTV)2.5 had treatment deescalated to 54Gy in 27 fractions. The primary endpoint was LRR. Plasma HPVctDNA was evaluated weekly and in surveillance.
> 
> RESULTS: Of 84 evaluable patients, 43% met de-escalation criteria. With a median follow-up of 37.8 months, 24-month LRR for the entire cohort was 7.8% (90% CI: 2.6% - 12.6%), which was less than the 25% rate specified for assessing non-inferiority, thereby meeting the primary endpoint. At 1 month post RT, the mean of multiple quality of life measures between the two groups were improved in the 54Gy cohort, exceeding the minimal clinically important difference (MCID) threshold. During CRT, week 1 percentage increase in ctDNA relative to baseline was significantly associated with worse LRC (HR=1.052 per 10 percentage points increase in ctDNA, 95% CI: 1.007-1.099; p=0.023) and LRPFS (HR=1.038, 95% CI: 1.002-1.076; p=0.035).
> 
> CONCLUSION: FDG-PET-based RT dose personalization resulted in promising LRR outcomes in early stage oropharynx cancer with improved short- term PROs. Furthermore, HPVctDNA changes early in treatment may predict LRC.

> **中文摘要：**
> 目的：我们开展了一项多中心II期临床试验，以验证基于FDG-PET的化放疗（CRT）剂量减量方案在早期p16阳性口咽癌患者中是否能获得不劣于历史对照的局部区域控制率（LRC）。我们还假设，治疗过程中HPVctDNA的变化可预测局部区域复发（LRR）。
> 
> 患者与方法：I/II期p16阳性口咽鳞状细胞癌患者原计划接受35次放疗，总剂量70Gy，同时每周联合使用卡铂和紫杉醇。所有患者在治疗前（基线）和放疗第10次时接受FDG-PET检查。从基线到治疗中期代谢肿瘤体积（MTV2.5）下降≥50%的患者，放疗剂量减至54Gy共27次。主要终点为LRR。血浆HPVctDNA每周及随访期进行评估。
> 
> 结果：在84例可评估患者中，43%符合减量标准。中位随访37.8个月，全队列24个月LRR率为7.8%（90%置信区间：2.6%-12.6%），低于评估非劣效性的25%参考率，从而达到主要研究终点。放疗结束后1个月，54Gy组在多个生活质量指标上的平均值较对照组明显改善，超过了临床最小重要差异（MCID）阈值。在CRT过程中，与基线相比，第1周ctDNA百分比升高与较差的LRC（HR=1.052，每增加10个百分点ctDNA，95%CI：1.007–1.099，p=0.023）及LRPFS（HR=1.038，95%CI：1.002–1.076，p=0.035）显著相关。
> 
> 结论：基于FDG-PET的放疗剂量个体化在早期口咽癌中取得了令人鼓舞的LRR结果，并改善了短期患者报告结局（PROs）。此外，治疗早期HPVctDNA的变化可能用于预测LRC。

### 第二部分 AI 大师评价

本研究为一项多中心II期临床试验，旨在验证利用FDG-PET指导的放化疗剂量个体化在早期HPV相关口咽癌中的安全性与有效性。研究发现，基于代谢肿瘤体积变化的放疗减量能在维持优良局部控制率的同时改善生活质量，显示了剂量精准调整的可行性。ctDNA的动态变化被证实具有早期预测复发风险的潜力，为实时疗效监测提供了生物学依据。研究创新性在于整合影像组学与分子检测以指导治疗，但样本量有限及随访时间仍需扩展以验证长期预后。

---

## 66. 循环肿瘤DNA可预测患者预后并实现转移性葡萄膜黑色素瘤的治疗监测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385580)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41385580
**DOI：** 10.1158/1078-0432.CCR-25-2274

### 第一部分 原文与翻译

**英文原标题：** Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma.

> **英文摘要：**
> BACKGROUND: Circulating tumor DNA (ctDNA) refers to small DNA-fragments, shed from tumor cells into the bloodstream. Measuring ctDNA provides a non-invasive tool for real-time disease monitoring. While ctDNA predicted overall survival (OS) in metastatic uveal melanoma (mUM) treated with tebentafusp, its broader prognostic value across treatment modalities remains unclear. Here, we assess the prognostic relevance of longitudinal ctDNA detection and mutant allele fraction (MAF) in patients with mUM treated with different modalities.
> 
> OBJECTIVE: To assess ctDNA monitoring as a tool in evaluating therapy response and clinical outcomes in patients with mUM, using an IVDR-certified digital PCR assay targeting GNAQQ209 and GNA11Q209 mutations.
> 
> RESULTS: We analyzed 655 samples from 75 patients with mUM. Absence of detectable ctDNA in baseline samples prior to first-line therapy was associated with improved OS (HR=0.13, p=0.02) and progression-free survival (PFS) (HR=0.31, p=0.008). Similar associations were observed in patients treated with any-line of therapy (OS: HR=0.19, p=0.002; PFS: HR=0.27, p=0.02). Detection of ctDNA within 3months of therapy initiation was associated with worse outcomes, independent of baseline detection. Furthermore, patients with MAF >5% any timepoint had a significantly poorer prognosis compared to patients with MAF <5% (median OS 4months vs 21months, p<0.001; median PFS 2.5months vs 3.6months, p=0.004), emphasizing the added value of quantitative assessment.
> 
> CONCLUSION: Both the presence and level of ctDNA at baseline, along with persistence of ctDNA within 3months of treatment-start, are strong negative prognostic markers in mUM. These findings support the clinical utility of ctDNA as a non-invasive tool for disease monitoring.

> **中文摘要：**
> 背景：循环肿瘤DNA（ctDNA）指从肿瘤细胞释放到血液中的小片段DNA。检测ctDNA为实时疾病监测提供了一种无创工具。虽然ctDNA已被证明可以预测以tebentafusp治疗的转移性葡萄膜黑色素瘤（mUM）患者的总生存期（OS），但其在不同治疗方式下更广泛的预后价值仍不明确。本研究评估了在接受不同治疗方式的mUM患者中，纵向ctDNA检测和突变等位基因频率（MAF）的预后相关性。
> 
> 研究目的：使用通过IVDR认证的数字PCR检测（靶向GNAQQ209和GNA11Q209突变），评估ctDNA监测在评估mUM患者治疗反应和临床结局中的作用。
> 
> 结果：我们分析了来自75名mUM患者的655个样本。初始一线治疗前基线样本中未检测到ctDNA的患者，其OS（HR=0.13，p=0.02）和无进展生存期（PFS）（HR=0.31，p=0.008）均显著改善。接受任意治疗线的患者中也观察到类似的关联（OS：HR=0.19，p=0.002；PFS：HR=0.27，p=0.02）。在治疗开始后三个月内检测到ctDNA的患者，其预后较差，且与基线检测结果无关。此外，任何时间点MAF>5%的患者，其预后显著劣于MAF<5%的患者（中位OS分别为4个月 vs 21个月，p<0.001；中位PFS分别为2.5个月 vs 3.6个月，p=0.004），突显了定量评估的附加价值。
> 
> 结论：基线时ctDNA的存在及其水平，以及治疗开始后三个月内ctDNA的持续存在，均是mUM的不良预后标志物。这些结果支持ctDNA作为一种无创疾病监测工具的临床应用价值。

### 第二部分 AI 大师评价

该研究聚焦于转移性葡萄膜黑色素瘤中循环肿瘤DNA的预后和监测价值，通过IVDR认证的数字PCR定量检测GNAQ和GNA11突变，验证ctDNA与总体及无进展生存的显著相关性。结果显示，基线或治疗早期持续阳性的ctDNA提示预后不良，MAF水平具有独立预测能力。此研究的创新之处在于跨治疗模式的纵向分析与定量ctDNA阈值的提出，但样本量相对有限，仍需更大规模研究验证其临床推广潜力。

---

## 67. 基于风险与年度乳腺癌筛查的比较：研究摘要

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385358)
**期刊：** JAMA
**PMID：** 41385358
**DOI：** 10.1001/jama.2025.24865

### 第一部分 原文与翻译

**英文原标题：** Risk-Based vs Annual Breast Cancer Screening: Research Summary.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究旨在总结基于风险与固定年度乳腺癌筛查模式之间的核心差异与研究进展。此类综述通常探讨如何根据个体风险因素（如年龄、家族史、基因突变等）制定个性化筛查策略，以提高早期发现率并减少过度筛查。尽管全文摘要不可用，但从标题推测，该研究可能提供了现有证据的系统整合，为临床筛查指南的优化提供参考。其创新性在于强调风险驱动筛查的潜力，但具体方法与效果仍需进一步验证。

---

## 68. 基于风险与年度乳腺癌筛查的比较：WISDOM随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385349)
**期刊：** JAMA
**PMID：** 41385349
**DOI：** 10.1001/jama.2025.24784

### 第一部分 原文与翻译

**英文原标题：** Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Individual breast cancer risk can guide screening initiation, frequency, use of supplemental imaging, and preventive measures to improve breast cancer screening by shifting resources from low-risk women to high-risk women.
> 
> OBJECTIVE: To determine whether risk-based breast cancer screening is a feasible alternative to annual mammography.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Parallel-group, pragmatic, multicenter randomized clinical trial comparing risk-based (n = 14 212) with annual (n = 14 160) breast cancer screening. Women aged 40 to 74 years without prior diagnoses of breast cancer or ductal carcinoma in situ, or prophylactic bilateral mastectomy, were recruited from all 50 US states from September 2016 to February 2023, with follow-up through September 5, 2025 (median follow-up, 5.1 years). Statistical analysis was conducted between July and November 2025. All study procedures were conducted via an online platform. Women who declined randomization were enrolled in an observational cohort.
> 
> INTERVENTIONS: Risk assessment included sequencing of 9 susceptibility genes, polygenic risk score, and the Breast Cancer Surveillance Consortium version 2 model. The risk-based group received 1 of 4 recommendations: (1) highest risk (≥6% 5-year risk, high-penetrance pathogenic variant): alternating mammography and magnetic resonance imaging (MRI) every 6 months and counseling; (2) elevated risk (top 2.5 risk percentile by age): annual mammography and risk-reduction counseling; (3) average risk: biennial mammography; and (4) low risk (aged 40-49 years and <1.3% 5-year risk): no screening until risk is 1.3% or greater or age 50 years.
> 
> MAIN OUTCOMES AND MEASURES: The coprimary outcomes included noninferiority for stage ≥IIB cancers and superiority in reducing biopsy rates. Secondary outcomes included identification of stage ≥IIA cancers, mammogram rates, uptake of prevention strategies in higher risk cohorts, preference for screening group in the observational cohort, ductal carcinoma in situ, MRI, and stage-specific cancer rates.
> 
> RESULTS: A total of 28 372 women were randomized. The mean (SD) age was 54 (9.6) years and the majority were non-Hispanic White (77%). The rate of stage ≥IIB cancers was noninferior in the risk-based compared with the annual group (risk-based: 30.0 [95% CI, 16.3-43.8] vs annual: 48.0 [95% CI, 30.1-65.5] per 100 000 person-years; rate difference, -18.0 per 100 000 person-years [95% CI, -40.2 to 4.1]). The rate of breast biopsies was not lower in the risk-based group (rate difference, 98.7 per 100 000 person-years [95% CI, -17.9 to 215.3]) despite fewer mammograms (rate difference, -3835.9 [95% CI, -4516.8 to -3154.9]). The cumulative incidence of cancer, biopsy, mammogram, and MRI increased as risk category increased. In the observational cohort, 89% of participants (15 980/18 031) chose risk based.
> 
> CONCLUSIONS: Risk-based breast cancer screening that includes population-based genetic testing safely stratified risk and screening intensity, but did not reduce biopsy rates.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02620852.

> **中文摘要：**
> 重要性：个体乳腺癌风险可指导筛查的启动、频率、补充影像学检查的使用及预防措施，从而通过将资源从低风险女性转向高风险女性来改进乳腺癌筛查。
> 
> 研究目的：确定基于风险的乳腺癌筛查是否是年度乳腺X线检查的可行替代方案。
> 
> 研究设计、地点与参与者：一项平行组、实用性、多中心随机临床试验，比较基于风险的乳腺癌筛查（n = 14,212）与年度筛查（n = 14,160）。研究对象为40至74岁、无既往乳腺癌、导管原位癌或预防性双侧乳房切除史的女性，招募自2016年9月至2023年2月，覆盖美国全部50个州。随访至2025年9月5日（中位随访期5.1年）。统计分析于2025年7月至11月间进行。所有研究程序均通过在线平台完成。拒绝随机分配的女性被纳入观察性队列。
> 
> 干预措施：风险评估包括9个易感基因的测序、多基因风险评分及乳腺癌监测联盟第二版模型。基于风险的组别接受以下四种建议之一：(1) 最高风险（5年风险≥6%，高渗透性致病变异）：每6个月交替进行乳腺X线摄影和磁共振成像（MRI）并接受咨询；(2) 升高风险（按年龄处于风险前2.5百分位）：年度乳腺X线摄影及风险降低咨询；(3) 平均风险：每两年乳腺X线摄影一次；(4) 低风险（40–49岁且5年风险<1.3%）：在风险达到1.3%或年龄50岁前不筛查。
> 
> 主要结局与测量指标：共同主要结局包括分期≥IIB癌症的非劣效性及降低活检率的优势。次要结局包括分期≥IIA癌症的检出率、乳腺X线摄影率、高风险队列采取预防策略的比例、观察性队列中筛查方式偏好、导管原位癌、MRI及不同分期癌症的发生率。
> 
> 结果：共28,372名女性被随机分组。平均年龄（标准差）为54（9.6）岁，主要为非西班牙裔白人（77%）。与年度筛查组相比，基于风险组分期≥IIB癌症发生率不劣于年度组（基于风险组：每10万人年30.0 [95% CI, 16.3–43.8]；年度组：48.0 [95% CI, 30.1–65.5]；率差：每10万人年-18.0 [95% CI, -40.2至4.1]）。虽然乳腺X线摄影次数较少（率差：每10万人年-3835.9 [95% CI, -4516.8至-3154.9]），但基于风险组的活检率并未降低（率差：每10万人年98.7 [95% CI, -17.9至215.3]）。癌症、活检、乳腺X线摄影及MRI的累积发生率随着风险类别升高而增加。在观察性队列中，89%的参与者（15,980/18,031）选择了基于风险的筛查。
> 
> 结论：包含人群遗传学检测的基于风险的乳腺癌筛查可安全地进行风险与筛查强度分层，但并未降低活检率。
> 
> 试验注册号：ClinicalTrials.gov 编号 NCT02620852。

### 第二部分 AI 大师评价

该研究通过WISDOM随机临床试验评估了基于个体风险的乳腺癌筛查是否可替代年度筛查。试验结合遗传测序、多基因风险评分和流行病学模型，对不同风险女性实施差异化筛查策略。结果显示，基于风险的筛查在癌症检出率方面不劣于年度筛查，但未能减少活检率，提示其在精准分层与资源优化方面具潜力。创新之处在于将大规模遗传风险评估纳入筛查流程，但其复杂性与对医疗系统的依赖是潜在局限。

---

## 69. 释放基于风险的乳腺癌筛查潜力：从检测到预防

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385344)
**期刊：** JAMA
**PMID：** 41385344
**DOI：** 10.1001/jama.2025.24817

### 第一部分 原文与翻译

**英文原标题：** Unlocking the Potential of Risk-Based Screening for Breast Cancer: From Detection to Prevention.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该论文关注基于风险的乳腺癌筛查策略，旨在拓展从单纯疾病检测向早期预防的转变。尽管摘要缺失，但标题暗示研究可能探讨如何利用个体风险评估来优化筛查频率与方法，以提高预防效果。文章可能强调精准医学在乳腺癌防控中的应用潜力，同时指出当前风险分层筛查在实际推广中的挑战与局限。该研究方向对未来公共卫生政策与个体化医学均具有重要意义。

---

## 70. Orca-T与同种异体造血干细胞移植（PRECISION-T）的比较：一项多中心、随机、Ⅲ期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385341)
**期刊：** Blood
**PMID：** 41385341
**DOI：** 10.1182/blood.2025031313

### 第一部分 原文与翻译

**英文原标题：** Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial.

> **英文摘要：**
> To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plus methotrexate is routinely used. Early phase studies suggested improved outcomes with Orca-T, an allogeneic T-cell immunotherapy that uses purified donor Treg cells to prevent GVHD with significantly less immunosuppression. This phase 3 trial randomized adult patients (N=187) with acute leukemias or myelodysplastic syndrome undergoing myeloablative conditioning to receive either Orca-T with tacrolimus or a conventional allograft with tacrolimus and methotrexate (Tac/MTX), using granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood from HLA-matched donors. The primary endpoint was survival free from moderate-to-severe chronic GVHD (cGFS). Using a stratified log-rank test, cGFS was significantly higher in the Orca-T arm compared to Tac/MTX (P<0.001; HR 0.26; 95% CI, 0.14 to 0.47). One-year estimates were as follows: cGFS was 78.0% with Orca-T versus 38.4% with Tac/MTX; cumulative incidence of moderate-to-severe chronic GVHD (cGVHD) was 12.6% with Orca-T and 44.0% with Tac/MTX (Gray's test P<0.001), while overall survival (OS) was 93.9% with Orca-T versus 83.1% with Tac/MTX (P=0.12); GVHD and relapse-free survival (GRFS) was 63.1% and 30.9% in the Orca-T and Tac/MTX arms (P<0.001), respectively; non-relapse mortality (NRM) was 3.4% with Orca-T versus 13.2% with Tac/MTX (P=0.03). Orca-T met the primary endpoint of improved survival free from cGVHD compared to Tac/MTX prophylaxis and should be considered a new therapeutic option with low toxicity for GVHD prophylaxis. Additionally, significantly less toxicity was observed with Orca-T patients including fewer serious infectious complications and less non-relapse mortality. (ClinicalTrials.gov number NCT05316701).

> **中文摘要：**
> 为预防接受骨髓消融性同种异体造血干细胞移植（alloHSCT）的患者发生移植物抗宿主病（GVHD），常规使用钙调磷酸酶抑制剂联合甲氨蝶呤。早期研究提示，采用Orca-T这种利用纯化供者调节性T细胞（Treg）以显著减少免疫抑制的同种异体T细胞免疫疗法，可改善治疗结局。本Ⅲ期试验将接受骨髓消融性预处理的急性白血病或骨髓增生异常综合征成年患者（N=187）随机分配为两组：一组接受Tacrolimus联合Orca-T治疗，另一组接受传统的Tacrolimus加甲氨蝶呤（Tac/MTX）方案，供者均为HLA匹配者的G-CSF动员外周血。主要终点为无中重度慢性GVHD的生存率（cGFS）。分层log-rank检验结果显示，与Tac/MTX组相比，Orca-T组的cGFS显著更高（P<0.001；HR 0.26；95% CI 0.14–0.47）。一年时的估计结果如下：Orca-T组cGFS为78.0%，Tac/MTX组为38.4%；中重度慢性GVHD（cGVHD）的累积发生率分别为12.6%与44.0%（Gray检验P<0.001）；总体生存率（OS）分别为93.9%与83.1%（P=0.12）；无GVHD及无复发生存（GRFS）分别为63.1%与30.9%（P<0.001）；非复发死亡率（NRM）分别为3.4%与13.2%（P=0.03）。与Tac/MTX预防方案相比，Orca-T达到了改善无慢性GVHD生存的主要终点，应被视为一种低毒性的GVHD预防新疗法。此外，Orca-T组患者还表现出显著更低的毒性，包括严重感染并发症更少及较低的非复发死亡率。（ClinicalTrials.gov编号NCT05316701）。

### 第二部分 AI 大师评价

本研究旨在验证新型同种异体T细胞免疫疗法Orca-T在骨髓消融性造血干细胞移植中的GVHD预防效果。通过Ⅲ期多中心随机对照试验，结果显示Orca-T较传统Tac/MTX方案显著提高患者无慢性GVHD生存率，并降低非复发死亡和感染相关并发症。研究强调了富集调节性T细胞介导的免疫重建策略在移植免疫管理中的潜力。其创新性在于实现了免疫抑制强度的显著下降与临床获益的平衡，但长期复发风险与成本效益仍需进一步评估。

---

## 71. T细胞白血病中LMO2的降解导致转录复合物伴侣的连带崩解并引发LMO2依赖性细胞凋亡

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385269)
**期刊：** eLife
**PMID：** 41385269
**DOI：** 10.7554/eLife.106699

### 第一部分 原文与翻译

**英文原标题：** Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis.

> **英文摘要：**
> LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multi-protein complex that has bipartite DNA binding through heterodimeric basic-helix-loop-helix (bHLH) and GATA proteins. To determine if degradation of LMO2 in the context of T cell acute leukaemias (T-ALL) has therapeutic potential, a chimeric intracellular antibody has been developed fusing an anti-LMO2 single-domain variable region with one of three E3 ligases to create biodegraders. The intracellular binary interaction of these biodegraders with LMO2 leads to its proteasomal degradation but, in addition, concomitant loss of bHLH proteins that associate with LMO2 in the DNA-binding complex. Chemical compound surrogates of the intracellular antibody paratope (called antibody-derived [Abd] compounds) have been modified to create proteolysis targeting chimeras (PROTACs) for orthogonal assays of effects of LMO2 degradation. These form a ternary complex with LMO2 and E3 ligase in leukaemia cells that induces degradation of LMO2 and is also accompanied by loss of associated bHLH proteins. This is accompanied by T-ALL growth inhibition, alterations in proteins involved in cell cycling and instigation of apoptosis. These effects do not occur in the absence of LMO2. Our work demonstrates that degradation of LMO2 affects T-ALL, and the lead compounds can eventually be developed into drugs for patient treatment. Our work describes methods for drug discovery starting with antibody fragments.

> **中文摘要：**
> LMO2是一种内在无序的转录因子，在T细胞白血病中被激活，且难以作为靶点。它构成一个多蛋白复合物的组成部分，该复合物通过异源二聚的基本螺旋-环-螺旋（bHLH）蛋白与GATA蛋白实现双位点DNA结合。为了确定在T细胞急性白血病（T-ALL）背景下LMO2的降解是否具有治疗潜力，研究者开发了一种嵌合细胞内抗体，该抗体将抗LMO2的单域可变区与三种E3连接酶中的一种融合，形成可降解器。此类可降解器与LMO2的细胞内二元相互作用不仅引发其蛋白酶体降解，还伴随与LMO2在DNA结合复合物中结合的bHLH蛋白的同步丢失。研究者进一步将细胞内抗体的互补决定区化学模拟物（称为抗体衍生化合物[Abd]）进行修饰，构建了用于正交检测LMO2降解效应的蛋白降解靶向嵌合体（PROTACs）。这些PROTACs在白血病细胞中与LMO2和E3连接酶形成三元复合物，引发LMO2的降解，同时伴随相关bHLH蛋白的丧失。这一过程导致T-ALL的生长抑制、与细胞周期相关蛋白的变化以及细胞凋亡的启动。上述效应在缺乏LMO2的情况下不会发生。本研究表明LMO2的降解会影响T-ALL，并且这些领先化合物最终可开发为患者治疗用药。本研究还描述了以抗体片段为起点的药物发现方法。

### 第二部分 AI 大师评价

本研究聚焦于T细胞急性白血病中LMO2这一关键转录因子的靶向降解，利用细胞内嵌合抗体和PROTAC技术实现其蛋白酶体介导的清除。作者系统展示了LMO2降解后复合物伴侣蛋白的连带丧失以及由此引发的细胞凋亡，证明该策略可抑制T-ALL生长。工作创新性地将抗体片段转化为降解分子，为蛋白质靶向药物开发提供新路径。然而，临床可行性及特异性仍需进一步验证。

---

## 72. 消除宫颈癌的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385236)
**期刊：** JAMA
**PMID：** 41385236
**DOI：** 10.1001/jama.2025.20021

### 第一部分 原文与翻译

**英文原标题：** Strides in Cervical Cancer Elimination.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

本文可能是一篇综述性或评论性文章，概述全球在宫颈癌消除方面取得的重要进展，包括疫苗接种、筛查策略及公共卫生政策的强化。其核心目的在于强调国际协作和持续干预对降低宫颈癌发病率与死亡率的关键作用。尽管未提供详细研究方法或数据，但该文对于推动政策制定与临床实践的整合具有重要启示意义。

---

## 73. HIF-1介导的ISG20表达促进乳腺癌干性与免疫逃逸

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385111)
**期刊：** The Journal of experimental medicine
**PMID：** 41385111
**DOI：** 10.1084/jem.20250777

### 第一部分 原文与翻译

**英文原标题：** HIF-1-mediated ISG20 expression promotes breast cancer stemness and immune evasion.

> **英文摘要：**
> Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the highest rates of recurrence, metastasis, and patient mortality due to the absence of effective therapies. Hypoxia-inducible factor 1 (HIF-1) regulates the expression of thousands of RNAs in TNBC. Here, we demonstrate that transcription of the ISG20 gene, which encodes an RNA exonuclease, is activated by HIF-1 in TNBC cells. ISG20-mediated degradation of RHOBTB3 mRNA increases HIF-1α protein expression and activates NANOG signaling, which increases breast cancer stem cell specification and lung metastasis. ISG20 also degrades STAT1 and IRF1 mRNAs, leading to decreased expression of CXCL10 and impaired recruitment of CD8+ T cells and natural killer cells, thereby promoting breast cancer immune evasion. Silencing ISG20 increases the sensitivity of mouse TNBC cells to anti-PD1 antibody immune checkpoint blockade. Our data suggest that targeting ISG20, in combination with immunotherapy, could be an effective therapeutic strategy for TNBC.

> **中文摘要：**
> 三阴性乳腺癌（TNBC）是最具侵袭性的乳腺癌亚型，由于缺乏有效的治疗手段，其复发、转移及患者死亡率最高。缺氧诱导因子1（HIF-1）在TNBC中调控数千种RNA的表达。在本研究中，我们证实编码RNA外切核酸酶的ISG20基因在TNBC细胞中受HIF-1激活。ISG20介导的RHOBTB3 mRNA降解可增强HIF-1α蛋白表达并激活NANOG信号，从而促进乳腺癌干细胞特性形成及肺转移。ISG20还可降解STAT1和IRF1的mRNA，导致CXCL10表达下降并削弱CD8+ T细胞及自然杀伤细胞的募集，从而促进乳腺癌的免疫逃逸。沉默ISG20可增强小鼠TNBC细胞对抗PD1抗体免疫检查点阻断的敏感性。我们的研究结果表明，靶向ISG20联合免疫治疗可能成为TNBC的有效治疗策略。

### 第二部分 AI 大师评价

该研究揭示了HIF-1通过上调ISG20在三阴性乳腺癌中形成正反馈机制，从而增强肿瘤干性与免疫逃逸能力。作者结合分子机制分析与动物模型实验，阐明了ISG20在mRNA降解层面的关键作用。研究创新之处在于将缺氧信号与免疫调控相连接，提供了潜在治疗靶点的证据。然而，该研究仍需临床验证以评估靶向ISG20联合免疫治疗在患者中的安全性与疗效。

---

## 74. 昼夜节律检查点调控中性粒细胞重新定位以最小化组织损伤

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41385080)
**期刊：** The Journal of experimental medicine
**PMID：** 41385080
**DOI：** 10.1084/jem.20250240

### 第一部分 原文与翻译

**英文原标题：** A circadian checkpoint relocates neutrophils to minimize injury.

> **英文摘要：**
> Inflammation-driven injury, a significant source of morbidity and mortality worldwide, is largely mediated by the cytotoxic activities of neutrophils, which extend the initial lesion and jeopardize organ function. Intriguingly, inflammatory injury naturally declines at specific times of day, suggesting that circadian mechanisms exist that mitigate the destructive activity of neutrophils and protect the host. Here, we show that the periods of diurnal protection coincide with peaks in plasma CXCL12, a chemokine that inhibits the neutrophil-intrinsic circadian clock by signaling through CXCR4. Genetic deletion of this clock, or a hyperactive form of CXCR4, prevented the diurnal spikes of injury, and treatment with a synthetic CXCR4 agonist conferred protection from myocardial and vascular injury. In tissues, this protection was mediated by repositioning neutrophils in the wound core, which spared neighboring host cells from apoptotic death. Thus, a circadian neutrophil checkpoint protects from exuberant inflammation and can be activated to protect the host.

> **中文摘要：**
> 炎症驱动的损伤是全球发病率和死亡率的重要来源，主要由中性粒细胞的细胞毒性活动所介导，这种活动扩展了初始病灶并危及器官功能。有趣的是，炎症性损伤在一天中的特定时间自然减少，提示存在昼夜节律机制来减轻中性粒细胞的破坏性作用并保护宿主。在本研究中，我们发现昼间保护期与血浆CXCL12水平的峰值相吻合。CXCL12是一种通过CXCR4信号途径抑制中性粒细胞内在昼夜节律时钟的趋化因子。该时钟的基因缺失，或CXCR4的高活性形式，均可阻止损伤的昼夜高峰，而应用合成CXCR4激动剂可提供对心肌和血管损伤的保护。在组织层面上，这种保护作用通过将中性粒细胞重新定位到创伤核心来实现，从而使邻近宿主细胞免于发生凋亡死亡。因此，昼夜节律性中性粒细胞检查点可防止过度炎症，并可通过激活该机制来保护宿主。

### 第二部分 AI 大师评价

本研究揭示了昼夜节律在炎症损伤调控中的关键作用，发现CXCL12–CXCR4信号轴可通过抑制中性粒细胞内在生物钟来限制组织损害。研究结合遗传学操控与药理学干预，验证了激活CXCR4途径可显著降低心血管等组织的炎症性损伤。该发现为昼夜节律介导的免疫稳态提供了新机制，并提示靶向CXCR4的治疗策略具有潜在临床价值。然而，本研究主要基于动物模型，未来需进一步证实其在人类中的可转化性。

---

## 75. 基于单细胞与空间转录组学揭示的结直肠癌空间定义多细胞功能单元

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41384492)
**期刊：** eLife
**PMID：** 41384492
**DOI：** 10.7554/eLife.104815

### 第一部分 原文与翻译

**英文原标题：** Spatially defined multicellular functional units in colorectal cancer revealed from single cell and spatial transcriptomics.

> **英文摘要：**
> While advances in single-cell genomics have helped to chart the cellular components of tumor ecosystems, it has been more challenging to characterize their specific spatial organization and functional interactions. Here, we combine single-cell RNA-seq, spatial transcriptomics by Slide-seq, and in situ multiplex RNA analysis to create a detailed spatial map of healthy and dysplastic colon cellular ecosystems and their association with disease progression. We profiled inducible genetic CRC mouse models that recapitulate key features of human CRC, assigned cell types and epithelial expression programs to spatial tissue locations in tumors, and computationally used them to identify the regional features spanning different cells in the same spatial niche. We find that tumors were organized in cellular neighborhoods, each with a distinct composition of cell subtypes, expression programs, and local cellular interactions. Comparing to scRNA-seq and bulk RNA-seq data from human CRC, we find that both cell composition and layout features were conserved between the species, with mouse neighborhoods correlating with malignancy and clinical outcome in human patient tumors, highlighting the relevance of our findings to human disease. Our work offers a comprehensive framework that is applicable across various tissues, tumors, and disease conditions, with tools for the extrapolation of findings from experimental mouse models to human diseases.

> **中文摘要：**
> 虽然单细胞基因组学的进展有助于描绘肿瘤生态系统的细胞组成，但要表征其特定的空间组织和功能性相互作用仍然具有挑战性。在本研究中，我们结合单细胞RNA测序、基于Slide-seq的空间转录组学以及原位多重RNA分析，建立了健康与异型增生结肠细胞生态系统的精细空间图谱，并探讨其与疾病进展的关联。我们分析了可诱导的遗传性结直肠癌小鼠模型，这些模型重现了人类结直肠癌的关键特征，并将细胞类型及上皮表达程序映射至肿瘤组织的特定空间位置，随后通过计算方法识别了同一空间生态位中不同细胞之间的区域特征。结果发现，肿瘤被组织成细胞邻域，每个邻域具有独特的细胞亚型组成、表达程序及局部细胞相互作用。与人类结直肠癌的单细胞RNA测序及整体RNA测序数据比较显示，不论细胞组成还是空间布局特征在两种物种间均具有保守性，小鼠邻域与人类患者肿瘤的恶性程度及临床预后呈相关性，进一步强调了本研究发现对人类疾病的相关性。本研究提供了一个适用于多种组织、肿瘤及疾病状态的系统性框架，并为从实验性小鼠模型外推至人类疾病提供了有效工具。

### 第二部分 AI 大师评价

本研究旨在跨越单细胞与空间分辨层面，揭示结直肠癌中细胞间组织与功能的空间架构。作者采用单细胞RNA测序、Slide-seq空间转录组及原位多重RNA分析的多维整合策略，在小鼠模型中建立了高分辨率的结肠细胞生态系统空间图谱。研究发现肿瘤内部存在由特定细胞亚型和表达程序构成的功能邻域，并且这些空间特征在人鼠之间具有保守性，可与人类肿瘤的恶性度与临床结局相关联。该研究在方法整合与跨物种转化层面具有创新性，但仍需进一步验证其在不同疾病类型中的普适性与动态演变规律。

---

速递结束，祝您工作愉快！